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ABSTRACT 
 
 
Neurogenesis, and the processes through which neural stem cells and progenitor 
cells differentiate into neurons, occurs most actively during embryonic development, 
although neural differentiation continues at lower levels in certain brain regions well into 
adulthood. A vast regulatory network involving many known and conserved transcription 
factors regulates these functions. We have identified a novel zinc finger transcription 
factor (TF), ZNF286A, which is conserved in all eutherians and marsupials and provide 
evidence that this novel TF plays a role in regulation of mammalian neurogenesis. 
ZNF286 occurs as a unique gene in most species. However, we demonstrate 
evidence that a gene duplication event in very recent primate history created a human-
specific duplicate of ZNF286A, called ZNF286B. ZNF286B arose as part of a larger 
duplication in human chromosome 17, approximately 600,000 kb in length, that also 
includes many surrounding genes. Concomitant with (or shortly after) duplication, a 
processed and incomplete FOXO3B pseudo-gene was inserted into the ZNF286B 
genomic sequence and a DNA segment, encompassing a coding exon and regulatory 
sequences present in the ancestral ZNF286A gene, was deleted. As a result, ZNF286B 
encodes a protein with significant structural and expression differences relative to the 
ancestral gene. Most strikingly, the exon deleted in ZNF286B codes for the chromatin-
interacting KRAB-domains that are present in the ZNF286A gene; in this respect the new 
human paralog resembles a natural KRAB-less alternative isoform that we demonstrate to 
be expressed naturally from the parental ZNF286A gene.  
Using ChIP and siRNA knockdown, we show that ZNF286A protein binds to 
DNA at or near genes involved in the networks controlling the differentiation of neurons 
and the formation of axons during neurogenesis, and that both ZNF286A and ZNF286B 
directly regulate expression of many of those same genes.  The pattern of DNA binding 
closely parallels binding of well-known neuronal differentiation factor, REST, in the 
same cell lines; siRNA results suggest that ZNF286 proteins act antagonistically to REST 
during development. We show that the mouse gene, Zfp286, is expressed at high levels in 
the developing nervous system and that both mouse and human genes and proteins are 
up-regulated transiently over the course of neurogenic differentiation in vitro, consistent 
	 iii 
with the predicted biological role. We hypothesize that the duplication event that gave 
rise to ZNF286B allowed for independent regulation of the KRAB-less isoform of the 
ZNF286 protein, permitting this ancient mammalian gene to take on novel functions in 
the adult human brain. 
 
Keywords: KRAB-ZNF, recently evolved paralogs, neurogenesis, transcription factors 
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A bit of context 
 
In 1665, Englishman and natural philosopher Robert Hooke published his 
Micrographia, a book containing thorough descriptions of dozens of plants, animals, and 
other natural objects as observed under what we would today consider to be a very 
rudimentary compound microscope. Along with these descriptions were included dozens 
of very detailed illustrations of his microscopic observations. As described in Hooke’s 
preface to this work, the microscope was an instrument that would open up whole new 
worlds of exploration, and Micrographia served as a demonstration of the power that 
such technology held (Hooke, 1665). 
Among the items Hooke observed under his microscope were very thin slices of 
cork, which he famously observed as being composed of an arrangement of small pores: 
 
“I took a good clear piece of Cork, and with a Pen-knife ſharpen’d as 
keen as a Razor, I cut a piece of it off, and thereby left the ſurface of it 
exceeding ſmooth, then examining it very diligently with a Microſcope, me 
thought I could perceive it to appear a little porous; but I could not ſo 
plainly diſtinguiſh them, as to be ſure that they were pores… theſe pores, 
or cells, were not very deep, but conſiſted of a great many little Boxes... I 
no ſooner diſcern’d theſe (which were indeed the firſt microſcopical pores 
I ever ſaw, and perhaps, that were ever ſeen, for I had not met with any 
Writer or Perſon, that had made any mention of them before this) but me 
thought I had with the diſcovery of them, preſently hinted to me the true 
and intelligible reaſon of all the Phenomena of Cork.” (Obſerv. XVIII) 
 
This seemingly innocuous observation, made while trying to determine the cause of the 
material’s springiness and swelling nature (the “Phenomena of Cork” as he put it), was in 
fact a huge milestone in the field of biology, as it represented the very first discovery and 
naming of the cell – the smallest functional unit of life and capable of independent 
replication. Indeed, Hooke’s observations served as an academic launching pad, and in 
the subsequent 350 years of study our knowledge of the internal structures of these cells 
and how they function together has grown immeasurably, and our current understanding 
is that the first life to emerge on the planet originally developed as single-celled 
organisms – a concept that would have been completely unknown to Hooke. 
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We now know that within each eukaryotic cell is contained an organism’s entire 
genome. This information is arranged as a long series of nucleotides separated into 
multiple DNA molecules, with each ensemble of discrete DNA molecules separated into 
chromosomes. DNA sequences are defined into genes, which can be transcribed into 
RNA, which act as the template that ribosomes use to translate these sequences into 
proteins. These proteins then go on to perform the various functions necessary for cellular 
life. The interactions between these three types of molecules – DNA, RNA, and protein – 
are what the entire field of molecular biology was developed to study. 
This thesis attempts to elucidate just one small aspect of these interactions 
regarding a small but critical family of proteins, the functions of these proteins in 
regulating the genes that control neuronal development, and their fascinating heritage 
through the evolution of mammals and marsupials. The human brain is unique in the 
animal kingdom (as it is what enables you, dear reader, to understand the words in this 
chapter), and so it is a matter of keen interest that we study the aspects that make the 
human brain and its development different from those of other animals. 
This thesis represents only a small piece of a much larger puzzle that biologists 
are trying to put together everyday. While this topic is certainly specialized, representing 
a fine look at only a handful of genes singled out from a genome of thousands, it is 
important to remember that an entirely novel field of biology sprung forth following a 
lone Englishman asking himself why it was that cork floats. So it is that we come to 
understand that the most innocuous of studies can yield significant conclusions – perhaps 
even conclusions worth of popping a cork over. 
 
The incredible human brain 
 
There is a huge spectrum of intelligence across the animal kingdom, and humans 
are widely considered to be the kings in that arena. This self-coronated designation is 
interesting, but not as significant as the question of what properties of the brain exist 
beneath that crown, making humans more intelligent than other animals in the first place? 
Addressing these questions is difficult, and a huge literature of scientific and 
philosophical thought exists tackling precisely this issue. 
	 4 
Brain size alone does not seem to, by itself, explain intelligence. Many reports 
have been made of dogs, apes and corvids demonstrating remarkable cognition despite 
having much smaller brains, (Kaminski et al., 2004; Emery & Clayton, 2004). Therefore, 
the relationship between brains and intelligence appears to be qualitative in nature, as 
opposed to quantitative, and so the mechanisms underlying the brain and its development 
should be where we direct our focus. 
The human brain occupies only 2% of human body mass, and yet surprisingly it 
consumes about 20% of total metabolism, making it one of the most metabolically 
‘expensive’ organs in the body. The heart, the kidneys, the liver and the gastrointestinal 
tract are also relatively ‘expensive’ organs, and along with the brain consume about 70% 
of the basal metabolism of the human body (Aiello and Wheeler, 1995). More remarkable 
than the human brain’s energy consumption is the fact that it is significantly larger than 
what would be expected from a primate of our mass (Figure 1.1).  
In fact, human brain mass is disproportionately large when compared to any other 
mammal when accounting for body mass (Figure 1.2). Blue whales have enormous brain 
masses, but compared to their body masses it is clear that they are expending far less 
metabolic resources on their brain than what would be expected of an organism of their 
size. 
Encephalization is often brought up as a metric for approximating animal 
intelligence, expressed by an ‘encephalization quotient’, or EQ (Roth & Dicke, 2005). 
EQ is calculated as EQ=Ea/Ee (with Ea indicating actual brain size, and Ee indicating 
expected brain size based on the proportions of a same-taxon animal ‘standard’). When 
observing mammalian encephalization (Figure 1.3), the species with the highest level of 
encephalization is very clearly humans, with brains roughly 7-8 times larger than what is 
expected for a mammal of human mass, even when compared to most of our hominid 
ancestors! However, measuring encephalization has its limits, and some “higher 
cognition” species can find themselves with lower EQ scores than species generally 
accepted as having “lower cognition”; for example, gorillas have EQ scores just slightly 
higher than squirrels, despite countless examples of higher order thought processes and 
the capacity to express thought through language. As such, EQ is not the optimal 
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predictor for intelligence, but may serve as only one characteristic that explains humans’ 
increased intelligence. 
The increase in human brain size is balanced by a reduction in gut size (Figure 
1.1), which has been compensated for with an increase in food quality (ie. from cooked 
food, which provides higher nutritional content that is more easily digestible than raw 
food). Cooked food is also more easily acquired when increased intelligence is applied 
(Aiello, 1997; Aiello et al., 2001). This connection is supported by a significantly 
positive correlation between primate diet quality and brain size (Fish & Lockwood, 
2003), which is facilitated by the fact that primates with higher cognitive abilities are 
more capable of recognizing and processing high-quality foods than those with lower 
cognitive abilities (Aiello et al., 2001). Several hypotheses have attempted to explain the 
increases in relative brain size that have occurred during mammalian evolution, and while 
they may differ in their proposed mechanisms, they generally agree that the increase in 
brain size is primarily due to an increase in total cell number (Fish et al., 2008), with 
increases in total number of cortical neurons have been used to explain increases in 
intelligence (Roth & Dicke, 2005). 
The most energy-demanding period during the lifetime of the human brain occurs 
during prenatal development and early childhood growth, and this is also the period when 
the brain develops the most neuronal cells through neurogenesis (Martin, 1996; 
Blakemore, 2012; Götz & Huttner, 2005). As such, the regulation of the systems 
responsible for these developmental frameworks is critical to our understanding of what 
makes us human (Andersen, 2003). 
 
Neurogenesis, or the birth of neurons 
 
Neurogenesis describes the broad range of processes involved in generating 
neurons from neural stem cells and their derivative progenitor cells. Several regions of 
the adult brain have been shown to undergo neurogenesis, such as the subventricular zone 
lining the inside of the lateral ventricles, the interneurons of the striatum, as well as parts 
of the dentate gyrus of the hippocampus (Ernst et al., 2014; Bergmann et al., 2012; Dayer 
et al., 2003; Roberts et al., 2014). However, the majority of neurogenesis that occurs does 
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not take place in adults, but rather during development when neural stem cells give rise to 
all the neurons of the mammalian central nervous system (Götz & Huttner, 2005). Once 
the appropriate signal is recognized by a self-renewing neural stem cell, it will 
differentiate into a much more specialized neural progenitor cell. From there, the 
progenitor cell is capable of differentiating into mature neuronal cells (ie. neurons, 
astrocytes, or oligodenrocytes), where their cell fate is locked into that state until their 
cell death. 
Many proteins are involved in neurogenesis, acting within a network of enzymatic 
pathways that play specific roles in developing the structures and forms involved in a 
functioning brain and central nervous system (CNS). The three largest and most 
important pathways for these systems are the Notch, Shh, and Wnt signaling pathways, 
which have been shown to be hugely important in the process of neurogenesis and also in 
the regulation of self-renewal in embryonic stem cells. 
The Notch signaling pathway promotes proliferative signaling during 
neurogenesis neural differentiation of precursor cells (Artavanis-Tsakonas et al., 1999). 
Meanwhile, the sonic hedgehog (SHH) pathway plays many critical roles in the 
development and patterning of the vertebrate CNS, including the induction of the floor 
plate and neural tube, which are precursor structures to the mature CNS (Placzek, 1995; 
Litingtung & Chiang, 2000). During later stages of development, the Wnt signaling 
pathway has been shown to control the migration of neuroblasts and other embryonic 
processes included in controlling body axis patterning, cell fate specification, cell 
proliferation, and cell migration (Pawlowski et al., 2002). 
Changes in the ways that these systems are regulated can lead to drastic changes 
in the ways that the brain and CNS are formed. For this reason, the evolution of 
transcription factors (and primarily zinc finger transcription factors) plays a critical role 
in regulating these changes between species. 
 
Handing it over to zinc finger transcription factors 
 
In order to control their unique morphological and functional fates, cells regulate 
both the transcription of DNA into mRNA, and the translation of mRNA into proteins. A 
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broad range of transcription factor proteins regulates the former (Latchman, 1997; 
Blackwood & Kadonaga, 1998). These interactions are regulated by transcription factors 
that bind to DNA elements in order to promote, enhance, or silence gene expression. 
Promoter elements (like the TATA box) are always located at the 5’-end of the gene they 
regulate, while enhancer and silencer elements can be located very far away from their 
targets, utilizing DNA-looping to bridge the gaps (Su et al., 1990). Many of these 
regulators operate by either sitting at or near transcription start sites and directly 
regulating pre-initiation complex (PIC) binding specificity, or by recruiting other proteins 
to modify the chromatin structure of DNA, thereby making it easier or more difficult for 
the PIC to operate at those sites. These proteins can be broadly categorized into three 
groups: 
 
(i) General transcription factors that bind to specific promoter sites to 
activate transcription (like the previously-described TFIID). 
(ii) Sequence-specific transcription factors that interact with DNA-
regulatory elements to carefully up- or down-regulate gene 
transcription. 
(iii) Non-sequence-specific co-factors that mediate the previously 
described interactions. 
 
Most sequence-specific transcription factors are composed of three protein 
structural domains: a conserved DNA-binding domain, a regulatory domain that regulates 
transcription, and a connective domain that links the two (Latchman, 1997). In general, 
sequence-specific transcription factors are classified by their DNA-binding motifs, which 
are conserved throughout evolution. On the other hand, regulatory domains are much 
more diverse, and can activate or repress transcription through protein-protein 
interactions. These interactions either occur directly with transcriptional components 
(such as the PIC or RNA polymerases), or indirectly with co-factors that modulate 
transcriptional proteins or regulate transcription at the chromatin-level (Zawal et al., 
1996; Maldonado et al., 1999; Spitz & Furlong, 2012). Of these varied families of 
metazoan transcription factor domains, the most common domain is by far the C2H2 zinc 
finger motif. 
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Zinc fingers (sometimes abbreviated as ZNFs) are a large family of protein 
structural motifs that coordinate at least one zinc ion, used for stabilizing the fold 
structure of the domain. Depending on their structure, these zinc fingers are capable of 
binding to DNA, RNA, proteins, and/or small molecules. As such, they have proven 
themselves to be highly useful in serving the regulatory needs of the cell. One motif, the 
C2H2 zinc finger motif, contains conserved cysteine- and histidine-pairs in their amino 
acid sequence that coordinate a single zinc ion (Miller et al., 1985) and stabilize a 
“finger” structure that is required for proper folding and DNA binding (Stubbs et al., 
2011; Frankel et al., 1987; Pavletich & Pabo, 1991). There is variation between the amino 
acids that compose individual fingers, however C2H2 motifs are recognizable by the 
highly conserved, repetitive amino acid pattern – TGEKP(Y/F) – that often links 
consecutive fingers to one another (Figure 1.4). 
The most common family of transcription factors to use the C2H2 motif are the 
“Krüppel-type” (KZNF) family of transcription factors, named after their discovery in the 
regulatory Krüppel-protein of Drosophila melanogaster (Ollo & Maniatis, 1987). These 
proteins are identifiable as having at least 3, and as many as 40, C2H2 finger domains in 
tandem (Iuchi, 2001; Huntley et al., 2006). Each individual finger recognizes 3 base pairs 
of DNA at its α-helix motif, such that the array of tandem fingers winds around the major 
groove of the DNA molecule (Figure 1.5) in a highly sequence-specific manner 
(Pavletich & Pabo, 1991). In addition, there are four specific amino acids that are 
responsible for DNA-binding, called fingerprints. These fingerprints can be compared 
across species to determine the conservation of a zinc finger domain’s binding (Stubbs et 
al., 2011). 
 
KAP-1’s regulation by chromatin modification 
 
The most common method of regulation utilized by sequence-specific 
transcription factors is to interfere with the structure of chromatin. In eukaryotes, DNA is 
wrapped around histone octamers in repeating motifs known as nucleosomes, colloquially 
referred to as a “beads-on-a-string” structure, and further packaged into several levels of 
higher order chromatin structure (Horn & Peterson, 2002; Voss & Hager, 2014). These 
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higher-order chromatin fibers play a critical role in transcriptional regulation, as their 
structures can either be modified to be more open and accessible to other proteins 
(euchromatin) or more closed and inaccessible (heterochromatin). In addition, histones 
can aid in regulation by undergoing a variety of post-translational modifications that alter 
the way that they interact with DNA and proteins. These modifications typically occur on 
the long nucleosomal tails of the H3 and H4 histone proteins; the most common methods 
include acetylation, phosphorylation, methylation, deimination, ADP-ribosylation, 
ubiquitylation, sumoylation, and the removal of these aforementioned modifications 
(Bannister & Kouzarides, 2011). These modifications not only regulate chromatin 
through their presence, but they also recruit ATP-dependant chromatin remodeling 
complexes. 
Krüppel-type transcription factors typically possess a regulatory domain that is 
attached to the finger domain by a “tether” region of connective amino acids (Figure 
1.6). There are many families of effector domains for Krüppel-type zinc fingers, such as 
SCAN, ZAD, BTB/POZ, and Poly-C2H2 (Collins & Sanders, 2000; Jauch et al., 2003; 
Geyer et al., 2003), but the most common regulatory domain in Krüppel-type zinc fingers 
is the Krüppel-Associated Box (KRAB) (Stubbs et al., 2011). Each effector domain 
functions differently (Collins et al., 2001), and KRABs have been shown to function as 
repression domains that recruit the Krüppel-Associated Protein 1 (KAP-1) cofactor in 
order to recruit methyltransferases and histone deacetylases (Friedman et al., 1996; Peng 
et al., 2000; Zeng et al., 2008), which have long been known to modify the structure of 
chromatin and repress transcription (Allfrey et al. 1964). This strongly implies that 
KRAB-containing Krüppel-type proteins are involved in transcriptional repression 
(Figure 1.6). 
The mechanism of KRAB begins with the recruitment of KAP-1 – also known as 
TRIM28, TF1β, TIF1β, and KRIP-1 (Friedman et al., 1996; Moosmann et al., 1996; Kim 
et al., 1996) – which has several domains that interact with different cofactors. An HP1-
interacting domain binds to the heterochromatin protein, HP1, which anchors 
heterchromatin subunits, although its specific mechanisms are not known (Singh & 
Georgatos, 2002). A plant homeodomain finger conjugates SUMO proteins after 
activation, and these proteins sumoylate a nearby bromodomain on KAP-1 (Hay, 2005; 
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Ivanov et al., 2007). This SUMOylation of KAP-1 post-translationally modifies it to 
interact with SETDB methyltransferase, which adds methyl-groups to cysteines on 
nearby nucleosomes (Schultz et al., 2002). In addition, the SUMOylated bromodomain 
also recruits a NuRD-complex containing a histone deacetylase, which removes acetyl-
groups from lysines on histone H3 (Lai & Wade, 2011). Together, these cofactors tighten 
chromatin structure and silence genes that are bound in the heterochromatin. 
In humans, there are over 400 KRAB-containing, Krüppel-type zinc finger 
transcription factors, each with their own specific DNA-binding sequences and regulatory 
targets. This work investigates the binding and function of one pair of transcription 
factors within this large family – ZNF286A and ZNF286B. 
 
The ZNF286 family of transcription factors 
 
In eutherian mammals and marsupials, there exists one ZNF286 gene that codes 
for a KRAB-containing Krüppel-type zinc finger transcription factor possessing 10 
tandem C2H2 zinc fingers separated by a spacer region. ZNF286 is an especially deeply 
conserved member of this dynamic gene family, being one of only 37 human KRAB-
ZNF genes with a clear and highly conserved 1:1 ortholog in marsupials (Liu & Stormo, 
2008). This unusual level of conservation suggests that the gene has acquired an essential 
mammalian regulatory function. 
However, the human version of this gene (referred to as ZNF286A) has duplicated 
to produce a second gene called ZNF286B, which is found in humans but is not detected 
in any other primate species (Nowick et al., 2011). Despite its very recent advent, 
ZNF286B differs from the parental gene in several significant ways. In particular, despite 
the sequences coding for the zinc finger domains of ZNF286A and ZNF286B being nearly 
identical, ZNF286B does not include any KRAB-encoding exons, and instead includes 
novel exons that are not included in the parental gene. In lieu of a KRAB-coding region, 
ZNF286B contains a unique sequence of similar length, identified as a FOXO3B 
pseudogene, inserted into the gene sequence after the duplication event that brought 
about ZNF286B. While previous studies have shown that deletion of KRAB in proteins 
results in a loss of repression function (Li et al., 2008), this has not been demonstrated for 
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ZNF286B specifically. Indeed, experimental data demonstrates that this protein includes 
other types of regulatory functions alongside ZNF286A in neural tissues. 
This duplication behavior is entirely commonplace for KRAB-ZNF, and in 
vertebrates (and especially in mammals) the KRAB-ZNF family has grown through 
repeated rounds of tandem segmental duplication to include hundreds of lineage-specific 
genes (Chung et al., 2002, 2007). Differences in KRAB-ZNF copy number are even seen 
between closely related species, such as humans and chimpanzees (Huntley, 2006; 
Hamilton, 2006; Nowick et al., 2011). New duplicates can diverge significantly over 
relatively short evolutionary times, changing in expression pattern, splicing, and/or 
coding sequence in ways that predict distinct functions (Hamilton, 2006; Nowick, 2011). 
Past studies into the history of Krüppel-type zinc fingers have annotated the 
repertoire of human KZNF genes, and carried out a preliminary comparison with genes in 
other species (Huntley et al., 2006). Most KZNF genes are deeply conserved across 
evolution, however the KRAB-ZNF is substantially over-represented among genes that 
have undergone repeated rounds of recent segmental duplications (Nowick et al., 2010), 
as is the case with ZNF286A and ZNF286B. In this case, a “recent duplication” is defined 
as having occurred within the past 35–40 million years. These segmental duplications 
have produced an evolutionary sandbox for the evolution of proteins with primate-
specific functions, and novel lineage-specific genes across many other species (Nowick et 
al., 2010; Huntley et al., 2006; Bellefroid et al., 1993; Looman et al., 2002). This is 
because duplications create raw genetic material that can evolve beyond the selective 
pressures of a deeply conserved gene that may be too critical to mutate (Bailey & Eichler, 
2006). Interestingly, these duplication events appear to have significantly accelerated in 
the last 12 million years within the genome of the African ancestor of the great ape 
(Marques-Bonet et al., 2009). This evolutionary diversity, and the evidence that KZNF 
genes play an important role in novel gene expression differences between the human and 
chimpanzee brain (Nowick et al., 2009), indicate an important role for recently evolved 
KRAB-ZNF duplicates like ZNF286A and ZNF286B (Nowick et al., 2011). 
Aside from having a gene duplicate, ZNF286A also transcribes an alternative 
transcript that is similar to ZNF286B in that it lacks a KRAB domain (Figure 1.7), but is 
conserved in both humans and mice. This aligns with previous studies that show that 
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conserved human/mice alternative transcripts are enriched in regulatory genes and are 
frequently expressed in brain (Yeo et al., 2005). Both ZNF286A isoforms, along with 
ZNF286B, share identical or near-identical DNA binding motifs. For this reason we 
hypothesize that KRAB-less ZNF286A and ZNF286B act as competitors to ZNF286A 
and fine-tune the regulation of target genes by varying concentrations of each protein in 
different tissues at different times. During preliminary tests, we found that ZNF286A 
expresses in tissues at different levels than ZNF286B, suggesting that the human-specific 
duplicate has evolved to fit a functional niche that is not occupied by the full-functioning 
ancestral gene, however a similar niche may be occupied by the KRAB-less ZNF286A 
isoform. Alternative splicing acts as a means of creating protein diversity (Keren et al., 
2010; Nilsen & Graveley, 2010), so this suggests that it is possible for the function of 
KRAB-less ZNF286A has become part of the “official” non-alternative proteome in the 
form of the ZNF286B genetic duplicate. Our data show that ZNF286A and ZNF286B are 
of interest because they regulate genes involved in neurogenesis, and bind to regions that 
are enriched for binding sites of a well-known zinc finger, the RE-1 silencing 
transcription factor (REST) discussed in the following section, and most likely play 
complementary roles to REST in transcriptional regulation. 
 
Repressor-element-1 silencing transcription factor (REST) 
 
REST, also known as the neural-restrictive silencer factor (NRSF), is a Krüppel-
type zinc finger transcription factor that binds to an element known as the NRSE (neuron-
restrictive silencer element, also known as RE-1) for the critical role of repressing 
neuronal gene expression in non-neuronal cells (Schoenherr & Anderson, 1995; 
Schoenherr et al., 1996). Furthermore, REST is required for proper timing of neuronal 
gene expression in embryonic stem cells by repressing genes that control for the terminal 
differentiation of cell lines (Chen et al., 1998). It is also directly regulated by the 
canonical Wnt pathway, which controls the fates of neural progenitor cells (Nishihara et 
al., 2003). As with many regulatory cells in these pathways, REST has been implicated in 
different forms of cancer (Bronson et al., 2010; Coulson et al., 2000; Ly et al., 2010). 
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REST contains eight unique tandem zinc fingers (distinct from ZNF286), and 
expresses multiple isoforms (Spencera et al., 2006; Raj et al., 2010). It has been shown 
that in non-neuronal adult tissues, REST is ubiquitously expressed (Scholl et al., 1996), 
however REST decreases after neuronal differentiation (Nishimura et al., 1996; Singh, 
2011; Xiaohua et al., 2004). REST is critical for neurogenesis, and mice that lack the 
protein actually die during fetal development (Chen et al., 1998). 
There are four alternatively spliced isoforms of REST – a full length isoform (122 
kDa), a truncated isoform that retains only the first four zinc fingers and localizes to the 
cytoplasm (35 kDa), a truncated isoform known as REST4 that retains the first five zinc 
fingers and nuclear localization signal (37 kDa), and an isoform with a selective deletion 
of the fifth zinc finger (119 kDa) (Palm et al., 1999; Coulson et al., 2000; Shimojo et al., 
2001). The full-length REST and REST4 are the most abundantly expressed isoforms. 
Full-length REST is localized to the nucleus, but due to the truncation of the 
nuclear localization signal that directs the protein to the nucleus, some REST isoforms 
behave differently (Shimojo et al., 2001), with REST4 playing the most active role in 
regulating full-length REST’s function. REST and REST4 are expressed at different 
levels in different cell types (Spencer et al., 2006; Uchida et al, 2010), even within the 
same family of derived cell lines – as an example in neuroblastoma cell lines, glial SH-
EP cell express full length REST while neuronal SH-SY5Y expresses REST4, with the 
mixed SK-N-SH cell type expressing both isoforms (Hamelink et al., 2004; Raj et al., 
2011). With these two main versions of the same protein existing at varying levels in 
conjunction with each other, previous studies have shown that REST4 acts to inhibit 
REST function by competing with REST over NRSE sites (Shimojo et al., 1999; Tabuchi 
et al., 2002). However, REST4 itself does not actually repress transcription function, or 
does so very weakly (Magin et al., 2002; Lee et al., 2000). Therefore, REST4 does not act 
as a transcriptional repressor, but blocks the repressor activity of REST. Under certain 
circumstances, REST is actively sequestered outside of the cytoplasm by other proteins, 
which also prevents it from binding to the NRSE altogether (Zuccato et al., 2003; Lunyak 
& Rosenfeld, 2005). 
Repression by REST begins after the protein’s zinc finger domain binds to a highly 
specific and highly conserved DNA sequence known as the neuron-restrictive silencer 
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element (NRSE) (Figure 1.8). An ATP-dependent chromatin-remodeling helicase 
enzyme called SMARCA4 stabilizes this interaction (Ooi et al., 2006). The canonical 
NRSE binding element is a ~21 base DNA sequence divided into two “half-sites” by a 
variant-size “spacer” region. REST can bind to either or both half-sites, depending on the 
specific locus and the size of the spacer, while maintaining its function (Johnson et al., 
2007). This allows REST to assume a less stressful configuration when binding to the 
DNA molecule (Pavletich & Pabo, 1991; Lee et al., 1989), while simultaneously leaving 
part of the NRSE exposed for potential binding by another transcription factor. As will be 
discussed in detail in the following chapters, we hypothesize that ZNF286 may be 
binding at or near to these exposed half-sites. 
After binding to the NRSE, a Sim3 Interaction Domain located at the N-terminus of 
REST interacts with the Sim3 complex, which recruits several subunits (SAP18, SAP30, 
RbAP46) including histone deacetylases (HDAC1/2) (Roopra, 2000). REST also has 
repression domains on both termini of the protein that bind to histone deacetylation 
complexes for genetic regulation (Roopra et al., 2001). A CoREST-interaction domain 
located at the C-terminus of REST interacts with a CoREST cofactor, which recruits a 
variety of proteins including HDAC1/2, the chromatin remodeling SMARCA4, H3K4 
demethylase LSD1 and H3K9 methylases G9a (Andrés et al., 1999). 
Together, or separately, the co-repressors recruited by Sim3 or CoREST remove 
several gene-activating chromatin modifications and inhibit RNA polymerases, thus 
silencing specific genes as a result of REST’s presence at the NRSE binding site. 
 
Experimental overview 
 
To uncover the functions of the ZNF286 genes, we mapped gene and protein 
expression in human cell lines and tissues, and designed custom siRNA molecules to 
specifically knock down the expression of both paralogs. We also used custom antibodies 
designed to unique portions of each protein to carry out chromatin immunoprecipitation 
followed by high-throughput sequencing (ChIP-seq) in human neuroblastoma cells. 
Putative regulatory targets, defined as differentially expressed genes (DEGs) that are 
flanked by or contain ChIP-enriched binding sites, implicate ZNF286A in the negative 
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regulation of cell proliferation and positive regulation of neuronal differentiation; 
expression of the genes and proteins during neuronal differentiation in culture support 
this functional role. Surprisingly, ZNF286B knockdowns yielded enrichment for many of 
the same genes and very similar functional categories, suggesting that (at least in 
neuroblastoma cells) the KRAB(+) and KRAB(-) versions of the ZNF286 protein do not 
function as an opposed repressor-competitor pair. Possibly due to the deletion and 
insertion following ZNF286B duplication, the two paralogs are expressed differently: 
most notably, ZNF286A is expressed at its highest levels in adult brain, while ZNF286B 
is highest in fetal neural tissues. 
A closer look at the highest affinity ZNF286 binding regions revealed a high 
degree of overlap with both the known recognition motif and ENCODE-measured 
binding sites for REST in neuroblastoma cells. Using electrophoretic mobility assays 
(EMSA), we confirmed that both human ZNF286 proteins indeed recognize the known 
REST binding motif. The predicted functions of the ZNF286 proteins – inhibition of 
proliferation and stimulation of neuronal differentiation – are opposite to the known 
functions of REST (Schoenherr & Anderson, 1995). This fact, combined with the 
observation that ZNF286 proteins rise as REST falls in expression during differentiation 
of neuroblastoma cells, support the hypothesis that the ZNF286 proteins evolved as 
competitive modulators of REST activities in the brain. Given their similar predicted 
functions, we postulate that duplication and divergence of ZNF286B has allowed separate 
regulation of this deeply conserved protein, adding a novel layer of REST modulation in 
fetal and adult brain, as well as other human tissues. 
 
Significance 
 
From an evolutionary perspective, ZNF286B is a perfect example of recent 
KRAB-ZNF segmental duplication, and provides an opportunity to observe the various 
ways in which functional novelty arises in a species (Lynch & Conery, 2000), a classical 
example of this being the modification of duplicates in Antarctic icefish that have led to 
the introduction of antifreeze proteins (Logsdon & Doolittle, 1997; Chang & Duda, 
2012). Few examples are as recently duplicated as ZNF286B, however, as alignment data 
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reveals that ZNF286B is a human-specific gene, especially when taking into account the 
high identity of the inserted FOXO3B pseudogene sequence with the human FOXO3 
gene. From a biological perspective, ZNF286A and B are proteins that seem to work in 
conjunction with REST, which implicates them in several neural pathways. For example, 
knockdown of REST leads to down-regulation of SMARCA2, a gene that codes for 
proteins used in the SWI/SNF chromatin remodeling pathway, the down-regulation of 
which is a phenotype of schizophrenia and leads to abnormal axonogenesis (Loe-Mie et 
al., 2010). Our preliminary data suggest that knockdown of ZNF286A/B up-regulates 
SMARCA2 and other related candidate genes that are conversely regulated by REST. 
The following chapters will elucidate the functions and regulatory activities of 
both human ZNF286A isoforms, ZNF286B and mouse Zfp286, and investigate the 
predicted interactions between the ZNF286 proteins and REST, such that their potential 
role in the pathways of neurite outgrowth and maintenance might be clarified. 
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FIGURES 
 
Figure 1.1. Observed and expected masses for “expensive” human organs. The energy 
requirements of an organ are not proportional to the mass of that organ. The brain, the heart, the 
kidneys, the liver and the gastrointestinal tract collectively constitute only 7% of total body mass, 
but account for almost 70% of the total basal metabolic rate of the body. One way for humans to 
maintain their relatively larger brains without suffering an increase in basal metabolic rates would 
be to reduce the size of another expensive tissue in the body; this would offset the metabolic cost 
of the much larger organ at the expense of the other organ’s mass. This explanation is known as 
the ‘Expensive Tissue Hypothesis’ (Aiello and Wheeler, 1995; Aiello, 1997) and was tested by 
comparing the observed mass of the aforementioned “expensive” organs with the expected mass 
for each organ in average primates, which were then scaled to human body mass. The observed 
masses for each human organ (in an average 65 kg human male) were taken from Synder (1975), 
with the expected organ masses for an average primate having been calculated from the least-
squares regression equations for primates (Stahl, 1965). As can be seen, there is an obvious 
tradeoff between the observed mass of the human brain in relation to its expected mass, at the 
expense of a decrease in the observed mass of human gastro-intestinal tract. Data was calculated 
based on a “standard” 65 kg human male with a BMR of 90.6 W (Aschoff et al., 1971); figure 
modified from Aiello and Wheeler (1995). 
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Figure 1.2. Mammalian brain mass and body mass comparison. The brain mass (g) and body 
mass (kg) of 20 mammals are plotted from smallest body mass (rodents) to largest body mass 
(whales). In all vertebrates, brain size can be found to scale to body size to the 0.6–0.8 power, 
increasing with “negative allometry” (meaning that the values are smaller than those predicted 
through simple “isometric scaling” that is governed simply by the square-cube law). The data in 
this plot are plotted in log-log coordinates, with a regression line drawn through the data points. 
The slope of the regression line represents the exponent of the power function. Perpendicular 
lines can be drawn through the regression line (as has been done with chimpanzee, human, and 
dusky dolphin), with longer distances above (or below) the line representing greater positive (or 
negative) brain size deviations from what would be expected based on average mammalian 
brain:body ratios. As can be seen, humans and dolphins possess much larger brains than would 
be expected for their bodies, while hippos and whales possess much smaller brains compared to 
their large masses. Figure modified from Roth and Dicke (2005); data from Van Dongen (1998). 
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Figure 1.3. Mammalian encephalization quotients. The following diagram plots the average 
encephalization quotients for 38 mammals, arranged in ascending order of magnitude. Depicted 
in the plot are ten non-primate mammals (by genus), nineteen monkeys and great apes (by genus), 
and nine hominids including humans (by species). Encephalization quotient EQ is calculated as 
EQ=Ea/Ee with Ea indicating actual brain size and Ee indicating expected brain size based on the 
proportions of a same-taxon animal ‘standard’. In this case, the cat is used as a standard and has 
an EQ of 1.0 for the purposes of this comparison. Humans, considered to be the most intelligent 
animal, possesses the highest EQ of 7.4-7.8, indicating that the human brain is 7-8 times larger 
than what is expected of an animal its size. This is substantially greater than the EQ of most of 
humans’ closest ancestors – extinct members of the genus homo – that have EQ values only half 
that of humans. However, measuring encephalization has its limits, as can clearly be seen by the 
fact that chimpanzees and gorillas have lower EQ values than squirrel monkeys and capuchin 
monkeys, despite the fact that Great Apes are in general much more intelligent than New World 
monkeys. As such, EQ is not the optimal predictor for intelligence, but may serve as only one 
characteristic that explains humans’ increased intelligence. Mammalian data assembled from 
Haug (1987) and Roth & Dicke (2005); hominid data from Aiello & Wheeler (1995). 
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Figure 1.4. Structure of tandem Krüppel-type zinc fingers displaying the C2H2 motif. 
Individual zinc ions interact with paired cysteine and histidine residues, stabilizing two β-sheets 
and one α-helix (as indicated by the areas within the dotted lines) into the recognizable “finger” 
structure shown here, with the latter containing the DNA-binding interface as indicated in the 
figure at the –1, +2, +3, and +6 positions relative to the helix. The structure of a finger sequence 
motif is represented, with X denoting an amino acid residue of any type with the subscript 
representing the number (ie. X2-4 represents a chain of between 2 and 4 non-specified amino acid 
residues). The consensus sequence – TGEKP(Y/F) – is a highly conserved “H/C link” region 
between consecutive fingers. 
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Figure 1.5. DNA binding properties of tandem C2H2 zinc finger domains. The α-helices of 
KZNF motifs contain amino acid residues that bind to DNA nucleotides at the -1, 2, 3, and 6 sites 
(as described in Figure 1.4), represented here as white dots on the helices of a set of tandem zinc 
fingers. The relationship between fingers and nucleotides is not one-to-one, as the amino acid at 
the +2 position will interact with the nucleotide complementary to the neighboring finger’s +6 
binding site. In this fashion, fingers wind around the major groove of the DNA molecule. 
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Figure 1.6. Mechanism of KRAB-domain repression. Krüppel-type zinc fingers that contain a 
KRAB-domain regulate gene expression by recruiting the KRAB-Associated Protein (KAP-1), 
which has several domains that interact with different co-factors. KAP-1 interacts with KRAB 
through an RBCC (RING Finger-B Box-Coiled Coil) binding domain, which is a common zinc-
finger motif found in over 1500 proteins (Massiah et al., 2007). SUMO (Small Ubiquitin-like 
Modifier) is a 17 kDa ubiquitin-like molecule capable of post-translationally modifying many 
proteins. Unlike ubiquitin, SUMO does not mark proteins for degradation, and follows an 
enzymatic cascade to ubiquitin (Hay, 2005) in the KAP1 pathway. SAE1/2 (SUMO-Activating 
Enzyme Subunits 1 and Subunit 2) act as an E1 SUMO-activating enzyme, after which the E2 
SUMO-conjugating enzyme UCB9 (Ubiquitin Carrier Protein 9) attaches SUMO to the E3 
intramolecular-ligase PHD (Plant Homeodomain) finger domain of KAP-1 (Ivanov et al., 2007). 
Once properly recruited to KAP-1, sumoylation may begin on specific lysines on the adjacent 
Bromodomain. The modified complex is recognized by Histone-Lysine N-Methyltransferase 
SETDB1 and the NuRD (Nucleosome Remodeling and Histone Deacetylation) Complex. 
SETDB1 is a histone-H3 lysine-9 specific methyltransferase (Schultz et al., 2002), and the NuRD 
Complex is a histone deacetylase containing sets of both CHD3/4 (Chromodomain Helicase 
DNA-Binding Proteins 3 and 4) and HDAC1/2 (Histone Deacetylase 1 and 2) (Lai & Wade, 
2011). These interactions are aided by HP1 (Heterochromatin Protein 1), which recognizes an 
HP1-Interacting Domain on KAP-1 and anchors chromatin subunits. Together, these cofactors 
tighten chromatin structure and silence genes that are bound in the heterochromatin. Model 
adapted from Ivanov et al., 2007. 
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Figure 1.7. Structure of ZNF286 and REST. (A) The human ZNF286A protein is a KRAB-
containing Küppel-type zinc finger transcription factor. It contains ten tandem C2H2 zinc finger 
within a DNA-binding domain. A spacer/tether region connects this domain to a KRAB-Box, 
which contains both KRAB-A and KRAB-B protein motifs in ZNF286A. Most mammals also 
produce a KRAB-less alternate transcript that is expressed alongside the KRAB-containing 
isoform. Both isoforms are very conserved in mammals. (B) Similarly, ZNF286B contains a 
nearly identical finger domain with a nearly-identical fingerprint. However, instead of a KRAB-
domain, ZNF286B contains a FOXO3B pseudo-gene insert in its place. As such, ZNF286B does 
not have any known direct regulatory function. (C) REST is also a Krüppel-type zinc finger 
transcription factor, with seven DNA-binding zinc fingers (and one additional, structural, finger). 
At both ends of the protein lie cofactor interaction domains – one for Sim3 and one for Co-REST. 
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Figure 1.8. Mechanism of REST. Repression by REST begins after the protein’s zinc finger 
domain binds to a highly specific and highly conserved DNA sequence known as the neuron-
restrictive silencer element (NRSE). The interaction between REST and the NRSE is stabilized 
by an ATP-dependent chromatin-remodeling helicase enzyme called SMARCA4. SMARCA4 
contains a bromodomain that recognizes acetylated H4K8 and repositions nucleosomes, thereby 
allowing REST to form more stable DNA interactions – simply increasing H4K8 acetylation 
leads to increases in REST recruitment (Ooi et al., 2006). A Sim3 Interaction Domain located at 
the N-terminus of REST interacts with the Sim3 complex, which recruits several subunits 
(SAP18, SAP30, RbAP46) including histone deacetylases (HDAC1/2) (Roopra, 2000). A 
CoREST-interaction domain located at the C-terminus of REST interacts with a CoREST 
cofactor, which recruits a variety of proteins including HDAC1/2, the chromatin remodeling 
SMARCA4, H3K4 demethylase LSD1 and H3K9 methylases G9a (Andrés et al., 1999). 
Together, or separately, the corepressors recruited by SIM3 or CoREST remove several gene-
activating chromatin modifications and inhibit RNA polymerases, thus silencing specific genes. 
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Abstract 
 
ZNF286A is one of only a few members of the large and diverse KRAB-
containing zinc finger gene family represented by a unique ortholog in marsupials and 
most eutherian species. However, this ancient gene gave rise to a single duplicate, called 
ZNF286B, in very recent primate history. Here, we show that ZNF286B arose as part of a 
larger duplication event including many surrounding genes; concomitantly or shortly 
after duplication, a processed FOXO3 pseudogene was inserted into ZNF286B and DNA 
encompassing the KRAB-encoding exons and regulatory sequences was deleted. As a 
result, ZNF286B encodes a human-specific protein with structural differences and a 
distinct expression pattern; most notably, while both genes are most highly expressed in 
human brain, ZNF286A is highest in adults while ZNF286B is expressed primarily during 
fetal development. Chromatin immunoprecipitation (ChIP-seq) and in vitro binding 
assays revealed that ZNF286A and ZNF286B proteins bind preferentially to known 
motifs for the neuronal regulatory factor, REST/NRSF in neuroblastoma cells. 
Furthermore, gene knockdown experiments suggested that despite their structural 
differences, the human ZNF286 proteins act cooperatively to inhibit cell proliferation. 
Intriguingly, REST is known to activate proliferation in neuroblastoma and neural 
progenitor cells; consistently, we show that as REST protein levels fall, ZNF286 levels 
rise during neuron differentiation in vitro. We hypothesize that the ZNF286A evolved in 
mammals as a negative modulator of REST activities, and that the ZNF286B duplication 
allowed for independent transcriptional control and enhancement of this function in the 
developing human brain. 	  
	 37 
Introduction 
 
ZNF268A is a member of the large and evolutionarily dynamic KRAB-ZNF 
family of genes, encoding proteins in which a tandem array of multiple Krüppel-type zinc 
fingers (ZNFs) is typically tethered by a short unstructured sequence to one or more N-
terminal Krüppel-associated box (KRAB) chromatin interacting domains. The ZNF 
arrays in these proteins are thought to function primarily in site-specific DNA binding, 
whereas KRAB (particularly the most common version of this domain, KRAB-A) is 
predicted to function in transcriptional repression through interactions with a ubiquitous 
co-repressor called KAP1 (also known as TRIM28, TF1β, TIF1β, and KRIP-1; Friedman 
et al., 1996; Moosmann et al., 1996; Kim et al., 1996). In vertebrates and especially in 
mammals, the KRAB-ZNF family has expanded through repeated rounds of tandem 
segmental duplication to include hundreds of lineage-specific genes (Chung et al., 2002). 
Differences in KRAB-ZNF copy numbers are seen even between closely related species, 
such as humans and chimpanzees (Huntley et al., 2006; Hamilton et al., 2006; Nowick et 
al., 2011). New duplicates can diverge significantly over relatively short evolutionary 
times, changing in expression pattern, splicing, and/or coding sequence in ways that 
predict distinct functions (Hamilton et al., 2006; Nowick and Stubbs, 2010; Nowick et al., 
2011). 	
ZNF286A is an especially deeply conserved member of this dynamic gene family, 
being one of only 37 human KRAB-ZNF genes with a clear 1:1 ortholog in marsupials 
(Liu et al., 2014). This unusual level of conservation suggests that the gene has acquired 
an essential mammalian regulatory function. However, ZNF286A has given rise to a 
single gene duplicate in very recent primate history; this duplicate gene, called ZNF286B, 
is found in humans but not in the rhesus macaque, orangutan or chimpanzee genomes 
(Nowick et al., 2011). Despite its very recent advent, ZNF286B differs from the parental 
gene in several significant respects. In particular, although the ZNF arrays in ZNF286A 
and ZNF286B are nearly identical, ZNF286B does not include KRAB-encoding exons, 
and instead includes novel exons that are not present in the parental gene. These novel 
features suggest that the duplicates may have evolved distinct functions, with ZNF286A 
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acting primarily as a KAP1-binding repressor and ZNF286B serving a distinct, perhaps 
dominant-negative competitive regulatory role. 
To uncover the functions of the ZNF286 genes, we mapped gene and protein 
expression in human tissues and designed custom siRNA molecules to knock down 
expression of each paralog specifically. Probably due to deletions and insertions that 
accompanied ZNF286B duplication, the paralogs are differently expressed; most notably, 
both genes are expressed at highest levels in brain, but ZNF286A is expressed most 
highly in adults whereas ZNF286B was is dominant in fetal brain. Surprisingly despite 
their structural differences, ZNF286A and ZNF286B knockdowns yielded enrichment for 
many of the same up- or down-regulated genes, suggesting cooperative rather than 
competitive functions. We also used a custom ZNF286A antibody to carry out chromatin 
immunoprecipitation (ChIP-seq), revealing significant overlap between ZNF286 binding 
regions and the known recognition motif for the important neuronal regulator, RE1-
silencing transcription factor (REST), also called NRSF. ChIP-seq with a REST antibody 
confirmed that ZNF286A and REST binding regions overlap extensively in 
neuroblastoma cells; we also demonstrate that ZNF286 proteins bind the REST-binding 
RE-1 motif in vitro, as well as an alternative REST motif (Satoh et al., 2013; Rockowitz 
et al., 2014). However, the dominant function predicted for the ZNF286 proteins – 
inhibition of cell proliferation – is opposite to the known functions of REST in neural and 
neuroblastoma cells (Guardavaccaro et. al., 2008; Negrini et al., 2013). Together our data 
support the hypothesis that the ZNF286 proteins evolved in mammals as competitive 
modulators of REST activities, and that duplication and divergence of ZNF286B provided 
a novel, independently regulated layer of REST modulation in the developing human 
brain. 
 
Materials and Methods 
 
QPCR of cell line RNA: RNA was collected by homogenizing tissue samples or cell 
pellets in TRIzol Reagent (Invitrogen Cat. 15596). Samples were purified and DNase-
treated using the standard Qiagen protocol with RNeasy columns (Qiagen Cat. 74104), 
from which cDNA was synthesized using using M-MuLV Reverse Transcriptase (New 
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England Biolabs Cat. M0253S). QPCR was performed on each sample using sequence-
specific primers (Supplemental Table S2.1A) in Power SYBR Green PCR Master Mix 
(ThermoFisher Cat. 4367659). PCR reactions proceeded using the Applied Biosystems 
7900HT Fast Real-Time PCR System. 
 
Cell line culture and neuroblast differentiation: SH-EP cells acquired from Dr. Martin 
Reick (Reick et al., 2001) were cultured and maintained in DMEM containing 10% fetal 
bovine serum (FBS). Neuro2A cells (ATCC® CCL-131) were grown in DMEM 
containing 10% FBS prior to differentiation, and induced to differentiate at 25-40% 
confluence by replacing growth media with media containing 2% FBS and 20 µM 
retinoic acid, replacing the media every 24 hours, with cells reaching full differentiation 
after 72 hours (Tremblay et al., 2010). SH-SY5Y cells (ATCC® CCL-131) were grown in 
1:1 DMEM/F12 media containing 10% FBS, and were induced to differentiate at 50-60% 
confluence by replacing growth media with DMEM media containing 15% FBS and 10 
µM retinoic acid. Media was replaced every 2-3 days. On the fifth day of RA-treatment, 
cells were washed three times with DMEM, and 50 ng/mL BDNF was added to the media 
(without serum) to maintain division. SH-SY5Y cells are fully differentiated after 6-10 
days (Encinas et al., 2002). SK-N-SH (ATCC® HTB-11) cells were grown in 1X MEM 
media containing 10% FBS, and were induced to differentiate at 50-60% confluence by 
replacing growth media with DMEM (without serum) containing 20 µM retinoic acid. 
Media was replaced every 3 days. SK-N-SH cells are fully differentiated after 6-10 days 
(Preis et al., 1988). Genomic DNA to test human variation of ZNF286B was collected 
from a variety of human lymphoblast and fibroblast cell lines (Supplemental Table 
S2.1B) as supplied by the Coriell Institute, and grown in RPMI 1640 containing 15% 
FBS. 
 
Knockdown using siRNA: Custom siRNA oligonucleotides were designed to target 
ZNF286A sequence 5’-CACCTACCATTCAGTGCTTAT-3’ (Qiagen. Cat. SI04135600) 
and 5’-TAGCAGTACGAACATTGTGAA-3’ (Qiagen Cat. SI03227448). Targets for 
ZNF286B were 5’-TACCATCAATTAAGTTTCATT-3’ (Qiagen Cat. SI05457697) and 
5’-TAACTCTTACCTATTACAGAA-3’ (Qiagen Cat. SI05457704). In addition, the 
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AllStars scrambed siRNA with Alexa Fluor 488 modification (Qiagen Cat. 1027284) was 
used as a negative control (called “siScr” in this paper). SH-EP cells were grown under 
normal growth conditions, and transfection proceeded using 5 nM concentrations of 
siRNA in HiPerFect Transfection Reagent (Qiagen Cat. 301704), following the standard 
protocol. Cells were incubated under normal growth conditions with Opti-MEM I 
Reduced Serum Medium (Gibco Cat. 31985) for 32 hours, then immediately collected for 
RNA and protein collection. 
 
Western blots: Nuclear extract was isolated from freshly pelleted mammalian cell lines 
using the Active Motif Nuclear Extract Kit (Cat. 40010), freezing aliquots of the extracted 
proteins at -80	°C until they were ready for use. Detection of specific proteins was 
accomplished by Western blot using 10% SDS-PAGE gels and between 1-2 µg of nuclear 
extracted protein was used per lane as an input. Primary rabbit antibodies used for 
detection were Rb-α-KAP1 (Abcam Cat. ab10483, 1:1000), Rb-a-Lamin-B1 (Abcam Cat. 
ab16048, 1:2000), Rb-α-RCOR1 (Abgent AP17018A, 1:300), Rb-α-REST (Santa Cruz 
Cat. Sc-25398, 1:500), Rb-α-TBP (Santa Cruz Cat. sc-273, 1:2000), Rb-α-ZNF286A 
(Abgent RB21720, 1:200, custom generated with epitope NGKEPLKLERKAPK), Rb-α-
ZNF286B (Abgent RB21665, 1:200, generated with epitope PLHPAPAREEIKST), and 
Rb-α-ZNF431 (Abgent RB10670, 1:200, epitope CSVDEYKVHKEGYNE). Primary 
mouse antibodies were Ms-α-KAP1 (Abcam Cat. ab22553, 1:1000) and Ms-α-REST 
(Abcam Cat. ab52849, 1:600). Secondary antibodies used were Bovine-α-rabbit IgG-HRP 
(Santa Cruz Cat. sc-2379, 1:3000) and Bovine-α-mouse IgG-HRP (Santa Cruz Cat. sc-
2375, 1:3000). ImageJ (v1.49) was used to measure western blot band density, using the 
standard tools to calculate the area of optical spectrum peaks generated for each band, 
with densitometry values normalized against the control antibody bands of each lane (Tan 
and Ng, 2008; Gassmann et al., 2009). 
 
ChIP-seq: Cells were cross-linked by adding 1% formaldehyde to cell growth media and 
incubated for 10 minutes at room temperature. The cross-linking reaction was quenched 
with 0.125M glycine for 5 minutes at room temperature before washing cells with PBS. 
The cell suspension was washed using 1X PBS with Roche cOmplete™ Protease 
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Inhibitor Cocktail (Roche Cat. 11873580001) and cells collected by centrifugation at 4°C. 
Washed cell pellets were re-suspended with 2ml per ~107 cells in lysis buffer (5% 1M 
Tris-HCl pH8.1, 0.4% 0.5M EDTA pH8.0, 0.5% NP-40, 10% glycerol) with protease 
inhibitor and incubated on ice for 30 minutes. Nuclei were collected and re-suspended in 
300 µl SDS-lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH8.1) with protease 
inhibitor, rotated for 20 mins at 4°C, and sonicated using a Covaris M220 Focused-
Ultrasonicator (Covaris Cat. 500295). The sonicated mixture was centrifuged at 16,000 
rcf. Each sonicated sample was diluted 10-fold with cold ChIP dilution buffer (0.01% 
SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7 mM Tris-HCl pH8.1, 167mM NaCl). A 
total of 75 µl Dynabeads® magnetic beads (Life Technologies Cat. 10009D) were added 
to the 1 mL samples, and incubated for one or more hours 4°C. The beads were 
magnetically separated, and the supernatant was removed for IP. Samples were prepared 
using 10-20 µg of IP-antibody or a non-specific Rb-α-IgG antibody (Santa Cruz Cat. sc-
2027) and incubated for 18 hours at 4°C with rotation. To each solution, 100 µl of 
magnetic particles were added, incubating for 1 hour at 4°C with rotation before 
magnetically separating the beads. Samples were sequentially washed at 4°C using Low 
Salt Buffer (EMD Millipore Cat. 20-154), High Salt Buffer (EMD Millipore Cat. 20-155), 
LiCL Buffer (EMD Millipore Cat. 20-156), and TE Buffer (EMD Millipore Cat. 20-157). 
Magnetic pellets were then re-suspended in 250 µl ChiP Elution buffer (1% SDS, 0.1M 
NaHCO3), incubated for 15 minutes and then magnetically separated, transferring the 
supernatant containing the chromatin complexes. To reverse-crosslink the DNA from the 
proteins, 20µl of 5M NaCl was added to each eluate and incubated at 65°C overnight, 
followed by a one hour incubation at 45°C with Proteinase K (New England Biolabs Cat. 
P8107S) and a 30 minute incubation at 37°C with RNaseA (Qiagen Cat. 19101). DNA 
was recovered by phenol-chloroform extraction and isopropanol precipitation. DNA was 
quantified by Qubit® 2.0 Fluorometer (Life Technologies Cat. Q32866), and 
subsequently used for whole genome amplification using GenomePlex® Complete 
Whole Genome Amplification (Sigma-Aldrich Cat. WGA2). Amplified samples were 
sequenced using the Illumina HiSeq 2500 System. ChIP experiments were conducted in 
duplicate for each antibody, and duplicates were examined for similarity before being 
combined for final peak analysis. A total 38,104,016 of 100 bp single-end mapped reads 
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were analyzed for the ZNF286A ChIPseq experiment and 36,257,606 reads were 
generated from the sonicated input DNA for comparison. REST ChIP-seq was pooled to 
generate 8,851,563 reads and compared to a total of 14,894,269 reads from the input 
control from that experiment. 
 
Computational analysis of microarray and ChIP-seq data: Total RNA from siRNA 
knockdown experiments were labeled and hybridized to Affymetrix HuGene_1.0-st-v1 
microarrays (Affymetrix). Preliminary analysis, including quantitation, RMA 
normalization and gene annotation, was carried out using the Affymetrix Expression 
Console software. Differentially expressed gene lists, determined using a multi-tTest in 
the Bioconductor R package (Gentleman et al., 2004), were corrected for multiple testing 
using Benjamani-Hochberg (BH) correction. Genes with a BH-corrected p value of ≤0.05 
and an absolute fold change of ≥1.5 were collected (Supplemental Table S2.2) and 
analyzed as described in the text. Up- or down-regulated differentially expressed genes 
(DEGs) were examined for functional enrichment using the DAVID program functional 
clustering settings (Huang et al. 2009a). The top listed category from each cluster with 
the lowest false discovery rate was used to describe the clusters in Table 2, with only 
those clusters with an enrichment score of 1.5 reported. ChIPseq data were mapped to the 
human genome (hg19) using Bowtie2 (Langmead and Salzburg, 2012) allowing 1 
mismatch, but otherwise using default settings. Mapped ChIP-seq reads were analyzed 
using the MACS 1.4.2 package (Zhang et al., 2008) to generate peaks in comparison to 
the matched input control. REST ChIP-seq was analyzed using default settings; for 
ZNF286A ChIP-seq we set the –bw at 400 bp to accommodate the slightly longer input 
fragments used in those experiments, with other settings left as default. Genes were 
assigned to peak regions using GREAT version 3.0 (McLean et al., 2010) with “Two 
nearest genes” association rules setting.  
 
Motif identification: To identify enriched motifs, we used a number of different 
programs, all pointing to a similar set of motifs. Representative examples of the enriched 
motifs scored most highly by this suite of programs are summarized in Figure 4A, 
displaying the motifs and p-values derived from MEMEchip, from the MEME suite 
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(Bailey et al., 2009). We used sequence from 200 bp regions surrounding peak summits 
as estimated by MACS as input for each program. MEME input giving rise to motifs 
displayed in Figure 2.4A was selected from the fdr=0 peak sets as described in the text 
(Supplemental Table S2.3). 
 
EMSA: Sense and antisense 40-mer oligonucleotides were designed (Supplemental 
Table S2.1) and annealed together to form double-stranded probes. Biotinylated duplexes 
were annealed together using 1X biotinylated sense strands for every 5X unbiotinylated 
antisense strand, to minimize un-annealed biotinylated products from being detected on 
the membrane. EMSA was performed using the LightShift™ Chemiluminescent EMSA 
Kit (ThermoFisher Cat. 20148), following the manufacturer’s protocol. Samples were 
prepared using 1 µL of biotinylated probe (1:400 diluted from 10 µM stock solution), 5 
µg SH-EP nuclear extract to shift samples, along with 0.5 µL of select antibodies at 
optimized dilutions to super-shift samples. Super-shift antibodies included Rb-α-YY1 
(1:25; Santa Cruz Cat. sc-1703), Rb-α-ZNF286A (1:250; Abgent Cat. RB21720), Rb-α-
ZNF286B (1:250; Abgent Cat. RB21665), and Rb-α-REST (1:15; Santa Cruz Cat. Sc-
25398). If competition was being tested, 1 µL of unbiotinylated probe (10 µM stock 
solution) was added to the sample. Each sample contained 1X Binding Buffer, 50 ng/µL 
Poly(dI•dC), 2.5% Glycerol, 0.05% NP-40, and 5mM MgCl2. Ultrapure water was added 
to a total sample volume of 10 µL. Samples were allowed to sit for 5 minutes before 
being run through a pre-run, 8% native gel, touch-transferred to a nylon membrane for 1 
hour, and cross-linked to the membrane using a 254 nm UV light source for 5 minutes. 
Biotin-labeled DNA was detected by chemiluminescence using 1:3000 Stabilized 
Streptavidin-HRP Conjugate (ThermoFisher Cat. 89880D). 
 
Co-IP: SH-EP nuclear extract was isolated using the Active Motif Nuclear Extract Kit 
(Cat. 40010) for use in co-IP reactions. For samples that were cross-linked prior to co-IP, 
cells were incubated for 10 minutes at room temperature using 0.5% formaldehyde and 
quenched using 0.125M glycine for 5 minutes at room temperature (sensu Kim et al., 
2009) prior to nuclear extract isolation. Co-IPs proceeded using 14 µg of nuclear extract 
using the Pierce™ Co-Immunoprecipitation Kit (ThermoScientific Cat. 26149) and 10 µg 
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of affinity-purified antibodies, coupled to AminoLink™ Plus Coupling Resin 
(ThermoScientific Cat. 20501). Coupling-antibodies used in this study include Rb-α-YY1 
(Santa Cruz Cat. sc-1703), Rb-α-KAP1 (Abcam Cat. ab10483), Rb-α-ZNF286A (Abgent 
Cat. RB21720), Rb-α-ZNF286B (Abgent Cat. RB21665), Rb-α-REST (Santa Cruz Cat. 
Sc-25398), Rb-α-RCOR1 (Abgent AP17018A), Ms-α-KAP1 (Abcam Cat. ab22553), and 
Ms-α-REST (Abcam Cat. ab52849). Co-IP products were eluted by boiling resin for 5 
minutes and running an SDS-page gel for protein detection. For samples using rabbit 
antibodies for immunoprecipitation, mouse antibodies were used for detection, to avoid 
cross-detection of the resin-antibodies. Likewise, rabbit antibodies were used to detect 
samples immunoprecipitated by mouse antibodies. 
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Results 
 
The ZNF286B duplicon includes flanking genes and KRAB-sequence deletion 
The ZNF286A gene is ancient, existing as a unique locus in most eutherian 
mammals and in the genome of the marsupial Monodelphus domestica (Liu et al., 2014), 
while ZNF286B is detected only in the human genome (Nowick et al., 2011). To gain a 
more concise view of gene structure and duplicon history, we compared the two human 
paralogs and surrounding genomic sequences (Figure 2.1). Alignment between the two 
genomic regions showed that ZNF286B is embedded within a larger segmental 
duplication located about 2 million base pairs (Mbp) away from ZNF286A on human 
chromosome 17 (chr17). The duplication spans approximately 600 kb and includes 12 
neighboring genes that are inverted in telomeric-to-centromeric order relative to genes 
surrounding ZNF286A. Contained as they are within this multigenic duplicon, the two 
ZNF286 paralogs share a very similar overall genomic environment.	
In addition, the two genes encode very similar proteins, including tandem arrays 
of 10 C-terminal ZNF motifs; except for zinc fingers 1 and 8 (numbered from N- to C-
terminal positions (Table 2.1) the two proteins have identical amino acid sequences at 
DNA-contacting positions (positions -1, 2, 3 and 6 relative to the alpha helical regions in 
each finger; Choo and Klug, 1994; Wuttke et al., 1997). Surprisingly however, the N-
terminal regions of ZNF286A and ZNF286B predicted proteins differ significantly. First, 
the genomic region encompassing both KRAB-A and KRAB-B-encoding exons of 
ZNF286A has been deleted in the ZNF286B gene (Figure 2.2A). Furthermore, a 
retroposed pseudogene of the chr6 gene FOXO3 was inserted into the duplicated gene, 
positioned directly downstream of the deletion. In fact, ZNF286B co-opted its novel third 
exon, encoding 30 amino acids that are not present in ZNF286A, from this FOXO3B 
pseudogene. This 90 bp open reading frame (ORF) is not a coding sequence in FOXO3 
but rather, overlaps with 5’-untranslated sequences. Furthermore, ZNF286B utilizes a 
novel splice acceptor site that adds a short segment of amino acid sequence derived from 
the intron of ZNF286A and is only included in the ZNF286B protein (Figure 2.2A).  
Interestingly, the deletion that removed KRAB-encoding exons also interrupted a 
predicted enhancer element that is present in a ZNF286A intron, marked by modified 
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histone H3 (H3K4Me1 and H3K27Ac) (Figure 2.2B). However, a novel region marked 
by modified histones and a DNase-sensitive site were brought in by the FOXO3B 
pseudogene insertion (Figure 2.2C). Therefore, despite the fact that ZNF286B arose as a 
very recent copy of ZNF286A, rearrangements in the novel human duplicate have altered 
the predicted protein significantly, and have likely altered regulatory element 
composition of the novel locus as well. 
Despite these and other internal rearrangements, the overall sequence similarity 
across the two gene duplicates is 98.6% for regions flanking the FOXO3B insertion site, 
including several short insertion-deletion events (indels). Similarity between the 
FOXO3B insertion and the parental FOXO3 gene is similar although slightly higher, at 
99% identity confirming a very recent duplication event (not shown). In a previous study 
we used PCR to demonstrate that this juxtaposition of ZNF286 and FOXO3 sequences 
can be detected only in the human genome (Nowick et al., 2011), and a BLAST search 
for a similar fusion event in the updated chimpanzee, orangutan and other primate 
genomes found matches only to separate unique ZNF286A and FOXO3 genes (not 
shown).  
These results prompted the question of whether the current version of the 
ZNF286B gene has been fixed in the human population. To test this hypothesis we used 
the same FOXO3- and ZNF286B-based PCR primers to screen DNA from a panel of 
lymphoblastoid cells from humans of diverse American, African, Asian, and European 
origins. A PCR product of the correct length and sequence was detected in all of the 46 
DNA samples we tested (Supplemental Figure S2.1). These data support the hominin 
(and for extant species, the human) specificity of the ZNF286B locus, and demonstrates 
the fixation of this duplication in the human population, suggesting that local 
rearrangements not only altered protein-coding capacity but also potentially altered the 
expression patterns of otherwise very similar genes. 
 
ZNF286 paralogs are differentially expressed in human tissues 
To examine expression of the two human genes, we compared steady-state RNA 
levels of ZNF286A and ZNF286B transcripts in quantitative RT-PCR (qRT-PCR) 
experiments in a panel of RNA from human tissues. We used primer pairs designed 
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against sequences that are uniquely included in transcripts arising from each gene 
(locations illustrated in Figure 2.2A). These data confirmed that ZNF286A and 
ZNF286B are expressed with different tissue-specific patterns. Notably, of the tissues we 
tested, ZNF286A displayed highest levels of expression in adult brain with relatively 
lower levels in fetal brain (Figure 2.3A), whereas ZNF286B displayed highest levels of 
expression in fetal brain with substantially reduced expression in adults (Figure 2.3B). 
These data therefore indicate that the two human duplicates have indeed evolved distinct 
patterns of tissue-specific expression.  
 
ZNF286A and ZNF286B regulate genes involved in cell proliferation 
Developing paralog-specific reagents 
Our next goal was to identify the functions associated with the two paralogous 
human genes. Our initial hypothesis was that the KRAB-containing ZNF286A should 
function primarily as a repressor, whereas the KRAB-less ZNF286B protein would 
function distinctly, possibly as a “dominant negative” binding competitor to the parental 
protein. This hypothesis would predict that “knockdown” of ZNF286A and ZNF286B 
would produce very different, and potentially opposite, effects on expression of direct 
and secondary target genes. To test this hypothesis we looked for cell lines in which both 
ZNF286A and ZNF286B were expressed at relatively robust levels so that results of 
functional assays could be directly compared. Among the human cell lines we tested, the 
S-type SH-EP neuroblastoma cell line (Reddy et al., 1991) was one of the few that 
expressed relatively robust levels of both ZNF286A and ZNF286B, and we selected this 
cell line for further analysis.  
To test gene function, we designed custom siRNAs targeting the diverged 
transcribed sequences in each paralog. After siRNA treatment for 32 hours, ZNF286A 
RNA was reduced by over 70% of levels in cells treated with a “scrambled” control, 
whereas ZNF286B transcripts levels were not affected significantly. Likewise, ZNF286B 
RNA levels were similarly reduced by over 70% when targeted by custom siRNA, 
whereas ZNF286A transcripts were not affected (Fig 2.3C). These results indicated that 
the reagents were acting relatively efficiently and specifically. 
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We also developed custom rabbit polyclonal antibodies from unique protein 
regions (epitope locations presented in Figure 2.2, and sequences detailed in Methods). 
Both antibodies detected proteins of expected size (~60 kD) in SH-EP cells (Figure 
2.3D). In proteins prepared from nuclear extracts of the siRNA-treated and control cells, 
the proteins were also specifically decreased, confirming specificity of both antibodies as 
well as the efficient knockdown of the proteins in the siRNA experiments (Figure 2.3C). 
 
siRNA knockdown reveals overlapping collections of differentially expressed genes 
We analyzed global gene expression after siRNA knockdown in the SH-EP cell 
line on microarrays using two siRNAs from each gene that gave the highest knockdown 
levels (Figure 2.3). These experiments yielded a total of 261 significant (at least 2x fold 
change; p≤0.05 after correction for multiple testing) differentially expressed genes 
(DEGs) after knockdown of ZNF286A, including 209 up-regulated and 52 down-
regulated unique genes. Knockdown of ZNF286B yielded similar ratios of up- and down- 
regulated DEGs: 300 and 78 respectively (Supplemental Table S2.2). Surprisingly given 
our original hypothesis, DEG lists from the two knockdown experiments were very 
similar, with significant up- or down-regulation of many of the same genes. In fact, 233 
out of 261 DEGs obtained after ZNF286A knockdown (89.2%) were also found on the 
ZNF286B DEG list and all of these genes were differentially expressed in the same 
direction (Table S2). These data indicated that when they are present in the same cell 
types, the two human ZNF286 paralogs serve to regulate the same genes, and in the same 
fashion. The two human genes do not appear to be redundant in function, since the 
knockdown of one gene mimics the effects of knocking down the other. Rather, these 
results suggested that ZNF286A and ZNF286B might in fact act cooperatively and 
dependently when expressed together in human cells. 
Not surprisingly therefore, DEGs in the two experiments were enriched in very 
similar functional categories. Up-regulated DEGs, corresponding to genes that are 
repressed by ZNF286 expression, were very highly enriched in functions generally 
related to mitosis, DNA replication, chromatin structure, and hormone response, whereas 
down-regulated DEGs (activated by ZNF286 expression) were commonly enriched in 
functions related to cellular signaling, and regulation of steroid biosynthesis (Table 2.2).  
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Identification of ZNF286A binding sites and target genes 
We carried out ChIP with the ZNF286A antibody in SH-EP cells, identifying 
1,502 ChIP peaks (False Discovery Rate (FDR)<5% and Enrichment Factor (EF)>5) and 
their nearest genes (Supplemental Table S2.3). Unfortunately the custom ZNF286B 
antibody did not work well for ChIP. However, given the similarity between the 
fingerprints of the two human genes and especially the very similar effects of their 
knockdowns, we identified potential direct target genes by overlapping the list of genes 
nearest ZNF286A ChIP peaks with DEGs from both the ZNF286A and ZNF286B SH-EP 
knockdown experiments (adjusted p-value ≤ 0.05 and absolute value of fold-change 
greater than 1.5). We found 165 peak regions that either flanked or contained DEGs, 
including 50 down-regulated and 74 up-regulated genes (Suppl Table S2.4). Thus despite 
the predominance of down-regulated genes after siRNA knockdown, the genes nearest 
ZNF286A peaks could be either activated or repressed.  
Of note, predicted repressed targets of ZNF286 proteins (siRNA up-regulated), 
were dominated by essential mitotic regulators (including AURKB, NCS1, CLSPN, 
NEK6, CDC25B, CDCA8, E2F7, CKS2, GSG2, SMARCA2). On the other hand, 
positively regulated targets (siRNA down-regulated DEGs located near ChIP peaks) 
included genes involved in neural differentiation and development (ID4, SMAD6, INA, 
TLE3, NEUROD6, SEMA3E, GPRC5B) or adult neuron function (GLRA3, CADM1, 
SYT12, SCG3). Most peaks were distal (>10kb) to the transcription start sites (TSS) of 
the nearest DEGs. However, a small number of DEG TSS (32 genes) was located within 
10kb of ZNF286A peaks. These included 21 up-regulated (e.g. CDC25B, CENPJ, 
SMARCA2) and 11 down-regulated genes (e.g. GLRA3, INA, ID4, SMAD6). 
We validated a selection of predicted target genes in repeat siRNA knockdown 
experiments followed by quantitative PCR to compare experimental samples to the 
appropriate controls. These data confirmed gene expression changes and ChIP peak 
enrichment for several genes and peaks (Supplemental Table S2.5). Together these data 
suggested that ZNF286A and ZNF286B proteins are involved in negative regulation of 
cell proliferation and positive regulation of neuron differentiation and function in 
neuroblastoma cells. 
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Analysis of ZNF286A binding motifs reveals high enrichment for RE-1 motifs 
We examined ZNF286A bound regions identified from the ChIP-seq for evidence 
of a potential DNA recognition motif, and potentially, of evidence for TF binding sites 
that might correspond to interacting TF proteins. We used the MEME suite (Bailey et al., 
2009; Machanick and Bailey, 2011) to derive motifs from 200 bp regions centered at 826 
FDR0 peak summits. The analysis yielded strong enrichment for two sequence motifs. 
The first motif which was present in 199 peaks (E-value 6.7 e-698), showed a remarkable 
level of similarity to the consensus motif for the well known neuronal ZNF TF, REST; 
this protein is also referred to as NRSF, and the binding site called RE-1 or NRSE 
(Figure 2.4A). This motif is centrally located in the ZNF286A peak summit regions and 
detected as high-scoring matches in a significant fraction of the ZNF286A FDR0 peaks 
(199 peaks, or 24%). The RE-1 motif is organized as two adjacent “half sites” with 
variable spacing, which can also bind REST in isolation (Johnson et al., 2007) and a 
number of ZNF286A peaks that did not include the full RE-1 motifs contained one of 
these half sites (91 peaks; not shown).  
In addition to RE-1 a second, distinct G-rich motif was, detected in 46 peaks (E-
value 6.6e-15), was a (Fig 2.4B); this motif is very similar to a G-rich motif identified as 
an alternative binding site for REST in neuronal cells (Johnson et al., 2008; Satoh et al., 
2013). Other than these two motifs, no other significant enrichments were identified. 
Thus, REST motifs are highly enriched within ZNF286A binding regions in SH-EP cells. 
To examine whether ZNF286A peaks also overlap with actual REST binding, we 
examined overlap between ZNF286A peaks and REST binding sites as determined in 
multiple cell types in the ENCODE project, including SH-SY-5Y which is related to SH-
EP (Biedler et al., 1973). Indeed, many of the ZNF286A peak regions coincide with high-
scoring NRSF/REST ENCODE binding sites (Supplemental Table 2.2). However since 
SH-EP was not included in ENCODE ChIP experiments, we carried out ChIP with the 
REST antibody in SH-EP chromatin to permit direct comparison. This analysis confirmed 
that more than half of the ZNF286A binding peaks – a total of 899 of the 1,502 FDR<5, 
EF>5 sites (59.9%), and 607 of the 876 peaks detected at FDR0 (69.3%) – can also be 
occupied by REST in SH-EP cells (Supplemental Table 2.3). The ZNF286A peaks that 
did not overlap with REST binding in SH-EP chromatin were still highly enriched in the 
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RE-1 binding site (with an E-value score of 5.3 e-57) and the G-rich motif as the second 
best match (E-value 6.2e-12), thus showing no clear distinction in sequence between the 
overlapping and non-overlapping peaks. 
 
ZNF286 proteins bind RE-1 and an alternative REST motif 
To confirm ZNF286 binding, we designed 40-mer oligonucleotide duplexes from 
two ZNF286A binding regions. The first region was identified to be centered on a strong 
consensus RE-1 motif (chr20:36255472-36255692); this region is also occupied by the 
REST protein in ENCODE ChIP assays and in our SH-EP ChIP (Supplemental Table 
S2.3). We will refer to this 40-mer as “Oligo1” in the following discussion (Figure 
2.4D). A second 40-mer was designed from a region including the alternative “G-rich” 
motif (chr20:36201383-36201602); this sequence will be referred to as “Oligo2” (Figure 
2.4E). We also generated three unlabeled “competitor” 40-mer duplexes that overlap 
each labeled Oligo sequence in 20 bp steps (downstream competitor [-20], upstream 
competitor [+20], and a direct [0] competitor that completely overlaps the labeled 
oligonucleotide (Figure 2.4D; Figure 2.4E). We incubated the biotin-labeled 40-mer 
with protein extract from SH-EP cells to conduct electrophorectic mobility assays 
(EMSA) with SH-EP protein extracts; we included competition experiments for the 
ZNF286A and ZNF286B super-shift experiments, in order to more precisely determine 
the locations of protein binding within the sequence.  
SH-EP protein incubation caused a clear shift in labeled oligonucleotide mobility 
in the case of both Oligo1 and Oligo2 sequences, indicating that the 40-mers are bound 
by SH-EP proteins (Figure 2.4F). We then completed “super-shift” assays with several 
different antibodies. For example, as a negative control, we used an antibody to a 
ubiquitous zinc-finger protein, YY1, which recognizes a distinct motif and did not shift 
Oligo1 or Oligo2 sequences (Figure 2.4F lanes 3 and 9). As a positive control, we added 
REST antibody to the mixture to complete a “super-shift”, and as expected saw an 
additional upward shift in complex size for both labeled Oligos (Figure 2.4F lanes 4 and 
10). 
Furthermore, both ZNF286A and ZNF286B antibodies generated a clear super-
shift of both Oligo1 and Oligo2 when incubated with the same mixtures (Figure 2.4F 
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lanes 5, 6, 11, and 12). Upon pre-incubation of the protein mixture with the unlabeled 
competitor sequences overlapping Oligo1, ZNF286A super-shift was most significantly 
reduced with upstream and direct competition, indicating a potential binding preference 
for sequences surrounding the 5’-most REST half site. Competition experiments 
confirmed binding within the center portion of Oligo2, which includes the match to the 
G-rich motif (Figure 2.4G). Competition experiments with the ZNF286B antibody, on 
the other hand, suggested a preference for the 3’-most RE-1 half-site and possibly a 
preference also for the 5’ side of the G-rich motif (Figure 2.4H).  
 
ZNF286A binds to KAP1 but not REST in SH-EP cells 
Together these data show that ZNF286A protein can occupy binding sites that 
overlap with the known REST canonical and non-canonical motifs, and that both 
ZNF286A and ZNF286B proteins can both bind to those motif sequences in vitro. One 
possible explanation for this finding is that the ZNF286 proteins interact with REST, 
either binding indirectly to the RE-1 sites through REST interaction or binding directly, 
but adjacent to the REST protein at bound sites. In either case one would expect that the 
two proteins might be detected as interacting intimately in SH-EP cells. A third 
possibility would be that the ZNF286 proteins compete with REST for binding and 
exclude it from engagement with the binding sites; in this case interaction would not be 
expected. 
To examine these possibilities, we used co-immunoprecipitation (co-IP) in SH-EP 
protein extracts. We carried out reciprocal co-IP experiments, first pulling down REST 
with the anti-REST antibody, and then staining eluted proteins on a western blot to query 
the possible presence of ZNF286A, while also carrying out IP with the ZNF286A 
antibody and staining co-IPed proteins with an antibody for REST (Figure 2.5A). In 
repeated attempts to demonstrate interaction between the proteins, we could find no 
evidence of direct binding between REST and ZNF286A. This included attempts to trap 
each protein in immuoprecipitations with each other antibody after cross-linking, which 
would trap the two sequences on the same DNA fragments or more solidly, through 
covalently linked protein:protein bonds. Since interactions were also not detected after 
cross-linking (not shown), we conclude that ZNF286A and REST proteins do not interact 
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intimately in SH-EP cells. This was surprising considering how closely ZNF286A and 
REST would be juxtaposed if located on the same binding site at the same time; the co-
IPs were repeated using cross-linked SH-EP chromatin in case the binding between the 
two proteins was particularly weak and disturbed by the experimental manipulations. 
However, no such binding was observed, further validating the previous co-IP results (not 
shown).	
We also used co-IP experiments to determine whether ZNF286A is able to recruit 
the repressive co-factor KAP1, as it contains KRAB-A and KRAB-B domains. However 
the KRAB-A domain of ZNF286A has an unusual structure suggesting that it might not 
recruit the co-repressor. In particular, it is significantly shorter than the canonical KRAB-
A sequence due to a 5 amino acid deletion near the C-terminal KAP1 interaction region, 
despite the fact that it includes all amino acids known to be critical to KAP1 binding 
(indicated by the asterisks in Table 2.3). To test this function, we carried out co-IP 
experiments using nuclear extracts with SH-EP proteins. In addition to the ZNF286A and 
ZNF286B antibodies, we also included two controls: (1) an antibody designed against 
another KRAB-ZNF protein with a canonical KRAB domain, ZNF431, as a positive 
control, and (2) the YY1 antibody as a negative control.  
These results indicated clearly that despite its unusual conserved structure, the 
ZNF286A KRAB-A domain efficiently recruits KAP1 (Figure 2.5B). In contrast, as 
expected, ZNF286B does not recruit the co-repressor. The available literature about 
KAP1 function would predict that through KAP1 binding, ZNF286A should possess 
histone deacetylase (HDAC) recruiting activities similarly to REST, which is also known 
to recruit HDAC to repress target genes (Huang et al., 1999; Ballas and Mandel, 2005). 
 
Opposite expression of ZNF286 proteins and REST in differentiating cells 
These data suggested that ZNF286 proteins might compete with REST binding at 
RE-1 sites. REST is well known to be involved in neuronal differentiation, and was 
originally described as a negative regulator of neuronally-expressed genes in neuroblasts 
and non-neuronal cells (Schoenherr and Anderson, 1995). More recently REST has been 
demonstrated to play a wider role in stem cell development, acting in neurons to 
stimulate cell proliferation thus preventing neuronal commitment (Jørgensen et al., 2009). 
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To ask how the ZNF286 proteins are expressed during neuron differentiation, we 
examined two additional neuroblastoma lines, SH-SY-5Y and SK-N-SH, both of which 
undergo neuronal differentiation in culture when treated with retinoic acid (RA) (Sidell et 
al., 1983; Encinas et al., 2000). In fact, although SH-EP does not respond to RA 
treatment, SH-EP and SH-SY-5Y were both originally derived as subclones of the SK-N-
SH line (Biedler et al., 1973). REST transcripts are produced throughout differentiation 
in these cell models; however, the REST protein is rapidly degraded after synthesis in the 
differentiating cells, and therefore protein levels decline once the cells are committed to 
neuronal lineages (Nishimura et al., 1996; Chen et al., 1998). 
We treated SH-SY-5Y cells with RA and examined expression of ZNF286A and 
ZNF286B proteins over the course of 8 days of differentiation. ZNF286A was 
dramatically increased by the end of the differentiation period (approximately 6.3 fold 
according to densitometry, Figure 2.5D; Supplemental Table S2.4); ZNF286B was also 
up-regulated but more modestly, to approximately 2.9 fold. REST, on the other hand, was 
expressed at highest levels in the undifferentiated cells with protein expression dropping 
dramatically as differentiation nears completion (by day 8 of differentiation; a reduction 
to a ratio of 0.13 relative to day 0, or a change of -7.69 fold) consistent with the published 
reports. RA treatment of the parental SK-N-SH cell line yielded very similar results (not 
shown). The up-regulation of ZNF286A and B proteins, on the one hand, and down-
regulation of REST on the other, is consistent with the idea that these proteins exert 
opposite functional effects on neuron development. 
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Discussion 
 
ZNF286A is an unusual member of the mammalian KRAB-ZNF gene family, having 
arisen in marsupial lineages and having been highly conserved throughout most of 
mammalian history. Unlike most other members of the mammalian KRAB-ZNF gene 
family, ZNF286A was maintained as a unique gene, suggesting an essential function and 
important interactions that ruled out profligate expansion. The retroposition of the 
FOXO3B pseudogene into the ZNF286B sequence, which may or may not have occurred 
concomitantly with the duplication, is arguably a hominin-specific event; as detailed here 
this insertion event changed protein structure and also altered regulatory elements within 
the gene that may explain the novel pattern of ZNF286B expression. Therefore, 
regardless of the precise timing of duplication, the modern version of ZNF286B is very 
likely to be human-specific; our data also indicate that this novel TF gene has been stably 
fixed in the human population. 
Fortunately, these structural innovations provided us with the means to examine 
and target ZNF286A and ZNF286B transcripts and proteins specifically. We began with 
the hypothesis, based on the widely accepted notions of KRAB-KAP1 function (Schultz 
et al., 2001; Urrutia, 2003), KRAB-containing ZNF286A and KRAB-less ZNF286B 
should have distinct regulatory functions. Specifically, despite containing an unusual and 
truncated KRAB domain, the ZNF286A protein does interact with KAP1 in SH-EP 
neuroblastoma cells and thus, theoretically, should function as a potent transcriptional 
repressor. On the other hand, ZNF286B – with very similar zinc fingers but no KRAB 
domain – should be able to bind to ZNF286A binding sites but not to exert a repressive 
function. 
We were thus surprised to find that siRNA knockdowns of ZNF286A and 
ZNF286B led to differential expression of very similar sets of genes, a result suggesting 
cooperative rather than competitive function. In both cases, most DEGs were up-
regulated and very highly enriched in functions related to DNA replication, chromosome 
structure, cell-cycle checkpoint activities and cytokinesis. The results point clearly to the 
hypothesis that human ZNF286A and ZNF286B commonly work to negatively regulate 
cell cycle progression in SH-EP cells.  
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Intriguingly - especially given the high levels of overlap we discovered between 
ZNF286A and REST binding regions and motifs - those same functions, and many of the 
same genes, are known to be activated by REST in neuroblastoma and other types of 
neural cells (Su et al., 2004; Tomasoni et al., 2011; Pozzi et al., 2013). However, co-
immunoprecipitation experiments provided no suggestion that REST and ZNF286A or 
ZNF286B interact, either directly (as tested in native protein extracts), or indirectly 
through adjacent DNA binding (as tested after trapping the proteins to cross-linked 
chromatin).  
Although other explanations are possible, together these data suggest that 
genomic binding sites may be occupied either by REST or by ZNF286 proteins in a 
particular cell. The results are most consistent with a model in which ZNF286 proteins 
compete with REST by excluding or inhibiting stable REST binding at occupied RE-1 or 
G-rich sites. Such a competitive model would be consistent with opposing functions, such 
as the opposite effects of ZNF286 proteins and REST on genes promoting the 
progression of mitosis. In further agreement with this either/or competitive model, we 
found that while REST decreases during neuroblastoma cell differentiation in vitro, 
ZNF286 proteins rise in the same cells.  
Given these findings, what can we predict about the functions of and interactions 
between human ZNF286A and ZNF286B? Certainly, we found no evidence of 
competitive function and rather -with siRNA knockdown of one gene virtually equivalent 
to knockdown of the other, and with EMSA suggesting “side-by-side” occupancy at 
adjacent REST motifs (as shown in Figure 2.4) - our data are indicative of a positive, and 
likely cooperative function. If this model is correct, KRAB-less ZNF286B could 
“borrow” KAP1 interaction and regulatory function through cooperative binding with 
ZNF286A. 
However, present evidence does not support the idea that KAP1 binding translates 
simply into repression of nearby genes. On the one hand, the majority of all DEGs 
including most DEGs closest to ZNF286A peaks (21 of 32 genes) were up-regulated in 
siRNA experiments; this is consistent with repression by ZNF286A. Furthermore, several 
of these have important mitotic functions and their release from repression could explain 
the overwhelming signal of cell-cycle up-regulation in the overall DEG set. For example, 
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up-regulated DEG CDC25B is a well-known positive regulator of cell-cycle progression 
with a special role in nervous system development (Agius et al., 2015). However, another 
11 DEGs near ZNF286A peaks are down-regulated, and these also include some 
intriguing candidates. For example, down-regulated DEG, INA, with both ZNF286A and 
REST binding sites located 1876 bp downstream of its TSS, encodes the alpha-internexin 
component of intermediate neurofilaments with a role in neurite outgrowth; through 
REST binding to this intronic enancer, INA is known to be negatively regulated by REST 
(Ching and Liem, 2009). Therefore this down-regulated DEG is also likely to have a real 
regulatory interaction with ZNF286A.  
This leaves us with a puzzle regarding the regulatory functions of ZNF286A in 
living cells. KRAB repressive functions have are well documented, although mostly in 
studies involving over-expressed, engineered proteins in vitro (e.g. Moosmann et al., 
1996; Okumura et al., 1997; Peng et al., 2000). But genome-wide binding sites have been 
determined for only a handful of KRAB-ZNF proteins, and in even fewer cases have 
binding sites and target gene expression been compared. In the first-published study of 
this type, the authors concluded that ZNF263, a KAP1- binding KRAB-ZNF protein, can 
serve either to activate or repress neighboring target genes (Frietze et al., 2010). It is 
possible then, that like ZNF263 and also like REST (Negrini et al. 2013; Rockowitz et 
al., 2014; Baldelli and Meldolesi, 2015), the ZNF286 proteins function neither as classic 
repressive or activating TFs but modulate chromatin environment in a more complex, 
context-dependent mode. It is further possible to imagine a complex relationship between 
ZNF286 and REST proteins, dependent upon the balance of isoforms, paralogs and 
interacting proteins expressed in particular types of cells. 	
These data highlight ZNF286 proteins as a novel, mammalian-specific 
competitors of REST. Given suggestions of cooperative ZNF286A:ZNF286B binding 
and functions developed here, we speculate that cooperation between KRAB- and 
KRAB-less ZNF286 isoforms – the latter of which is generated in some cellular contexts 
by human, mouse and other mammalian genomes through alternative splicing – may be a 
natural property of this ancient protein. Furthermore we speculate that ZNF286B has 
evolved in recent primate history to provide an independently transcribed and regulated 
KRAB-less partner for this cooperation. In this model, ZNF286B has evolved to 
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supplement the ancestral protein’s functions in modulating REST’s control of cell cycle 
exit and neuron progenitor cell differentiation in the developing human brain. 	  
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FIGURES 
 
Figure 2.1. Duplicon located at human chromosome 17. A Blastz nucleotide alignment dotplot 
assembled by zPicture (Ovcharenko et al., 2004) of the ~600 kb long duplication that spans 
chr17:15300000-15900000 and chr17:18300000-18900000 and includes 12 neighboring genes, 
all of which are inverted in telomeric-to-centromeric order relative to ZNF286A. Dots correspond 
to identity between the sequences represented on the X- and Y-axes. The coordinates representing 
the locations of ZNF286A and ZNF286B are indicated by the space within the dotted lines, along 
with representations of the corresponding genes at the X- and Y-axis boundaries of the box. The 
non-duplicated region of ZNF286B that differs from ZNF286A is colored red, corresponding to a 
gap in the dotplot. 
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Figure 2.2. Insertion of FOXO3B into ZNF286B after duplication. (A) Domains regions for 
ZNF286A and ZNF286B are represented with letters above each exon: 5’ UTR (“5”), pre-KRAB 
region (“P”), KRAB-A (“A”) and KRAB-B (“B”) domains, the tether region (“T”), zinc finger 
domain (“F”), and the 3’ UTR (“3”). In addition, roman numerals below each gene represent the 
locations of primers, antibody epitopes, and siRNA targets used in this study: (i) ZNF286A 
forward primer; (ii) ZNF286A reverse primer; (iii) Abgent RB21720; (iv) Qiagen SI04135600; (v) 
Qiagen SI03227448; (vi) Abgent RB21665; (vii) SI05457704; (viii) ZNF286B forward primer; 
(ix) ZNF286B reverse primer; (x) Qiagen SI05457697. The FOXO3B sequence (colored in red) 
was inserted into ZNF286B at the location of a hAT-Charlie Charlie1a DNA repeat element, 
splitting it in two and end-capping the insertion. FOXO3B contains 98% identity with the 
originating FOXO3 gene. The figure shows ZNF286A, the hypothetical duplicate deletion product 
prior to FOXO3B insertion, and ZNF286B containing the pseudogene insertion in red. (B) 
Representations of both ZNF286A and (C) ZNF286B from the UCSC Genome Browser 
(ENCODE Project Consortium, 2012; Raney et al., 2014), along with the “Conservation: 
Vertebrate Multiz Alignment & Conservation (100 Species)” track, show that the highest levels of 
conservation are located in the finger exons and inter-exon region between the promoter and 
KRAB-A domain. The FOXO3B region has high levels of conservation carried over from the 
more ancient FOXO3 gene. In addition, histone modification in both genes is represented from 
the “ENCODE Regulation Super-track”, showing where H3K4Me1 and H3K27Ac histone 
modification is suggestive of enhancer activity. These histone modifications have similarly been 
conserved between ZNF286A and ZNF286B, but it is important to note that the FOXO3B region 
of ZNF286B has histone modifications that may indicate novel regulatory activity following the 
insertion event. Each histone mark uses colored transparent overlays to display data from a 
number of cell lines, outlined in the figure key at the bottom of the figure. 
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Figure 2.3. Relative expression of ZNF286 transcripts in adult and fetal human tissues. The 
expression of both (A) ZNF286A and (B) ZNF286B transcripts in various human tissues was 
determined by performing QPCR on each sample using sequence-specific primers for each gene. 
The 2-ΔCt values for each sample were calculated in relation to GAPDH positive controls (Livak 
and Schmittgen, 2001) and then normalized against the highest-expressed tissue for each primer 
set, in order to minimize primer-specific effects when comparing both genes. Samples are ordered 
from highest-to-lowest ZNF286A expression, with fetal/placental samples separated. The relative 
expression of ZNF286A and ZNF286B is not identical: ZNF286A expresses higher in adult brain 
than in fetal brain, while ZNF286B is expressed significantly higher in fetal brain compared to 
adult brain. (C) Using custom-designed siRNA oligonucleotides, knockdown of ZNF286A and 
ZNF286B was conducted in SH-EP neuroblasts over the course of 32 hours. Scrambled siRNA 
oligonucleotides (“siScr”) and transfection reagent with no siRNA (“0si”) were used as negative 
controls. This knockdown was validated using QPCR, with RNA expression independently 
calculated as a percentage siScr (which is set as 100% for each primer set), revealing 70-80% 
knockdown of target RNA after 32 hours of treatment, with minimal comparable effect of the 
paralog gene, confirming that the siRNA knockdown is specific to ZNF286A and ZNF286B. (D) 
Western blots detected protein expression for ZNF286A, ZNF286B, and REST in the knockdown 
samples, using control α-TBP antibody (Santa Cruz Cat. sc-273). Decrease in levels of the 
appropriate protein was observed for each knockdown, validating knockdown and additionally 
demonstrating antibody specificity for the custom αZNF286A and αZNF286B antibodies. 
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Figure 2.4. ZNF286 binding motif analysis and EMSA. ZNF286 binding motif analysis and 
EMSA. (A) The consensus REST binding motif is split into two “half-sites”, both of which REST 
is capable of binding (Schoenherr et al., 1996; Thiel et al., 1998). (B) ChIP-seq was performed on 
ZNF286A using ChIP-grade polyclonal rabbit antibodies; the highest-ranked binding motif 
prediction (called “Motif1”) was identified using the MEME suite (Bailey and Elkan, 1994) was 
found to match with the REST consensus binding site. (C) A secondary G-rich binding motif was 
predicted by MEME (called Motif2). (D) An example of Motif1 was located in the human 
genome (chr20:36255472-36255692) and used as the basis for the EMSA probe (“Oligo1”) that 
included a 10 bp buffer on each side of the binding motif. Five unbiotinylated probes were 
designed, acting as direct binding competitor “0”, a direct downstream competitor “-20”, a more 
distant downstream competitor “-30”, upstream competitor “+20”, and a more distant upstream 
competitor “+30”. (E) Similarly, an example of Motif2 was identified in the genome 
(chr20:36201383-36201602) and used as the template for an EMSA probe (“Oligo2”), with the 
five competition probes shown. (F) EMSA using Oligo1 and Oligo2, after being super-shifted 
using specific antibodies shows that all three proteins bind to the predicted binding motifs in SH-
EP, with YY1 serving as a negative control. (G) When the competitor probes were included in the 
mixture with the biotinylated probe and super-shifted with ZNF286A, the signal strength 
decreased as predicted for both oligos. (H) Likewise, super-shifted ZNF286B signal strength was 
affected by exposure to the five competition probes. 
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Figure 2.4 (Continued) 
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Figure 2.5. Validation of function by co-immunoprecipitation and RA-differentiation. Co-IP 
with 14 µg of input SH-EP nuclear extract (“SH-EP”) used for the IP, negative control using 
Pierce coupling resin (“Neg. Ctrl.”) and IPs with Rb-α-KAP1, Rb-α-ZNF431, Rb-α-YY1, Rb-α-
ZNF286A, Rb-α-ZNF286B, and Rb-α-REST. (A) REST-pulldown for each IP reaction was 
detected by Western blotting with Ms-α-REST (1:400) – REST is only detected in IPs for REST, 
confirming that there are no protein-protein interactions between REST and either ZNF286 
protein. (B) KAP1-pulldown for each IP reaction was detected by Western blotting with Ms-α-
KAP1 (1:1000) – KAP1 is confirmed in IPs for KAP1 and ZNF431 (a consensus-KRAB 
containing zinc finger transcription factor) as positive controls, while absent in YY1 negative 
control. KAP1 co-IPs with ZNF286A, confirming that it has a functional KRAB-domain, but is 
absent from ZNF286B and REST pull-downs as predicted, failing to demonstrate any protein-
protein interactions with those proteins and KAP1. (C) Positive control co-IP using Ms-α-REST 
(1:600) to confirm REST-RCOR1 interactions, demonstrating the efficiency of the REST 
antibody used in this study. Input SH-EP nuclear extract used for the IP (“SH-EP”), along with 
IPs using Rb-α-REST , Rb-α-RCOR1, Rb-α-YY1, Rb-α-ZNF286A, and Rb-α-ZNF286B. The 
REST-RCOR1 interaction was detected, confirming Co-IP using the Ms-α-REST antibody. (D) 
ZNF286A and ZNF286B (top two panels) increase over the course of RA-differentiation in SH-
SY5Y neuroblastoma cells (which are fully differentiated after 7 days of retinoic acid (RA) 
exposure); densitometry confirmed a rise at 8 days compared to 0 days of RA treatment of 6.3 
and 2.9-fold increase in protein levels respectively (Suppl. Table S4). In contrast, REST protein 
(third panel) decreased significantly (7.7 fold) over the same period of differentiation. The total 
protein amount for each time point was normalized to detected levels of Lamin-B1 (bottom 
panel).v 
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TABLES 
 
Table 2.1. Alignments of the four DNA-binding amino acids (“fingerprints”) of each of the ten 
ZNF286 fingers shows that they have very high identity between organisms, as well as between 
ZNF286A and ZNF286B in humans. Non-identical nucleotides are color-coded in red. The high 
conservation of ZNF286 fingerprints implies that the DNA-binding sites for these proteins are 
also conserved, as their binding affinity is fingerprint-specific. As such, the binding motifs for 
ZNF286A and ZNF286B is predicted to be the same. 
 
Table 2.1. Alignment of DNA-contacting residues in ZNF286A and ZNF286B fingerprints 
Finger Number: 01   02   03   04   05   06   07   08   09   10 
ZNF286A - HUMAN 
ZNF286B - HUMAN 
Znf286  – CHIMPANZEE 
Znf286  - MACAQUE 
Znf286  - ORANGUTAN 
Znf286  - PANDA 
Znf286  - CATTLE 
Zfp286  - MOUSE 
Znf286  - OPOSSUM 
 
YHVR HRNK ESST RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
CHVQ HRNK ESST RSHQ HSAK HCSK QSHQ QSNK HSAQ CSSR 
YHVR HRNK ESST RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
YHVR HRNK ESST RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
YHVR HRNK ESST RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
YHVR HRNK ESSI RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
YHVR HRNK ESSI RSHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
YRVR HRNK ESSV RSHQ HSAK HCSK QSHQ RSNK HSAQ SSSR 
YHVR HKNK ESAE RTHQ HSAK HCSK QSHQ RSNK HSAQ CSSR 
  *  * ** **   **** **** **** ****  *** ****  *** 
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Table 2.2. The Database for Annotation, Visualization and Integrated Discovery (DAVID) is a 
functional annotation tool used for analyzing gene enrichment, and describes biological patterns 
found in a user-inputted gene list (Huang et al., 2009a; 2009b). This table summarizes data 
generated by DAVID, including the functions of genes (GO term clusters) that Illumina 
microarrays indicate are enriched after ZNF286A or ZNF286B knockdown. Here, results are 
shown at enrichment > 2.0 levels, although results were comparable at high, moderate, and low 
enrichment stringencies (>1, >1.5, and >2 respectively). 
 
Table 2.2. Functionally enriched categories in DEGs detected at ≥2 fold change after 
ZNF286A and ZNF286B gene knockdown. 
siRNA Effect ZNF286A ZNF286B 
 
Up-Regulated 
 
DNA replication 
DNA metabolic process 
Cell cycle 
Chromosome organization 
Steroid biosynthesis 
ATP binding 
Cell cycle checkpoint 
Condensed chromosome 
DNA recombination 
DNA helicase activity 
Chromosome segregation 
DNA integrity checkpoint 
Response to endogenous stimulus 
 
DNA replication 
Cell cycle  
DNA metabolic process 
Chromosome organization 
DNA recombination 
Condensed chromosome 
Steroid biosynthesis 
ATP binding 
Homologous recombination 
Interphase of mitotic cell cycle 
DNA helicase activity 
Double strand break repair 
Microtubule-based process 
Cell cycle checkpoint 
Response to endogenous stimulus 
 
 
Down-Regulated 
 
Regulation of steroid 
biosynthesis 
Extracellular region 
Gonad development 
 
Secreted/signal 
Response to hormone stimulus 
Ureteric bud development 
Negative regulation of cell 
proliferation 
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Table 2.3. Comparison table of the amino acids making up the KRAB-A domains among 
ZNF286 orthologs in human, common chimpanzee, rhesus macaque, Sumatran orangutan, giant 
panda, cattle, house mouse, and opossum. These domains are further compared to the human 
KOX1 (also known as ZNF10) domain, with non-identical amino acids colored red. In relation to 
the consensus KRAB domain present in KOX1 which contains the consensus amino acids at the 
top of the table, present in >90% of KRAB-A domains (Witzgall et al., 1994), alignments of the 
ZNF286A KRAB-A domain show that it is somewhat unique among KZNF proteins in that it 
possesses a four amino acid deletion that is conserved across all mammalian species. Only 
targeted deletions in the DV and MLE amino acids of the consensus KRAB-A (underlined) have 
been shown to negatively impact KRAB-A interactions with KAP-1 (Margolin et al., 1994; Lim 
et al., 1998), so the deletion present in ZNF286 proteins is not predicted to have substantial 
impact on domain function. 
 
Table 2.3. KRAB-domain alignment of ZNF286 proteins and the canonical domain of KOX1 
CONSENSUS KRAB-A:    F DV   F  EEW  L   Q LY   VMLEN   L 
KOX1    - HUMAN 
ZNF286A - HUMAN 
Znf286  – CHIMPANZEE 
Znf286  - MACAQUE 
Znf286  - ORANGUTAN 
Znf286  - PANDA 
Znf286  - CATTLE 
Zfp286  - MOUSE 
Znf286  - OPOSSUM 
 
MVTFKDVFVDFTREEWKLLDTAQQIVYRNVMLENYKNLVSL 
TVTFKDVAMDFTPEEWGKLDPAQ----RDVMLENYRNLVSL 
TVTFKDVAMDFTPEEWGKLDPAQ----RDVMLENYRNLVSL 
TVTFKDVAMDFTPEEWGKLDPAQ----RDVMLENYRNLVSL 
KVTFKDVAMDFTPEEWGKLDPAQ----RDVMLENYRNLVSL 
SVTFKDVAMDFTPEEWGKLDPTQ----REVMLENYRNLVSL 
SVTFKDVAMDFTPEEWGRLDPTQ----RDVMLENYRNLVSL 
AMTFKDVAMDFTPEEWGKLDPAH----RAVMLENYRNLVSL 
-VTFKDVAMDFTPEEWGQLDPAQ----RDVMLENYRNLVSL 
  *****  *******  **       * ****** ***** 
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SUPPLEMENTARY FIGURES 
 
Supplemental Figure S2.1. Human variation of ZNF286B. FOXO3B- and ZNF286B-based PCR 
primers used in Nowick et al. (2011) were used to screen genomic DNA from a panel of 
lymphoblastoid cells from humans of diverse American, African, Asian, and European origins. 
All 46 cell lines used are outlined in Supplementary Table S2.1B. The 564 bp product is 
consistently produced in all samples, demonstrating the fixation of ZNF286B among the human 
population. 
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SUPPLEMENTARY TABLES 
 
Supplemental Table S2.1. Primer and probe sequences 
Gene Target FWD Primer (5’-to-3’)  RVS Primer (5’-to-3’) 
ARAP1  CTCCCACGTGGCTGCCATCG  GCGGTCAGGCTGCTCTGAGC 
EGFR  CTGTGCCCAGCAGTGCTCCG  GGCAGACCAGGCAGTCGCTC 
GAPDH  Qiagen Cat. QT01192646 
GRIA4  TGCTCCATGGGGCCAGGGAA  AGCAGCTGTGTCATTGCCAAGAGT 
HOMER1  CGCTGTCTCCTCCGCAAAGCA  CCACCCCCACCCCCAGATCC 
KCNH7  TTGTGCGCGTGGCCAGGAAA  TGCAAGCCAGCCAGTGAGCA 
MIR9-3  TGTCTGTCCATCCCCTCTG   GCTTTATGACGGCTCTGTGG 
NCS1  ACCCGTCCATTGTGCAGGCG  AGCCGGCTGTGTGTGGATGC 
NRG1  GGACTCGCTGCTCACCGTGC  TTCCGGCCCGTCTCCAGAGG 
NRXN3  TCCACCTCTTCCTCGCCGGG  TAGCGCCAGCGTGTCCTCCT 
REST  TGGGGCCTGCTCCCACAGAG  GCAGGCCGTATCTGGGCACC 
SNTG1  CGGGAGCAAGACCCCCTCCA  CCGTCGGTCCAGCAGGTCAC 
TLE3  GACGCCCCAACTCCAGGCAC  CGAAGGGCGCCGCATAGGAG 
ZNF286A  TGTGAGGCCCGGGATGGGAG  TGCCTCAGTCCTACGGCGCT 
ZNF286B  GCCATTCAGTGCATATTCAACACCAG  TACACTCATAGGGTTTCTCTCCAGTGTGA 
 
Peak Target FWD Primer (5’-to-3’)  RVS Primer (5’-to-3’) 
ARAP1  ACCCTCGGCCTAGCTCAGGC  GCTGCCCCTTGCCCTCTGTG 
EGFR  ACTGCGTCCTCCTGGAAGAGGT  TGCACATCTGAGGAAGTGGGGAGG 
GRIA4  ACTGCCTACATTGTCCCCACATCCT  TGTGAGCTAGCCAAGTCAGGCACT 
GRM1  CGGCGAGAGCAACCCGGAAG  TTGTTTCCCGCGGTGGGTGG 
HOMER1  GAGGGCACGGTGAGGGCAAC  ACACTTTACTGGTCAGACTGCTGCA 
KCNH7  TGCAGCTGTGCTTGGGAGACG  TGTCCCTGGTTGGTTGTAGGCAGA 
MIR9-3  CCCTGAGGGAAACGCGGAGC  TCACCGGCAAACTCGCTGGG 
NCS1  TGCAGCCATTGGGAAGCCGT  GCTGACCAACGCTGGGGGTG 
NRG1  TCTTCCGGGAGCTATCCACGGT  GGTTTGTTTTGCGGGGTTACAGGA 
NRXN3  TGGGGGTGGACCTCTCCATGG  TCCTGGCAGGGCCAGTGAGT 
PCSK1  GCCCACACACGATGAGCCCT  TGGGAATGGCCTGGGTCACCA 
SMARCA2 GGCGGGGTGAGAGTAGAAATATCCT  AGCAGCATGGTTTGGAGCAGTCT 
SNTG1  GCTTAGGGGCTCCCGTCCCC  CCGGGAGGCGAGGGGGTAATA 
TLE3  TGACCAGCCAACCGTCCTGGT  CGGCTGGCCACCCTATGAGGA 
 
EMSA Probe (S/AS) 40-mer Sequence (5’-to-3’) 
Oligo1_Probe_S /5BiodT/GCCAATACCATTCAGCACCACGGACAGAGCCACGCTCTGA 
Oligo1_Probe_AS TCAGAGCGTGGCTCTGTCCGTGGTGCTGAATGGTATTGGC 
Oligo1_[-20]_S GCAGAAGCACCACAGACAGCGCCAATACCATTCAGCACCA 
Oligo1_[-20]_AS TGGTGCTGAATGGTATTGGCGCTGTCTGTGGTGCTTCTGC 
Oligo1_[0]_S  GCCAATACCATTCAGCACCACGGACAGAGCCACGCTCTGA 
Oligo1_[0]_AS  TCAGAGCGTGGCTCTGTCCGTGGTGCTGAATGGTATTGGC 
Oligo1_[+20]_S CGGACAGAGCCACGCTCTGACGTCTTCTGCAGAAAAGTCC 
Oligo1_[+20]_AS GGACTTTTCTGCAGAAGACGTCAGAGCGTGGCTCTGTCCG 
Oligo2_Probe_S /5BiodT/AACTCTCAGAAGAAAGGGGAAAGAGAGGCGAGGCTTTAAG 
Oligo2_Probe_AS CTTAAAGCCTCGCCTCTCTTTCCCCTTTCTTCTGAGAGTT 
Oligo2_[-20]_S CTGTCAGGACCAGGGACAGCAACTCTCAGAAGAAAGGGGA 
Oligo2_[-20]_AS TCCCCTTTCTTCTGAGAGTTGCTGTCCCTGGTCCTGACAG 
Oligo2_[0]_S  AACTCTCAGAAGAAAGGGGAAAGAGAGGCGAGGCTTTAAG 
Oligo2_[0]_AS  CTTAAAGCCTCGCCTCTCTTTCCCCTTTCTTCTGAGAGTT 
Oligo2_[+20]_S AAGAGAGGCGAGGCTTTAAGAGACCTGTTTGGGCTGGGTG 
Oligo2_[+20]_AS CACCCAGCCCAAACAGGTCTCTTAAAGCCTCGCCTCTCTT 
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B. Supplemental Table S2.1B. Coriell Institute human variation panel cell lines 
Population Coriell Cat. Sex  Age  Description 
N. Europeans GM17001 Female  12 YR  Northern Europeans 
GM17002 Female  NA  Northern Europeans 
GM17003 Male  39 YR  Northern Europeans 
GM17004 Female  39 YR  Northern Europeans 
GM17005 Female  33 YR  Northern Europeans 
GM17006 Female  40 YR  Northern Europeans 
GM17007 Male  39 YR  Northern Europeans 
GM17008 Male  NA  Northern Europeans 
GM17009 Female  NA  Northern Europeans 
GM17010 Male  45 YR  Northern Europeans 
N. Africans GM17378 Male  4 YR  Africans N. of the Sahara 
GM17379 Female  NA  Africans N. of the Sahara 
GM17380 Female  1 MO  Africans N. of the Sahara 
GM17381 Male  16 YR  Africans N. of the Sahara 
GM17382 Male  6 DA  Africans N. of the Sahara 
GM17383 Male  1 YR  Africans N. of the Sahara 
GM17384 Male  3 YR  Africans N. of the Sahara 
S. Africans GM17341 Female  16 YR  Africans S. of the Sahara 
GM17342 Male  53 YR  Africans S. of the Sahara 
GM17343 Male  16 YR  Africans S. of the Sahara 
GM17344 Female  10 YR  Africans S. of the Sahara 
GM17345 Male  16 YR  Africans S. of the Sahara 
GM17346 Male  17 YR  Africans S. of the Sahara 
GM17347 Male  36 YR  Africans S. of the Sahara 
GM17348 Female  5 YR  Africans S. of the Sahara 
GM17349 Male  NA  Africans S. of the Sahara 
Mex. Indians GM17392 Male  NA  Mexican Indians 
GM17393 Female  NA  Mexican Indians 
GM17394 Female  NA  Mexican Indians 
GM17395 Male  NA  Mexican Indians 
GM17396 Male  NA  Mexican Indians 
Chinese GM16654 Male  51 YR  Chinese 
GM16688 Female  75 YR  Chinese 
GM16689 Male  74 YR  Chinese 
GM17014 Male  4 YR  Chinese 
GM17015 Male  51 YR  Chinese 
GM17016 Male  NA  Chinese 
GM17017 Male  NA  Chinese 
GM17018 Female  NA  Chinese 
GM17019 Female  NA  Chinese 
GM17020 Male  NA  Chinese 
Mbuti  GM10492 Male  NA  Mbuti, N.E. Zaire 
GM10494 Male  NA  Mbuti, N.E. Zaire 
Misc  GM12156 Female  NA  CEPH/Utah Pedigree 1463 
GM12878 Female  NA  CEPH/Utah Pedigree 1463 
GM15228 NA  NA  DNA Polymorph. Disc. Res. 
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Supplemental Table S2.2. DEGs following siRNA knockdown of ZNF286A or ZNF286B. 
OVERLAP GENE EXPT PROBESET SI-1 SI-2 CTRL-1 CTRL-2 rawP BH corrected P-values 
 
 A4GALT 286A 8076497 6.08 6.02 6.73 6.76 0 0 
ab AACS 286B 7959786 8.62 8.65 7.82 7.53 9.06E-11 3.90E-09 
ab AACS 286A 7959786 8.58 8.81 7.77 7.53 2.26E-10 1.28E-08 
 AADACL4 286B 7897955 3.99 4.05 4.77 5.11 6.74E-08 2.14E-06 
 AARSD1 286B 8015741 7.22 7.27 6.99 6.89 3.75E-08 1.22E-06 
 ABCA11P 286B 8098752 5.3 5.32 4.84 4.37 3.07E-03 0.03 
 ABCA6 286A 8017964 4.1 4.06 4.6 4.64 0 0 
ab ABCB10 286A 7924956 8.57 8.48 7.94 8.16 8.14E-05 2.02E-03 
ab ABCB10 286B 7924956 8.42 8.39 7.77 7.97 1.82E-07 5.46E-06 
ab ABCB6 286B 8059111 8.21 8.18 6.72 6.38 0 0 
ab ABCB6 286A 8059111 8.12 8.24 6.68 6.32 0 0 
 ABCC12 286B 8001235 4.37 4.32 4.64 4.88 7.48E-04 0.01 
ab ABCC3 286A 8008454 7.71 7.85 7.3 7.4 3.16E-07 1.22E-05 
ab ABCC3 286B 8008454 7.92 7.96 7.15 7.46 5.99E-05 1.21E-03 
ab ABCC5 286A 8092418 7.52 7.55 6.99 6.95 0 0 
ab ABCC5 286B 8092418 7.44 7.48 6.79 6.56 1.87E-11 8.56E-10 
 ABHD3 286A 8022488 6.25 6.15 5.76 5.54 7.56E-06 2.34E-04 
ab ABR 286A 8010983 8.66 8.98 8.17 7.72 1.71E-03 0.02 
ab ABR 286B 8010983 8.78 8.76 8.08 7.7 3.91E-06 9.85E-05 
ab ABT1 286A 8117522 7.64 7.46 7.14 6.95 1.18E-04 2.81E-03 
ab ABT1 286B 8117522 7.59 7.34 6.99 6.78 4.12E-04 6.80E-03 
 ACADS 286B 7959220 5.99 6.06 6.38 6.71 2.26E-03 0.02 
ab ACAT2 286A 8123137 9.72 9.43 7.1 6.45 2.89E-15 2.48E-13 
ab ACAT2 286A 8123137 9.72 9.43 7.1 6.45 2.89E-15 2.48E-13 
ab ACAT2 286B 8123137 9.68 9.61 7.01 6.34 0 0 
 ACAT2 286B 8123137 9.68 9.61 7.01 6.34 0 0 
 ACBD6 286B 7922656 6.41 6.58 6.15 6.15 9.34E-05 1.81E-03 
 ACBD7 286A 7932214 6.16 6.32 5.7 5.18 3.25E-03 0.04 
ab ACD 286A 8002057 8.22 8.27 7.6 7.92 2.60E-03 0.03 
ab ACD 286B 8002057 8.48 8.39 7.56 7.84 3.76E-07 1.09E-05 
 ACLY 286B 8015460 11.83 11.88 11.14 10.39 3.47E-03 0.04 
 ACLY 286B 8015460 11.83 11.88 11.14 10.39 3.47E-03 0.04 
 ACMSD 286A 8045368 4.41 4.39 4.6 4.54 3.66E-06 1.18E-04 
 ACOT2 286A 7975602 8.07 8.16 7.76 7.48 5.96E-04 0.01 
ab ACSBG2 286B 8025011 3.86 3.59 4.16 4.31 6.17E-04 9.70E-03 
 ACSL1 286B 8103951 8.2 8.08 6.96 5.75 3.52E-03 0.04 
 ACSL5 286B 7930498 5.28 5.32 5.93 5.66 3.14E-04 5.36E-03 
 ACSS2 286B 8062041 8.6 8.61 7.57 7.4 0 0 
 ACSS2 286B 8062041 8.6 8.61 7.57 7.4 0 0 
 ACSS2 286B 8062041 8.6 8.61 7.57 7.4 0 0 
ab ACTBL2 286A 8112198 4.47 4.54 6.6 5.71 2.36E-04 5.13E-03 
ab ACTBL2 286B 8112198 4.12 4.29 6.29 5.33 9.82E-04 0.01 
 ACTC1 286B 7987315 5.55 5.4 5.1 4.98 3.83E-06 9.69E-05 
ab ACTR5 286A 8062545 7.03 7.13 6.79 6.65 1.80E-05 5.24E-04 
ab ACTR5 286B 8062545 7.31 7.39 6.88 6.94 0 0 
 ACYP1 286B 7980265 7.19 7.04 6.46 6.73 8.25E-04 0.01 
ab ADAM20 286A 7979927 4.38 4.71 5.23 5.72 1.59E-03 0.02 
ab ADAM20 286B 7979927 4.51 4.43 5.1 5.6 5.91E-04 9.33E-03 
 ADAM3A 286B 8150375 3.03 3.03 3.23 3.26 0 0 
ab ADAMTS1 286A 8069676 5.43 5.64 7.07 6.42 4.72E-04 9.33E-03 
ab ADAMTS1 286B 8069676 5.71 5.7 6.9 6.34 1.02E-03 0.01 
ab ADAMTS6 286A 8112342 4.83 4.63 5.2 5.27 1.37E-06 4.81E-05 
ab ADAMTS6 286B 8112342 4.71 4.51 5.12 4.96 7.71E-04 0.01 
ab ADAMTSL1 286B 8154512 6.44 6.68 7.91 7.49 2.56E-06 6.66E-05 
ab ADAMTSL1 286A 8154512 6.55 6.72 7.74 7.36 7.49E-06 2.32E-04 
 ADC 286A 7899851 6.82 6.87 7.07 7.02 4.99E-09 2.44E-07 
 ADCY2 286B 8104394 5.24 5.29 5.56 5.69 1.08E-07 3.32E-06 
 ADCY3 286B 8050766 9.26 9.33 8.35 7.38 3.34E-03 0.04 
ab ADD1 286B 8093643 9.13 8.92 8.58 8.33 5.36E-04 8.57E-03 
ab ADD1 286A 8093643 9.03 9.01 8.61 8.19 3.24E-03 0.04 
 ADD2 286B 8052882 7.65 7.53 6.85 6.77 0 0 
 ADHFE1 286A 8146687 4.48 4.55 4.93 5.25 3.81E-04 7.71E-03 
ab ADO 286B 7927767 8.86 8.76 8.65 8.59 1.56E-03 0.02 
ab ADO 286A 7927767 8.62 8.7 8.4 8.5 5.75E-04 0.01 
 ADPRHL2 286A 7900087 7.98 7.95 7.89 7.86 1.51E-07 6.12E-06 
 ADRM1 286B 8063893 10.59 10.67 10.25 9.92 1.10E-03 0.01 
 ADRM1 286B 8063893 10.59 10.67 10.25 9.92 1.10E-03 0.01 
 AFARP1 286B 7904084 5.55 5.62 6.11 6.37 1.30E-06 3.54E-05 
 AFF2 286B 8170364 5.28 5.28 5.82 6.08 1.57E-07 4.74E-06 
ab AGAP4 286A 7927231 6.83 7.07 7.3 7.45 2.71E-03 0.04 
ab AGAP4 286B 7927231 6.99 7.05 7.28 7.36 2.46E-08 8.23E-07 
ab AGAP5 286A 7927305 6.64 6.81 7.12 7.11 1.79E-06 6.19E-05 
ab AGAP5 286B 7927305 6.7 6.82 7 6.98 2.24E-04 3.98E-03 
 AGPAT9 286A 8096116 6.59 6.45 5.95 5.63 2.94E-05 8.16E-04 
 AGXT2 286B 8111474 4.56 4.72 5.17 5.58 9.74E-04 0.01 
 AHNAK2 286B 7981514 8.32 8.31 7.53 7.02 4.23E-05 8.86E-04 
ab AHSP 286A 7995237 3.64 3.81 4.1 4.2 8.50E-06 2.60E-04 
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Supplemental Table S2.2. (Continued) 
OVERLAP GENE EXPT PROBESET SI-1 SI-2 CTRL-1 CTRL-2 rawP BH corrected P-values 
 
ab AHSP 286B 7995237 3.71 3.78 4.04 4.2 2.47E-05 5.42E-04 
 AKAP7 286B 8122045 5.75 5.78 5.34 4.94 1.66E-03 0.02 
 AKR1C1 286A 7925918 6.2 5.98 6.58 6.66 7.03E-06 2.18E-04 
 AKR1C3 286B 7925929 4.86 5.13 5.36 5.47 4.20E-03 0.04 
 ALDH3A2 286B 8005638 8.79 8.81 7.74 6.61 4.09E-03 0.04 
 ALDH5A1 286A 8117207 5.6 5.65 5.92 6.13 2.59E-04 5.54E-03 
 ALOX5AP 286A 7968344 5.6 5.27 6.09 6.26 8.31E-05 2.06E-03 
 ALOXE3 286B 8012326 5.21 5.36 5.73 5.95 2.64E-05 5.76E-04 
ab AMELY 286B 8177061 3.48 3.57 4.15 4.49 5.72E-06 1.41E-04 
ab AMELY 286A 8177061 3.39 3.56 4.21 4.16 1.31E-14 1.06E-12 
 AMFR 286A 8001477 9.44 9.46 8.87 8.27 3.22E-03 0.04 
 AMHR2 286B 7955797 5.19 5.31 5.57 5.78 5.30E-04 8.50E-03 
ab AMMECR1 286B 8174496 9.66 9.66 9.06 8.5 1.67E-03 0.02 
ab AMMECR1 286A 8174496 9.6 9.78 9.03 8.48 1.19E-03 0.02 
ab ANAPC10 286A 8103005 6.47 6.17 5.64 5.79 4.14E-04 8.28E-03 
ab ANAPC10 286B 8103005 6.6 6.53 5.36 5.61 2.22E-16 1.41E-14 
 ANK3 286A 7933772 8.25 8.44 7.29 6.55 1.81E-04 4.07E-03 
 ANK3 286B 7933772 8.55 8.64 7.34 6.48 1.04E-04 2.00E-03 
 ANKAR 286B 8047006 4.87 4.88 4.64 4.66 0 0 
 ANKRD16 286A 7931888 5.06 5.32 5.57 5.58 2.61E-03 0.03 
 ANKRD18A 286B 8161270 4.9 5.15 5.41 5.62 3.18E-03 0.03 
ab ANKRD29 286A 8022559 4.74 4.98 5.79 6.43 2.07E-04 4.57E-03 
ab ANKRD29 286B 8022559 4.97 5.05 5.75 6.47 2.37E-03 0.03 
 ANKRD36BP1 286B 7922121 5.45 5.21 4.27 4.29 0 0 
 ANKRD45 286B 7922382 5.17 5.1 4.5 3.87 2.65E-03 0.03 
 ANKRD49 286B 7943231 7.13 7.15 6.65 6.89 2.57E-03 0.03 
 ANKRD6 286A 8121095 5.12 5.13 5.56 5.54 0 0 
ab ANO5 286B 7938951 2.82 3.01 3.46 3.34 1.32E-05 3.06E-04 
ab ANO5 286A 7938951 3.23 2.96 3.53 3.54 1.16E-03 0.02 
 ANUBL1 286B 7933237 6.32 6.33 5.61 5.58 0 0 
 ANXA2P1 286B 8103240 7.3 7.17 6.77 6.31 3.90E-03 0.04 
ab ANXA3 286B 8095986 3.68 3.64 4.11 3.9 1.18E-03 0.01 
ab ANXA3 286A 8095986 4.1 4.15 4.34 4.28 1.91E-07 7.56E-06 
 AOC3 286B 8007420 4.91 4.6 5.46 5.83 1.78E-04 3.23E-03 
 AP1M1 286B 8026548 9.71 9.77 9.29 9.1 7.50E-08 2.36E-06 
ab APEX2 286A 8167854 7.9 7.93 7.53 7.33 8.41E-07 3.05E-05 
ab APEX2 286B 8167854 8.05 8.02 7.65 7.41 1.51E-05 3.46E-04 
 APOBEC3H 286A 8073096 5.41 5.4 6.04 5.93 0 0 
 APOLD1 286B 7954055 6.8 6.8 7.26 7.71 2.80E-03 0.03 
 APOM 286A 8118209 6.03 6.06 6.33 6.6 2.28E-03 0.03 
 APOM 286A 8178043 6.03 6.06 6.33 6.6 2.28E-03 0.03 
 APOM 286A 8179291 6.03 6.06 6.33 6.6 2.28E-03 0.03 
 AQP7 286A 8160663 6.48 6.45 6.66 6.81 4.10E-04 8.23E-03 
 ARAF 286B 8167165 9.06 9.11 8.7 8.64 0 0 
 ARFGAP2 286B 7947784 8.43 8.44 7.89 7.31 4.04E-03 0.04 
 ARHGAP28 286B 8019964 3.76 3.81 4.36 4.25 0 0 
ab ARHGDIA 286B 8019263 11.4 11.4 10.82 10.77 0 0 
ab ARHGDIA 286A 8019263 11.18 11.5 10.75 10.69 1.13E-04 2.70E-03 
ab ARHGDIA 286A 8019765 11.25 11.57 10.84 10.67 3.38E-04 6.96E-03 
ab ARHGDIA 286B 8019765 11.4 11.42 10.84 10.55 5.26E-07 1.50E-05 
 ARHGEF10 286B 8144281 7.13 7.12 6.84 6.56 3.16E-03 0.03 
 ARHGEF11 286B 7921179 8.03 7.93 7.78 7.63 2.12E-03 0.02 
 ARHGEF11 286B 7921179 8.03 7.93 7.78 7.63 2.12E-03 0.02 
 ARHGEF7 286B 7970111 8.32 8.47 7.85 7.68 3.23E-08 1.07E-06 
 ARID3B 286A 7984843 5.54 5.49 5.67 5.63 8.31E-05 2.06E-03 
 ARL4A 286B 8131573 5.65 5.58 5.88 5.79 8.73E-05 1.70E-03 
 ARPC5L 286A 8157828 7.56 7.59 7.13 7.34 1.02E-03 0.01 
 ARRDC1 286B 8159692 8.5 8.45 8.22 8.3 3.15E-06 8.06E-05 
 ARRDC4 286B 7986350 4.69 4.77 6.46 5.98 1.19E-09 4.59E-08 
ab ARSG 286A 8009443 6.34 6.24 7.07 6.98 0 0 
ab ARSG 286B 8009443 6.33 6.15 6.98 6.83 1.29E-08 4.47E-07 
 ASB1 286A 8049657 8.34 8.4 8.02 8.13 6.48E-06 2.02E-04 
ab ASB4 286A 8134376 4.14 4.17 4.43 4.55 2.38E-08 1.07E-06 
ab ASB4 286B 8134376 4.42 4.41 4.62 4.74 1.68E-05 3.83E-04 
 ASB5 286B 8103812 3.87 3.86 4.19 4.4 4.63E-05 9.62E-04 
 ASB7 286B 7986433 7.78 7.76 7.42 7.24 7.42E-07 2.08E-05 
 ASCL3 286B 7946436 4.17 4.36 4.9 5.38 8.08E-04 0.01 
ab ASF1B 286A 8034772 10.19 10.32 8.92 8.46 5.74E-11 3.51E-09 
ab ASF1B 286B 8034772 10.49 10.33 8.96 8.53 1.60E-13 8.58E-12 
 ASPA 286B 8003814 2.78 2.84 3.01 3.18 2.21E-03 0.02 
ab ASPHD1 286B 7994675 7.16 7.15 7.53 7.78 6.19E-05 1.25E-03 
ab ASPHD1 286A 7994675 7.47 7.3 7.7 7.89 1.53E-03 0.02 
ab ATAD3A 286A 7896952 9.03 9.08 8.38 8.6 3.79E-07 1.45E-05 
ab ATAD3A 286B 7896952 9.11 9.1 8.49 8.47 0 0 
 ATF7IP2 286A 7993167 3.4 3.16 3.65 3.7 1.43E-03 0.02 
 ATL1 286B 7974270 6.29 6.24 5.04 4.79 0 0 
 ATP6AP1L 286A 8106722 5.98 6.18 6.45 6.57 2.71E-04 5.75E-03 
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ab ATP6V0C 286A 7992646 11.92 11.93 11.51 11.51 0 0 
ab AURKB 286B 8012403 9.8 9.74 9.12 8.85 1.04E-08 3.64E-07 
ab AURKB 286A 8012403 9.67 9.66 9.04 8.67 1.65E-05 4.84E-04 
 AVIL 286A 7964555 5.38 5.45 5.79 5.86 0 0 
 B3GNT5 286B 8084206 3.65 3.53 4.09 4.09 8.22E-15 4.84E-13 
ab B4GALNT1 286A 7964484 9.2 9.52 8.25 8.33 6.99E-11 4.25E-09 
ab B4GALNT1 286B 7964484 9.47 9.53 8.4 8.39 0 0 
ab B9D1 286B 8013331 6.86 6.71 7.67 7.44 2.05E-08 6.94E-07 
ab B9D1 286A 8013331 6.9 7.13 7.72 7.66 2.12E-08 9.57E-07 
 BACE2 286B 8068671 5.09 5.08 5.77 6.44 2.14E-03 0.02 
 BAG1 286B 8160647 6.97 7.13 6.71 6.59 3.30E-05 7.05E-04 
 BAG3 286B 7930921 8.95 8.96 8.24 8.45 9.34E-09 3.29E-07 
 BAG5 286A 7981439 8.02 7.96 7.52 7.13 8.90E-04 0.01 
 BAG5 286A 7981439 8.02 7.96 7.52 7.13 8.90E-04 0.01 
 BAK1 286B 8125766 8.28 8.29 7.91 7.79 8.59E-14 4.70E-12 
ab BAP1 286B 8087885 9.31 9.37 9.06 8.95 2.46E-08 8.23E-07 
ab BAP1 286A 8087885 9.25 9.47 8.99 8.92 3.60E-04 7.33E-03 
 BASP1 286B 8104601 8.19 8.17 8.57 8.9 7.57E-04 0.01 
 BATF2 286B 7949340 6.66 6.73 7.3 7.86 1.90E-03 0.02 
ab BBOX1 286A 7939056 3.2 3.16 3.46 3.64 4.68E-05 1.25E-03 
ab BBOX1 286B 7939056 3.38 3.42 3.61 3.77 3.05E-04 5.23E-03 
 BCL10 286B 7917338 7.94 7.95 7.72 7.57 8.10E-05 1.59E-03 
ab BCL11A 286A 8052399 5.59 5.65 6.64 7.13 3.59E-07 1.38E-05 
ab BCL11A 286A 8052399 5.59 5.65 6.64 7.13 3.59E-07 1.38E-05 
ab BCL11A 286A 8052399 5.59 5.65 6.64 7.13 3.59E-07 1.38E-05 
ab BCL11A 286B 8052399 5.81 5.68 6.58 7.14 1.02E-04 1.97E-03 
ab BCL11A 286B 8052399 5.81 5.68 6.58 7.14 1.02E-04 1.97E-03 
ab BCL11A 286B 8052399 5.81 5.68 6.58 7.14 1.02E-04 1.97E-03 
ab BCL2A1 286A 7990818 4.6 4.4 4.97 5.06 3.91E-06 1.26E-04 
ab BCL2A1 286B 7990818 4.4 4.41 4.73 5.07 3.86E-03 0.04 
 BCL2L14 286B 7953993 5.17 5.29 5.45 5.43 7.94E-04 0.01 
ab BCMO1 286B 7997401 4.88 4.75 5.37 5.68 2.52E-05 5.52E-04 
ab BCMO1 286A 7997401 4.9 4.86 5.19 5.5 2.57E-03 0.03 
ab BDKRB2 286B 7976560 6.16 6.43 7.85 7.6 3.33E-15 1.99E-13 
ab BDKRB2 286A 7976560 6.75 6.71 8.17 7.94 0 0 
 BEND6 286B 8120362 6.67 6.48 5.64 4.88 7.33E-04 0.01 
 BEND6 286B 8120362 6.67 6.48 5.64 4.88 7.33E-04 0.01 
 BEX4 286B 8169009 6.55 6.56 7.07 7.51 1.05E-03 0.01 
 BIRC3 286A 7943413 3.53 3.43 3.95 4 0 0 
ab BIRC5 286A 8010260 8.62 8.56 7.99 8.15 2.32E-09 1.19E-07 
ab BIRC5 286B 8010260 8.71 8.57 7.94 8.18 2.09E-05 4.68E-04 
ab BLM 286A 7986068 8.91 8.92 7.32 5.86 1.48E-03 0.02 
ab BLM 286B 7986068 9.06 8.9 7.27 5.75 1.26E-03 0.01 
 BLVRA 286B 8132515 7.94 7.95 7.33 7.09 4.22E-10 1.71E-08 
ab BMP3 286B 8096070 5.36 5.4 6.21 6.24 0 0 
 BNC2 286B 8160260 7.72 7.75 7.16 6.59 2.45E-03 0.03 
 BOP1 286A 8153678 9 8.82 8.14 8.47 9.79E-04 0.01 
 BPESC1 286A 8083025 4.89 5.05 5.46 5.37 2.06E-06 7.02E-05 
 BPY2 286B 8176821 4.54 4.54 4.88 5.09 2.56E-05 5.59E-04 
 BPY2 286B 8176867 4.54 4.54 4.88 5.09 2.56E-05 5.59E-04 
 BPY2 286B 8177449 4.54 4.54 4.88 5.09 2.56E-05 5.59E-04 
ab BRCA1 286A 8015769 8.19 8.26 6.72 5.39 1.06E-03 0.01 
ab BRCA1 286B 8015769 8.36 8.42 6.65 5.22 5.66E-04 8.98E-03 
 BRD2 286B 8118580 10.57 10.58 10.27 10.07 4.59E-05 9.55E-04 
 BRD2 286B 8179504 10.39 10.4 10.08 9.76 3.60E-03 0.04 
ab BRI3BP 286A 7959777 9.3 9.39 8.49 7.67 2.26E-03 0.03 
ab BRI3BP 286A 7959777 9.3 9.39 8.49 7.67 2.26E-03 0.03 
ab BRI3BP 286B 7959777 9.75 9.69 8.78 8.06 3.59E-04 6.02E-03 
ab BRI3BP 286B 7959777 9.75 9.69 8.78 8.06 3.59E-04 6.02E-03 
 BST2 286B 8035304 5 4.87 6.13 6.44 1.55E-15 9.55E-14 
 BTBD11 286A 7958352 4.73 4.81 5.12 5.22 1.21E-09 6.34E-08 
 BTBD12 286B 7999008 7.57 7.51 7.06 7.16 3.09E-14 1.72E-12 
ab BTBD6 286A 7977340 8.12 8.17 6.92 7.4 4.90E-05 1.30E-03 
ab BTBD6 286B 7977340 8.25 8.07 6.87 7.15 9.35E-12 4.36E-10 
ab BTN2A1 286B 8117485 7.55 7.36 7.13 7.15 1.10E-03 0.01 
ab BTN2A1 286A 8117485 7.46 7.35 7 7.1 1.95E-06 6.68E-05 
 BUD13 286A 7951826 6.78 6.67 6.38 6.42 1.52E-08 6.99E-07 
 BUD13 286B 7951826 6.83 6.65 6.26 6.28 5.37E-08 1.72E-06 
ab BYSL 286A 8119492 8.69 8.47 8.02 8.01 2.08E-07 8.20E-06 
ab BYSL 286B 8119492 8.59 8.57 8.12 7.87 2.66E-06 6.90E-05 
 C10orf129 286A 7929497 4.38 4.47 4.7 4.76 1.12E-07 4.59E-06 
 C10orf31 286B 7932019 4.92 4.97 5.18 5.42 3.10E-03 0.03 
ab C10orf55 286A 7934505 4.4 4.29 4.54 4.66 1.78E-03 0.02 
Note: This supplementary table only includes an excerpt of 232 of 2,618 entries of the originating 
data file. The full supplementary file is available as part of the submitted manuscript. 
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ChIPExpt chr SummitStart-End  FoldEnr. FDR siRNADEG siExpt BH Adj p-values FC 
 
ZNF286A chr1 12663940-12664140 6.3 0.1 DHRS3 286B 0  -3.97 
ZNF286A chr1 12663940-12664140 6.3 0.1 DHRS3 286A 3.64E-09  -3.39 
REST chr1 44434106-44434306 35.41 0 DPH2 286B 2.40E-05  1.57 
ZNF286A chr1 44434159-44434359 10.23 0 DPH2 286B 2.40E-05  1.57 
ZNF286A chr1 65888130-65888330 5.34 0 PDE4B 286A 5.51E-07  -1.65 
ZNF286A chr1 65888130-65888330 5.34 0 PDE4B 286A 5.51E-07  -1.65 
ZNF286A chr1 199149349-199149549 5.32 1.89 NR5A2 286B 2.21E-07  -1.55 
REST chr1 205428152-205428352 36.54 0 CDK18 286A 3.36E-12  -1.77 
REST chr1 205428152-205428352 36.54 0 CDK18 286B 0  -1.74 
ZNF286A chr1 205428171-205428371 11.54 0 CDK18 286A 3.36E-12  -1.77 
ZNF286A chr1 205428171-205428371 11.54 0 CDK18 286B 0  -1.74 
ZNF286A chr1 205457231-205457431 6.92 0.1 LEMD1 286B 3.88E-07  -1.83 
ZNF286A chr1 205457231-205457431 6.92 0.1 LEMD1 286A 0.02  -1.55 
ZNF286A chr10 4715327-4715527  5.19 0.07 KLF6 286A 1.55E-04  2.14 
ZNF286A chr10 4715327-4715527  5.19 0.07 KLF6 286B 9.62E-04  2.19 
ZNF286A chr10 13391966-13392166 5.91 0 SEPHS1 286B 0.04  1.95 
ZNF286A chr10 61297338-61297538 5.24 0.07 SLC16A9 286B 0.01  1.59 
ZNF286A chr10 79088214-79088414 16.75 0 KCNMA1 286B 0  3.15 
ZNF286A chr10 79088214-79088414 16.75 0 KCNMA1 286A 0  3.77 
REST chr10 79088247-79088447 64.1 0 KCNMA1 286B 0  3.15 
REST chr10 79088247-79088447 64.1 0 KCNMA1 286A 0  3.77 
REST chr10 79397258-79397458 16.03 0 KCNMA1 286B 0  3.15 
REST chr10 79397258-79397458 16.03 0 KCNMA1 286A 0  3.77 
ZNF286A chr10 80872497-80872697 5.43 0 PPIF 286A 0  1.50 
REST chr10 81002959-81003159 14.19 0.44 PPIF 286A 0  1.50 
ZNF286A chr10 97151797-97151997 13.28 0 PDLIM1 286A 1.46E-07  -2.26 
ZNF286A chr10 97151797-97151997 13.28 0 PDLIM1 286B 2.36E-03  -1.62 
REST chr10 97151826-97152026 50.9 0 PDLIM1 286A 1.46E-07  -2.26 
REST chr10 97151826-97152026 50.9 0 PDLIM1 286B 2.36E-03  -1.62 
REST chr10 105038678-105038878 68.91 0 INA 286B 0  -2.37 
ZNF286A chr10 105038696-105038896 10.35 0 INA 286B 0  -2.37 
REST chr11 65121709-65121909 19.23 0.08 TIGD3 286B 0.02  -1.97 
ZNF286A chr11 65121734-65121934 9.54 0 TIGD3 286B 0.02  -1.97 
ZNF286A chr11 109295713-109295913 7.82 0.13 ZC3H12C 286A 7.83E-05  1.66 
ZNF286A chr11 109295713-109295913 7.82 0.13 ZC3H12C 286B 0  1.71 
REST chr11 109295768-109295968 33.7 0 ZC3H12C 286A 7.83E-05  1.66 
REST chr11 109295768-109295968 33.7 0 ZC3H12C 286B 0  1.71 
ZNF286A chr11 109512334-109512534 6.35 1.39 ZC3H12C 286A 7.83E-05  1.66 
ZNF286A chr11 109512334-109512534 6.35 1.39 ZC3H12C 286B 0  1.71 
REST chr11 109512378-109512578 26.53 0 ZC3H12C 286A 7.83E-05  1.66 
REST chr11 109512378-109512578 26.53 0 ZC3H12C 286B 0  1.71 
REST chr11 116001521-116001721 31.93 0.13 CADM1 286B 5.07E-06  -2.05 
ZNF286A chr11 116250182-116250382 14.49 0 CADM1 286B 5.07E-06  -2.05 
REST chr11 116250231-116250431 67.97 0 CADM1 286B 5.07E-06  -2.05 
ZNF286A chr11 121425301-121425501 5.65 0.06 SORL1 286A 0  1.89 
ZNF286A chr11 121425301-121425501 5.65 0.06 SORL1 286B 0  1.89 
REST chr11 121526807-121527007 16.62 1.46 SORL1 286A 0  1.89 
REST chr11 121526807-121527007 16.62 1.46 SORL1 286B 0  1.89 
REST chr11 121636321-121636521 66.67 0 SORL1 286A 0  1.89 
REST chr11 121636321-121636521 66.67 0 SORL1 286B 0  1.89 
ZNF286A chr12 53472349-53472549 5.23 2.27 IGFBP6 286A 3.73E-05  -2.24 
ZNF286A chr12 53472349-53472549 5.23 2.27 IGFBP6 286B 4.53E-05  -2.23 
ZNF286A chr12 108775942-108776142 10.25 0 FICD 286B 0  1.93 
REST chr12 108776014-108776214 71.68 0 FICD 286B 0  1.93 
ZNF286A chr12 108797804-108798004 7.97 0.08 FICD 286B 0  1.93 
REST chr12 108797828-108798028 25.81 0 FICD 286B 0  1.93 
ZNF286A chr12 109284057-109284257 8.18 0.07 DAO 286B 0.02  -1.88 
REST chr12 109284072-109284272 18.25 0.66 DAO 286B 0.02  -1.88 
ZNF286A chr12 113375633-113375833 5.91 0.06 OAS3 286A 9.35E-05  1.77 
ZNF286A chr12 113375633-113375833 5.91 0.06 OAS3 286B 0  1.95 
REST chr12 119499103-119499303 42.07 0 HSPB8 286B 5.48E-03  2.32 
REST chr12 119499103-119499303 42.07 0 HSPB8 286A 4.63E-04  2.74 
ZNF286A chr12 119499119-119499319 8.33 0 HSPB8 286B 5.48E-03  2.32 
ZNF286A chr12 119499119-119499319 8.33 0 HSPB8 286A 4.63E-04  2.74 
ZNF286A chr13 110959830-110960030 5.15 0.1 COL4A2 286B 0  1.66 
ZNF286A chr13 110959830-110960030 5.15 0.1 COL4A2 286A 1.08E-05  1.72 
ZNF286A chr14 51027144-51027344 9.09 0 ATL1 286B 0  2.54 
ZNF286A chr15 48623686-48623886 5.39 0.13 DUT 286B 6.00E-03  1.85 
REST chr15 48623810-48624010 20.6 1.28 DUT 286B 6.00E-03  1.85 
ZNF286A chr15 51973516-51973716 7.41 0.07 SCG3 286B 0.04  -1.57 
REST chr15 51973623-51973823 41.61 0 SCG3 286B 0.04  -1.57 
REST chr15 70265567-70265767 37.83 0 TLE3 286B 0  -3.55 
REST chr15 70265567-70265767 37.83 0 TLE3 286A 0  -3.02 
REST chr15 70268812-70269012 48.08 0 TLE3 286B 0  -3.55 
REST chr15 70268812-70269012 48.08 0 TLE3 286A 0  -3.02 
ZNF286A chr15 70268858-70269058 14.69 0 TLE3 286B 0  -3.55 
ZNF286A chr15 70268858-70269058 14.69 0 TLE3 286A 0  -3.02 
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REST chr15 70389137-70389337 15.26 0.27 TLE3 286B 0  -3.55 
REST chr15 70389137-70389337 15.26 0.27 TLE3 286A 0  -3.02 
ZNF286A chr15 70766921-70767121 5.13 0.06 TLE3 286B 0  -3.55 
ZNF286A chr15 70766921-70767121 5.13 0.06 TLE3 286A 0  -3.02 
ZNF286A chr15 70798758-70798958 5.44 0.32 TLE3 286B 0  -3.55 
ZNF286A chr15 70798758-70798958 5.44 0.32 TLE3 286A 0  -3.02 
REST chr15 74557444-74557644 60.31 0 CCDC33 286A 3.61E-11  -2.48 
REST chr15 74557444-74557644 60.31 0 CCDC33 286B 0  -2.39 
ZNF286A chr15 74557525-74557725 12.5 0 CCDC33 286A 3.61E-11  -2.48 
ZNF286A chr15 74557525-74557725 12.5 0 CCDC33 286B 0  -2.39 
ZNF286A chr15 74583888-74584088 27.5 0 CCDC33 286A 3.61E-11  -2.48 
ZNF286A chr15 74583888-74584088 27.5 0 CCDC33 286B 0  -2.39 
REST chr15 74583902-74584102 121.79 0 CCDC33 286A 3.61E-11  -2.48 
REST chr15 74583902-74584102 121.79 0 CCDC33 286B 0  -2.39 
ZNF286A chr16 20034617-20034817 9.77 0 GPRC5B 286B 1.30E-06  -1.58 
ZNF286A chr16 20034617-20034817 9.77 0 GPRC5B 286A 0.01  -1.56 
REST chr16 20034630-20034830 51.44 0 GPRC5B 286B 1.30E-06  -1.58 
REST chr16 20034630-20034830 51.44 0 GPRC5B 286A 0.01  -1.56 
ZNF286A chr16 71928703-71928903 5.45 0.87 DHODH 286B 0.03  1.73 
ZNF286A chr17 8123957-8124157  6.08 0 AURKB 286B 3.64E-07  1.73 
ZNF286A chr17 8123957-8124157  6.08 0 AURKB 286A 4.84E-04  1.75 
ZNF286A chr17 19411366-19411566 6.25 1.22 SLC47A1 286B 8.67E-03  -1.62 
ZNF286A chr17 48715689-48715889 5.29 0 ABCC3 286B 1.21E-03  1.55 
ZNF286A chr17 79894652-79894852 7.3 1.56 MAFG 286B 0  1.51 
ZNF286A chr17 79894652-79894852 7.3 1.56 MAFG 286A 2.43E-06  1.53 
ZNF286A chr17 79894652-79894852 7.3 1.56 MAFG 286B 0.01  1.80 
ZNF286A chr17 79894652-79894852 7.3 1.56 MAFG 286A 2.66E-03  1.98 
ZNF286A chr19 1383561-1383761  8.18 0.07 NDUFS7 286B 3.06E-09  -1.55 
ZNF286A chr19 55728401-55728601 27.95 0 PTPRH 286A 0  -1.53 
REST chr19 55728412-55728612 48.58 0 PTPRH 286A 0  -1.53 
REST chr19 55731960-55732160 24.04 0.25 PTPRH 286A 0  -1.53 
ZNF286A chr19 55731997-55732197 5.23 1.39 PTPRH 286A 0  -1.53 
ZNF286A chr2 12316659-12316859 5.03 0.07 TRIB2 286A 2.65E-04  1.75 
ZNF286A chr2 12316659-12316859 5.03 0.07 TRIB2 286B 1.07E-03  1.85 
REST chr2 12858538-12858738 18.63 0.11 TRIB2 286A 2.65E-04  1.75 
REST chr2 12858538-12858738 18.63 0.11 TRIB2 286B 1.07E-03  1.85 
ZNF286A chr2 12858554-12858754 5.19 0 TRIB2 286A 2.65E-04  1.75 
ZNF286A chr2 12858554-12858754 5.19 0 TRIB2 286B 1.07E-03  1.85 
ZNF286A chr2 27061411-27061611 6.86 0.06 DPYSL5 286B 0.01  -2.10 
ZNF286A chr2 27061411-27061611 6.86 0.06 DPYSL5 286A 0.01  -1.72 
REST chr2 27061477-27061677 22.51 0 DPYSL5 286B 0.01  -2.10 
REST chr2 27061477-27061677 22.51 0 DPYSL5 286A 0.01  -1.72 
REST chr2 54683492-54683692 35.26 0 EML6 286A 1.75E-05  1.50 
REST chr2 54683492-54683692 35.26 0 EML6 286B 0.01  1.81 
ZNF286A chr2 54951549-54951749 5.89 1.42 EML6 286A 1.75E-05  1.50 
ZNF286A chr2 54951549-54951749 5.89 1.42 EML6 286B 0.01  1.81 
REST chr2 186108234-186108434 46.88 0 FSIP2 286A 0  -1.50 
ZNF286A chr2 186406312-186406512 5.91 0 FSIP2 286A 0  -1.50 
ZNF286A chr2 186554009-186554209 5.86 0.23 FSIP2 286A 0  -1.50 
ZNF286A chr2 212501543-212501743 5.23 0.06 ERBB4 286B 0.01  -2.42 
REST chr2 212867829-212868029 36.25 0 ERBB4 286B 0.01  -2.42 
ZNF286A chr2 213824019-213824219 5.17 0.9 ERBB4 286B 0.01  -2.42 
REST chr2 234821540-234821740 28.37 0 HJURP 286B 0.05  3.07 
ZNF286A chr2 234821558-234821758 8.47 0 HJURP 286B 0.05  3.07 
ZNF286A chr20 656021-656221  7.5 0.21 SRXN1 286A 0.03  2.48 
ZNF286A chr20 656021-656221  7.5 0.21 SRXN1 286B 2.58E-03  2.48 
REST chr20 656239-656439  74.5 0 SRXN1 286A 0.03  2.48 
REST chr20 656239-656439  74.5 0 SRXN1 286B 2.58E-03  2.48 
ZNF286A chr20 3767725-3767925  5.13 0.6 CDC25B 286A 1.86E-09  1.76 
ZNF286A chr20 3767725-3767925  5.13 0.6 CDC25B 286B 0  1.97 
ZNF286A chr22 20068669-20068869 5.33 0.2 DGCR8 286A 1.11E-06  1.98 
ZNF286A chr22 20068669-20068869 5.33 0.2 DGCR8 286B 4.37E-08  2.17 
REST chr3 48699190-48699390 49.92 0 SLC26A6 286B 5.75E-12  2.12 
ZNF286A chr3 48699210-48699410 19.54 0 SLC26A6 286B 5.75E-12  2.12 
REST chr3 126877750-126877950 24.83 0 PLXNA1 286B 0  1.70 
REST chr3 126877750-126877950 24.83 0 PLXNA1 286A 4.48E-06  1.81 
REST chr3 126881756-126881956 31.93 0 PLXNA1 286B 0  1.70 
REST chr3 126881756-126881956 31.93 0 PLXNA1 286A 4.48E-06  1.81 
ZNF286A chr3 126881857-126882057 8.64 0 PLXNA1 286B 0  1.70 
ZNF286A chr3 126881857-126882057 8.64 0 PLXNA1 286A 4.48E-06  1.81 
REST chr3 126952226-126952426 17.74 0.36 PLXNA1 286B 0  1.70 
REST chr3 126952226-126952426 17.74 0.36 PLXNA1 286A 4.48E-06  1.81 
ZNF286A chr3 126952250-126952450 6.59 0.36 PLXNA1 286B 0  1.70 
ZNF286A chr3 126952250-126952450 6.59 0.36 PLXNA1 286A 4.48E-06  1.81 
ZNF286A chr3 137916043-137916243 6.69 0.21 DBR1 286B 1.14E-03  2.02 
REST chr3 137916061-137916261 13.96 0 DBR1 286B 1.14E-03  2.02 
ZNF286A chr4 47211615-47211815 5.23 0 GABRB1 286B 0  4.22 
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Supplemental Table S2.3. (Continued) 
ChIPExpt chr SummitStart-End  FoldEnr. FDR siRNADEG siExpt BH Adj p-values FC 
 
ZNF286A chr4 47211615-47211815 5.23 0 GABRB1 286A 0  4.23 
ZNF286A chr4 87514616-87514816 5.08 0.22 MAPK10 286A 2.05E-14  -1.73 
ZNF286A chr4 184424759-184424959 5.23 0.57 ING2 286A 4.75E-11  1.70 
ZNF286A chr4 184424759-184424959 5.23 0.57 ING2 286B 3.63E-05  2.03 
REST chr5 14628569-14628769 22.93 0 FAM105B 286A 0.01  1.58 
ZNF286A chr5 14628570-14628770 17.64 0 FAM105B 286A 0.01  1.58 
ZNF286A chr5 35128791-35128991 5.41 0.07 AGXT2 286B 0.01  -1.66 
REST chr5 56670474-56670674 54.99 0 ACTBL2 286A 5.13E-03  -3.13 
REST chr5 56670474-56670674 54.99 0 ACTBL2 286B 0.01  -3.04 
ZNF286A chr5 56679497-56679697 5.23 0.42 ACTBL2 286A 5.13E-03  -3.13 
ZNF286A chr5 56679497-56679697 5.23 0.42 ACTBL2 286B 0.01  -3.04 
REST chr5 56682816-56683016 15.96 1.97 ACTBL2 286A 5.13E-03  -3.13 
REST chr5 56682816-56683016 15.96 1.97 ACTBL2 286B 0.01  -3.04 
ZNF286A chr5 56682892-56683092 6.06 0.2 ACTBL2 286A 5.13E-03  -3.13 
ZNF286A chr5 56682892-56683092 6.06 0.2 ACTBL2 286B 0.01  -3.04 
ZNF286A chr5 132901754-132901954 13.87 0 FSTL4 286A 0.03  -2.27 
REST chr5 132901771-132901971 68.17 0 FSTL4 286A 0.03  -2.27 
REST chr5 132987069-132987269 33.7 0.1 FSTL4 286A 0.03  -2.27 
REST chr6 19771064-19771264 44.35 0 ID4 286B 0.04  -2.01 
ZNF286A chr6 19803714-19803914 5.23 0.06 ID4 286B 0.04  -2.01 
ZNF286A chr6 19988879-19989079 8.12 0 ID4 286B 0.04  -2.01 
REST chr6 19988898-19989098 14.9 0.36 ID4 286B 0.04  -2.01 
ZNF286A chr6 28625879-28626079 5.24 0.13 SCAND3 286B 0  -1.63 
ZNF286A chr6 28806321-28806521 5.23 0 SCAND3 286B 0  -1.63 
REST chr6 33291220-33291420 40.25 0 KIFC1 286A 4.39E-10  3.03 
REST chr6 33291220-33291420 40.25 0 KIFC1 286B 1.41E-14  3.08 
REST chr6 33291220-33291420 40.25 0 KIFC1 286A 6.48E-07  3.27 
REST chr6 33291220-33291420 40.25 0 KIFC1 286B 1.80E-08  3.43 
ZNF286A chr6 33291238-33291438 8.31 0.07 KIFC1 286A 4.39E-10  3.03 
ZNF286A chr6 33291238-33291438 8.31 0.07 KIFC1 286B 1.41E-14  3.08 
ZNF286A chr6 33291238-33291438 8.31 0.07 KIFC1 286A 6.48E-07  3.27 
ZNF286A chr6 33291238-33291438 8.31 0.07 KIFC1 286B 1.80E-08  3.43 
ZNF286A chr6 33559035-33559235 5.23 1.24 ITPR3 286B 9.16E-11  1.51 
ZNF286A chr6 36647765-36647965 5.68 0.14 RAB44 286A 8.93E-07  -1.57 
REST chr6 36702029-36702229 21.29 0.08 RAB44 286A 8.93E-07  -1.57 
ZNF286A chr6 130683384-130683584 8.67 0 SAMD3 286A 1.25E-12  2.30 
ZNF286A chr6 130683384-130683584 8.67 0 SAMD3 286B 0  2.68 
REST chr6 130683424-130683624 50.05 0 SAMD3 286A 1.25E-12  2.30 
REST chr6 130683424-130683624 50.05 0 SAMD3 286B 0  2.68 
ZNF286A chr6 132270310-132270510 5.45 1.04 CTGF 286B 0  1.51 
REST chr6 132718680-132718880 38.46 0 CTGF 286B 0  1.51 
REST chr7 75831098-75831298 186.78 0 HSPB1 286B 0.03  1.57 
ZNF286A chr7 75831191-75831391 10.86 0 HSPB1 286B 0.03  1.57 
REST chr7 75854789-75854989 49.04 0 HSPB1 286B 0.03  1.57 
ZNF286A chr7 75854895-75855095 9.85 0 HSPB1 286B 0.03  1.57 
ZNF286A chr7 75910433-75910633 5.91 0.61 HSPB1 286B 0.03  1.57 
ZNF286A chr7 150949333-150949533 5.68 0.13 NUB1 286B 2.95E-09  -1.87 
REST chr8 26435706-26435906 20.98 3.68 DPYSL2 286A 0.02  4.18 
REST chr8 26435706-26435906 20.98 3.68 DPYSL2 286B 5.85E-03  4.43 
ZNF286A chr8 26435754-26435954 5.45 0 DPYSL2 286A 0.02  4.18 
ZNF286A chr8 26435754-26435954 5.45 0 DPYSL2 286B 5.85E-03  4.43 
ZNF286A chr8 31652922-31653122 18.35 0 NRG1 286A 5.58E-04  2.01 
ZNF286A chr8 31652922-31653122 18.35 0 NRG1 286B 7.42E-05  2.42 
REST chr8 31652925-31653125 44.96 0 NRG1 286A 5.58E-04  2.01 
REST chr8 31652925-31653125 44.96 0 NRG1 286B 7.42E-05  2.42 
ZNF286A chr8 32161512-32161712 6.36 0 NRG1 286A 5.58E-04  2.01 
ZNF286A chr8 32161512-32161712 6.36 0 NRG1 286B 7.42E-05  2.42 
ZNF286A chr8 32487166-32487366 5.21 1.24 NRG1 286A 5.58E-04  2.01 
ZNF286A chr8 32487166-32487366 5.21 1.24 NRG1 286B 7.42E-05  2.42 
ZNF286A chr8 80941232-80941432 5.23 1.83 HEY1 286B 0.04  -1.99 
ZNF286A chr9 2018039-2018239  5.23 2.48 SMARCA2 286A 9.79E-06  1.52 
ZNF286A chr9 2018039-2018239  5.23 2.48 SMARCA2 286B 1.90E-03  1.72 
REST chr9 17744869-17745069 27.47 0 ADAMTSL1 286B 6.66E-05  -2.21 
REST chr9 17744869-17745069 27.47 0 ADAMTSL1 286A 2.32E-04  -1.88 
ZNF286A chr9 17744892-17745092 7.43 0.14 ADAMTSL1 286B 6.66E-05  -2.21 
ZNF286A chr9 17744892-17745092 7.43 0.14 ADAMTSL1 286A 2.32E-04  -1.88 
ZNF286A chr9 91800991-91801191 9.14 0 CKS2 286B 1.64E-06  1.77 
REST chr9 91801009-91801209 35.37 0 CKS2 286B 1.64E-06  1.77 
ZNF286A chr9 123676102-123676302 7.66 0 PHF19 286A 2.88E-08  2.40 
ZNF286A chr9 123676102-123676302 7.66 0 PHF19 286B 1.15E-08  2.48 
REST chr9 123676175-123676375 25.49 0 PHF19 286A 2.88E-08  2.40 
REST chr9 123676175-123676375 25.49 0 PHF19 286B 1.15E-08  2.48 
ZNF286A chr9 126872665-126872865 49.63 0 NEK6 286A 0.03  1.69 
Note: This supplementary table only includes an excerpt of 228 of 7,093 entries of the originating 
data file. The full supplementary file is available as part of the submitted manuscript. 
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Supplemental Table S2.4. 
IMAGEJ Raw Densitometry Data 
Cell Line ZNF286A ZNF286B REST  LaminB1 
SH-SY5Y RA-0 166.385 456.092 805.092 9739.548 
SH-SY5Y RA-3 752.113 650.456 594.506 11573.912 
SH-SY5Y RA-5 1641.184 802.698 526.92  10719.376 
SH-SY5Y RA-8 829.82  1043.527 83.728  7687.891 
 
IMAGEJ Corrected Values Based On LaminB1 
Cell Line ZNF286A ZNF286B REST  LaminB1 
SH-SY5Y RA-0 0.017083442 0.046828867 0.082662152 1 
SH-SY5Y RA-3 0.064983473 0.056200185 0.051366038 1 
SH-SY5Y RA-5 0.153104434 0.074882904 0.049155846 1 
SH-SY5Y RA-8 0.107938575 0.135736446 0.010890893 1 
 
Fold Change Of Retinoic Acid Day 0 vs Day 8 
  ZNF286A ZNF286B REST  LaminB1 
Fold Change: 6.432748538 2.893617021 0.13253012 
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Supplemental Table S2.5. (A) After observing certain genes become up-regulated after knocking 
down ZNF286A using siRNA, and using ChIP-Seq to find that those genes lay next to potential 
ZNF286A binding sites, we designed primers specific to the genes and validated their enrichment 
using QPCR in the ChIP input gDNA, IgG control DNA, and supernatant DNA (as a secondary 
control). Each of the "Input DNA", "IgG", and "Supernatant" values are compared to the 
ZNF286A-WGA (Whole Gene Amplification) material using 2-ΔCT to determine relative gene 
expression. The "siRNA KD" values are the expected values from our ZNF286A knockdown 
microarray. (B) After siRNA knockdown of ZNF286A and ZNF286B, microarrays were done on 
the resulting cells to identify genes that were either up-regulated (implying that ZNF286A or B 
was (in)directly involved in repressing the gene) or down-regulated (implying that ZNF286A or B 
was (in)directly involved in activating the gene). ChIP-Seq then identified areas where 
ZNF286A/B had binding sites, and identified the genes on the following list. 
 
A. Supplemental Table S2.5A. ZNF286A ChIP-seq peak fold enrichment (2-ΔCt) validation 
        MACS Fold Enr. QPCR Fold Enr.  
Peak Coordinates  Nearest Genes BP to Peak MACS FDR(%) Input IgG 
 
chr11:72452433-72452633 PDE2A,ARAP1 -67036; 10915 3.86 0.96 2.416 3.974 
chr7:54878443-54878643  EGFR,SEC61G -208251;-50876 4.38 0 2.97 1.566 
chr11:105543915-105544115 GRIA4,MSANTD4 63215; 348939 15.45 0 31.75 18.12 
chr6:146349511-146349711 RAB23,GRM1 -515244; 829 13.63 0 40.369 21.542 
chr5:78808148-78808348  HOMER1,JMY 1792; 276236 6.59 0 6.359 2.966 
chr9:133060996-133061196 HMCN2,NCS1 -224852;236239 15.44 0 27.098 19.474 
chr14:78986289-78986489 NRXN3  116296  6.02 0.2 12.445 9.196 
chr2:163697224-163697424 KCNH7,FIGN -2196; 895193 22.72 0 46.941 21.108 
chr15:89905022-89905222 POLG,MIR9-3 -27044; 6744 10.68 0 12.005 4.561 
chr8:31652922-31653122  NRG1,WRN -726043;788368 18.35 0 2.318 1.429 
chr5:95819672-95819872  CAST,PCSK1 -178169;-50788 12.78 0 6.882 4.226 
chr8:50824149-50824349  SNTG1  16  17.2 0 26.004 4.421 
chr15:70268858-70269058 RPLP1,TLE3 121887; 523835 14.69 0 15.898 12.178 
 
 
B. Supplemental Table S2.5B. Regulated genes after knockdown, near ChIP binding sites 
Gene ΔFold siSc ΔFold si0 FDR Gene ΔFold siSc ΔFold si0 FDR 
Up-regulated after ZNF286A KD Up-regulated after ZNF286B KD 
 
NCS1 
GABRB1 
NRG1 
SMARCA2 
EGFR 
HOMER1 
 
 
2.19 
4.23 
2.01 
1.52 
2.7 
1.14 
 
10.21 
3.43 
1.44 
2.7 
3.46 
3.04 
 
0 
0 
0 
0 
0.09 
0 
 
NCS1 
GABRB1 
NRG1 
SMARCA2 
EGFR 
 
 
2.16 
4.22 
2.42 
1.72 
2.95 
 
9.26 
4.35 
1.61 
3.51 
4.48 
 
0 
0 
0 
0 
0.0
9 
Down-regulated after ZNF286A KD Down-regulated after ZNF286B KD 
 
ARAP1 
NRXN3 
NRXN3 
 
 
-1.27 
-1.78 
-1.78 
 
-1.04 
-1.79 
-1.79 
 
0.75 
0.16 
0 
 
NRXN3 
NRXN3 
GRM1 
GRIA4 
 
 
-1.61 
-1.61 
-1.1 
-1.4 
 
-1.84 
-1.84 
-1.38 
-2.07 
 
0.1
6 
0 
0 
0 	
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CHAPTER 3 
 
ZNF286 AND REST ALTERNATIVE SPLICING ISOFORMS IN 
HUMANS AND MICE 
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Introduction 
 
As demonstrated in the previous chapters, the ZNF286A transcription factor codes 
for a Krüppel-type zinc finger transcription factor (TF) with a ten-finger long DNA-
binding domain, tethered to a KRAB domain. We showed that, despite possessing a non-
canonical KRAB, ZNF286A is still capable of interacting with the KRAB-interacting 
cofactor KAP-1. We also described how ZNF286A had experienced a human-specific 
duplication event, producing the ZNF286B gene that codes for a transcription factor that 
lacks ZNF286A’s KRAB-domain due to a pseudogene insertion event, but regulates the 
same genes, and in the same fashion as the originating TF. Indeed, our evidence suggests 
that despite their structural differences, both ZNF286A and ZNF286B serve primarily to 
repress genes involved in cell division and proliferation in neuroblastoma cells. In human 
tissues, ZNF286A and ZNF286B are both expressed in similar tissues, but at different 
levels – ZNF286A is most highly expressed in adult brain, while ZNF286B is most highly 
expressed in fetal brain – suggesting that both TFs serve different regulatory functions 
based on their independent regulation and differential expression. 
One of the remaining issues that may bear on our interpretation of our experimental 
results is that ZNF286A also transcribes an alternative transcript encoding a protein that is 
similar to ZNF286B in that it lacks a KRAB domain; this transcript uses an alternative 
splice acceptor site in the spacer-finger exon that is 59 base pairs upstream of the site 
used in the KRAB-containing transcript (Figure 3.1). We refer to these “KRAB(+)” and 
“KRAB(-)” isoforms as ZNF286A (K+) and ZNF286A (K-), respectively in the following 
discussion. Subsequent sequencing of amplified PCR products revealed that the 
alternative (K-) transcript includes an intronic sequence that shifts the finger region out of 
frame if the upstream starting methionine is used. An internal methionine codon, located 
just inside the spacer-finger exon is thus presumably used as the start of translation for 
this protein. 
As a truncated version of the full transcript, ZNF286A (K-) is theoretically capable 
of all the same DNA-binding functions as its full-length KRAB(+) isoform due to its 
possession of all the same DNA-binding zinc fingers. Our original hypothesis was that, 
therefore, this isoform would possess a distinct function, able to bind to the same 
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genomic binding sites but without the ability to repress due to the lack of KRAB(-) 
mediated silencing function. The functions of this (K-) isoform have not been studied, but 
these types of isoforms are commonly generated by ZNF transcription factors and have 
been generally presumed to encode “dominant negative” competitors that modulate the 
full-length protein’s function (Hsu et al., 1992; Bellefroid et al., 1997). 
The structure of ZNF286A is highly conserved in all marsupials and placental 
mammals, and in mice this unique gene is called Zfp286. The conservation between 
human and mouse genes also applies to splicing, meaning that the mouse Zfp286 gene 
also gives rise to (K+) and Zfp286 (K-) transcripts. This conservation aligns with 
previous studies that have shown that conserved human/mice alternative transcripts are 
enriched in regulatory genes and are frequently expressed in brain (Yeo et al., 2005). 
For these reasons we hypothesized that ZNF286A (K-) and ZNF286B, both lacking 
KRAB domains, may act as competitors to the human ZNF286A (K+), and fine-tune the 
regulation of target genes by varying concentrations of each protein in different tissues at 
different times. This competition would be comparable to the interactions of Zfp286 (K+) 
and Zfp286 (K-) in mice, with the caveat that mice do not have a duplicate of Zfp286 like 
humans do. However, our studies with ZNF286A and ZNF286B siRNA knockdown 
(Chapter 2) throw this assumption into question since both human genes appear to 
function similarly in cells where they are co-expressed, most likely as repressors of the 
same genes. 
Nevertheless, the fact that both humans and mice express both (K+) and (K-) 
isoforms still supports the idea that these isoforms may have distinct genetic functions. In 
alignment with this argument, ZNF286A and ZNF286B proteins may also function in 
subtly different ways. As our previous studies determined that ZNF286A and ZNF286B 
are expressed in human tissues at different levels, the human-specific duplicate may have 
evolved to fit a functional niche that is not occupied by the full-functioning ancestral 
gene. However, it is possible that a similar niche may in fact have been occupied by the 
ZNF286A KRAB(-) isoform in non-human species. Alternative splicing acts as a means 
of creating protein diversity (Keren et al., 2010; Nilsen & Graveley, 2010), so this 
suggests that it is possible for the function of KRAB-less ZNF286A has become part of 
the “official” non-alternative proteome in the form of the ZNF286B genetic duplicate.  
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In previous studies (Chapter 2) we showed that ZNF286A is enriched at binding 
sites of the RE-1 silencing transcription factor (REST) in human neuroblastoma cells and 
both ZNF286A and ZNF286B proteins can bind to the RE-1 motif in vitro. Therefore we 
hypothesize that ZNF286A (K+), (K-), and ZNF286B all play competitive and 
complementary roles to REST in transcriptional regulation. However these functions, 
while similar and perhaps cooperative and complementary, may nonetheless be distinct. 
To provide further clues to isoform and paralog function, we determined the 
expression patterns of both ZNF286A (K+) and (K-) isoforms in humans and mice, 
together with ZNG286B in human tissues. REST is also known to generate functionally 
distinct splicing isoforms in neuronal cells (Hamelink et al., 2004; Raj et al., 2011) and 
since it is clear from our previous studies (Chapter 2) that ZNF286 and REST act in a 
coordinated fashion, we also sought to correlate the expression of these isoforms with 
ZNF286 genes and isoforms in human and mouse tissues. Finally, we developed a series 
of expression constructs and transfected cells that should be crucial to unraveling the 
coordinated REST and ZNF286 protein functions in future studies. 
 
Materials and Methods 
 
Cell line culture and neuroblast differentiation 
SH-EP cells acquired from Dr. Martin Reick (Reick et al., 2001) were cultured 
and maintained in DMEM containing 10% fetal bovine serum (FBS). SH-SY5Y cells 
(ATCC® CCL-131) were grown in 1:1 DMEM/F12 media containing 10% FBS, and 
were induced to differentiate at 50-60% confluence by replacing growth media with 
DMEM media containing 15% FBS and 10 µM retinoic acid. Media was replaced every 
2-3 days. On the fifth day of RA-treatment, cells were washed three times with DMEM, 
and 50 ng/mL BDNF was added to the media (without serum) to maintain division. SH-
SY5Y cells are fully differentiated after 6-10 days (Encinas et al., 2002). Other cell lines 
cultured in this study were grown and maintained following the supplier’s recommended 
protocols: JEG-3 (ATCC® HTB-36), HEK-293 (ATCC® CRL-1573), NCCIT (ATCC® 
CRL-2073), GM-Hu-248 (Coriell Institute), Ntera-2 (ATCC® CRL-1973), PANC-1 
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(ATCC® CRL-1469), HeLa (ATCC® CCL-2), LNCap (ATCC® CRL-1740), and MDA-
MB-231 (ATCC® HTB-26). 
 
QPCR of tissue or cell line RNA 
RNA was collected by homogenizing tissue samples or cell pellets in TRIzol 
Reagent (Invitrogen Cat. 15596). Samples were purified and DNase-treated using the 
standard Qiagen protocol with RNeasy columns (Qiagen Cat. 74104), from which cDNA 
was synthesized using using M-MuLV Reverse Transcriptase (New England Biolabs Cat. 
M0253S). QPCR was performed on each sample using sequence-specific primers (Table 
3.1) in Power SYBR Green PCR Master Mix (ThermoFisher Cat. 4367659). PCR 
reactions proceeded using the Applied Biosystems 7900HT Fast Real-Time PCR System. 
 
Semi-QPCR of REST/REST4 
Semi-QPCR was used to visualize the amplification of REST and REST4 isoforms 
in differentiating SH-SY5Y. Unlike QPCR, which aims to fully amplify a product over 
the course of ~45 cycles, semi-QPCR seeks to minimize the number of cycles until the 
product is just barely able to visualized on an agarose gel. When a primer-set detects two 
products, then it is possible to determine which bands are brighter, and therefore have 
more starting RNA transcripts. The amount of starting template and number of PCR 
cycles is optimized according to the primers used. Primers used to test for REST/REST4 
were “h-p2-s” and “h-p8-as” as previously published and shown to detect both full-length 
REST and alternatively spliced REST4 isoforms (Palm et al., 1999). Samples were run for 
28 cycles at 55°C, and produced both REST and REST4 products in SH-SY5Y, as 
predicted.	
 
Inducible tagged Zfp286 vector 
The pTRE-tight vector (Clontech Cat. 631059) is designed with a tetracycline 
response element (TRE) promoter that is highly expressed in the presence of 
doxycycline, and a SV40 poly-A signal fragment to signal translation. This plasmid was 
edited to incorporate an two strep-tags and three hemagglutinin (HA) tags for easier 
detection of the activated protein, as well as a novel 89bp multiple cloning site that adds 
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40 additional restriction sites to the plasmid, making it easier to modify after construction 
(Table 3.2). Plasmids were purified from E. coli using a Midiprep Plasmid Purification 
system (Qiagen Cat. 12145). A Zfp286 sequence was isolated from an IMAGE clone 
(Mammalian Gene Collection IMAGE ID 5365187) and modified with two double-
stranded linker oligonucleotides on either side (Table 3.5), allowing for the insert to be 
ligated into the modified pTRE-tight vector. 
 
Inducible small hairpin RNA vector 
Small-interfering RNA (siRNA) oligos were designed (Table 3.3) and tested for 
knockdown efficiency in SH-EP cells. SH-EP cells were grown under normal growth 
conditions, and transfection proceeded using 5 nM concentrations of siRNA in HiPerFect 
Transfection Reagent (Qiagen Cat. 301704), following the standard protocol. Cells were 
incubated under normal growth conditions with Opti-MEM I Reduced Serum Medium 
(Gibco Cat. 31985) for 32 hours, then immediately collected for RNA and protein 
collection. Once siRNA were validated, the same designs were used to create shRNA-
hairpins with BglII and HindIII recognition sites (Table 3.4) for ligation into the 
pSUPERIOR.puro vector (OligoEngine Cat. VEC-IND-0006) using the manufacturer’s 
protocol and restriction enzymes from New England Biolabs. Samples were sequenced 
and returned with 100% identity (Table 3.5). Next, the plasmids were transfected into the 
Neuro2A cell line using Lipofectamine 2000 Transfection Reagent (ThermoFisher Cat. 
11668027) with the manufacturer’s protocol. 
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Results 
 
Pattern of ZNF286A isoform expression compared to ZNF286B and REST 
The previous study into ZNF286A and ZNF286B expression in tissues (Chapter 
2) generated a pattern of expression using human tissue RNA. However, the ZNF286A 
primer sequences used to do those studies amplified both KRAB(+) and KRAB(-) 
isoforms, offering little insight into ZNF286A’s more nuanced activity. To remedy this, 
primers were designed to target regions specific to each isoform – the 5’ UTR in the 
KRAB(+) transcript, and the 59 bp unique alternative splice region that was identified in 
the KRAB(-) transcript (Figure 3.1). 
Surprisingly, ZNF286A (K+) and ZNF286A (K-) display remarkably similar 
patterns of expression in human tissues (Figure 3.2). The highest expression for both 
isoforms was detected in adult brain with slightly less expression in fetal brain. This 
contrasts with ZNF286B, which is overwhelmingly expressed in fetal brain, with 
significantly lower expression in adults. Consistent with previous studies (Jones and 
Meech, 1999), REST is expressed much more highly in non-neuronal tissues (Figure 
3.2). 
In contrast, these genes and isoforms are differently expressed in established 
human cell lines (Figure 3.3). For example, ZNF286A (K+) and REST are both 
significantly expressed in SH-EP neuroblastoma and expressed at lower levels in JEG-3 
placental cells, while this pattern was reversed for ZNF286A (K-) and ZNF286B. It is thus 
clear that while ZNF286 isoforms may be co-expressed, in tissues, in individual cells – at 
least in immortalized cell lines – they are expressed in a more independent manner. 
 
Zfp286 and REST expression during mouse development 
Human tissue expression data suggested that ZNF286A and ZNF286B are 
expressed at high levels in fetal tissues (Fig 3.2). We were therefore interested to 
examine isoform expression over the course of development. As this task is complicated 
in human tissues, where both ZNF286A and ZNF286B can be monitored, measuring gene 
expression in mouse tissues throughout embryonic development is relatively 
straightforward. Therefore, Zfp286 (K+), Zfp286 (K-), and Rest transcript levels were 
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examined in mouse embryos from E13.5 to E18.5, in RNA from whole dissected head 
and body (Figure 3.4). Expression for all three genes was detected as highest in the head 
at embryonic day 14.5 (E14.5) and E15.5, a time during which a massive level of 
neurogenesis, and the first waves of neuronal differentiation, are occurring in the brain. 
During this period, the hippocampus reaches its peak of neurogenesis, and the 
hippocampal commissure appears (Ashwell et al., 1996; Finlay and Darlington, 1995). 
The cortex, overall, also growing and differentiating rapidly during this same period. The 
very high levels of Zfp286 expression at this timepoints is thus consistent with a role in 
neural differentiation, something that has already been confirmed with Rest (Ernsberger, 
2012; Rockowitz and Zheng, 2015). Our data indicate that in mouse, the Zfp286 (K-) 
isoform is dominantly expressed throughout mouse development, correlating well with 
the expression of Rest; similarly, although the (K-) isoform of Zfp286, was expressed at 
very low levels throughout mouse development, this transcript is also expressed most 
highly during the E14.5-E15.5 interval. The data also suggested a similar temporal 
pattern of expression for Zfp286 isoforms and Rest in these tissue samples. 
 
ZNF286 and REST expression during human neuronal differentiation in vitro 
These data suggest a dominant role for the Zfp286 (K+) isoform during mouse 
brain development, but also showed that the (K-) isoform is present in brain at the same 
developmental timepoints. However, since the embryonic samples include cell types 
other than neurons, questions regarding the specific roles of the Zfp286 isoforms during 
neuronal differentiation could not be addressed. Furthermore, since ZNF286B does not 
exist in mice, the similarities and differences between the ZNF286A (K-) isoform and the 
naturally (K-) human duplicate cannot be examined in mice.  
Fortunately, neuronal differentiation can be modeled in the human SH-SY5Y 
neuroblastoma cell line. SH-SY-5Y cells represent an undifferentiated neuronal 
progenitor state, and these cells can be induced to differentiate into mature neurons 
through retinoic acid treatment (Sidell et al., 1983; Encinas et al., 2000). We therefore 
tested expression of ZNF286A, ZNF286B, and REST in SH-SY-5Y samples over the 
course of neuronal differentiation (Figure 3.5A). 
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We observed that REST expression increases over the course of SH-SY5Y 
differentiation (Figure 3.5B). At first glance, this appears to contradict the observed 
decrease in REST protein levels by Western blots over the course of SY-SY5Y 
differentiation (Chapter 2). However, this result is actually expected, as it has been 
shown that REST transcription levels increase after neuroblast differentiation but are 
degraded before translation, leading to decreasing protein levels over the course of 
differentiatiation than what would be predicted based solely on the RNA expression 
(Singh et al., 2011). Meanwhile, expression of ZNF286A (K+) increases over 
differentiation (Figure 3.5B) consistent with our previous western blots (Chapter 2), but 
ZNF286A (K-) was detected at highest levels in undifferentiated SH-SY5Y cells and 
dropped in abundance over differentiation. The (K-) isoform is thus more similar to REST 
in that regard. In contrast, ZNF286B increased throughout differentiation, very much like 
the (K+) isoform of the ZNF286A gene.  
These results showed that – in this cell line, at least – the KRAB(+) and KRAB(-) 
isoforms of ZNF286A are not co-expressed throughout differentiation, despite the fact 
their co-expression during mouse development (Figure 3.4) and human fetal brain 
(Figure 3.2). These data must be interpreted with some caution since gene expression in 
the SH-SY-5Y cells may not necessarily be identical to isolated neurons differentiating in 
vivo. However, the contrast may be explained by the fact that the tissue samples include 
multiple cell types including neurons in different states of differentiation, whereas the 
neurons differentiated in vitro represent a single cell type differentiating in a coordinated 
time course and state.  
These data suggest that, although ZNF286A (K-) and ZNF286B share very similar 
sequences and domain structures, their functional role during neuron differentiation is 
likely to be distinct. In this model, the (K-) version of the ZNF286A protein is co-
expressed with REST, while the K+ isoform and ZNF286B are up-regulated as neuron 
differentiation proceeds. The data also suggest a functional cooperation between 
ZNF286A (K+) and ZNF286B, a hypothesis that is also supported by siRNA knockdown 
and Western blot data (Chapter 2), which also suggest similar, and perhaps cooperative 
roles for the two human proteins. 
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Alternative splicing of REST over the course of neuronal differnentiation in vitro 
One further part of this overall puzzle relates to the alternative splicing of REST 
throughout neuron differentiation. The REST4 truncated isoform retains the first five zinc 
fingers and nuclear localization signal of full-length REST (Palm et al., 1999; Coulson et 
al., 2000), and has unique expression patterns from REST in different cell types (Spencer 
et al., 2006; Uchida et al, 2010). While REST4 does not actually repress transcription, or 
does so very weakly (Magin et al., 2002; Lee et al., 2000), it functions as a full-length 
REST inhibitor by competing for NRSE binding sites (Shimojo et al., 1999; Tabuchi et 
al., 2002). 
We therefore tested the expression of full-length REST and REST4 isoforms 
throughout neuron differentiation at the same stages in which ZNF286 gene and isoform 
expression was tested (Figure 3.5B) using previously published primers demonstrated to 
amplify both isoforms of REST (Palm et al., 1999). We also included RNA from the SH-
EP cell line, in which functional assays for ZNF286A and ZNF286B were conducted 
(Chapter 2). These results confirm that REST alternative splicing is differentially 
regulated over neuron differentiation, with both full-length REST and truncated REST4 
isoforms being expressed at early stages, and REST4 being expressed exclusively when 
SH-SY-5Y cells are fully differentiated (at day 10, Figure 3.5C), consistent with 
published reports (Palm et al., 1999). Importantly, the data show that in the SH-EP cells 
we tested functionally, only the full-length REST isoform is detectably expressed, which 
is also consistent with published reports (Raj et al., 2011; Hamelink et al., 2004). This 
information may be critical in terms of understanding the relationships between REST, 
ZNF286A isoforms, and ZNF286B. 
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Tools for further study 
 
Inducible over-expression Zfp286 (K-) construct 
In order to better test the cellular functions of Zfp286 as they relate to cellular 
function and neuronal differentiation, we began construction of a Tet-inducible plasmid 
(Table 3.2) capable of over-expressing Zfp286 in vitro or (ultimately) wild type mice 
transfected with the vector. This plasmid utilizes a truncated Zfp286 insert sequence 
derived from the Mammalian Gene Collection that lacks the KRAB domain – 
unfortunately no IMAGE clones currently exist that can provide Zfp286 sequences with 
the KRAB domain included, and so restriction sites were added to the pTRE-tight vector 
to allow artificially synthesized KRAB oligos to be inserted in frame with the Zfp286 
plasmid sequence, effectively recreating the naturally occurring gene. The pTRE-tight 
vector was further modified to include two strep-tags and three HA-tags, allowing for the 
Zfp286 proteins induced from this plasmid to be detected using antibodies – as of now, 
there are no reliable Zfp286 antibodies that are commercially available, and this construct 
allows us to experiment on our proteins without possessing such an antibody. 
With this plasmid, we will be able to conduct future experiments allowing us to 
over-express Zfp286 (K-) in a variety of cell lines (ie. Neuro2A before and after 
differentiation with retinoic acid) and thereby evaluate the functions of the Zfp286 (K-) 
isoform. 
 
Inducible small hairpin RNA (shRNA) 
 
In order to better understand the functions of ZNF286A, ZNF286B, and REST, the 
expression of each of these genes was knocked down using specific siRNAs (Table 3.3). 
The results of these knockdowns in ZNF286A and ZNF286B were discussed in length in 
Chapter 2 of this thesis. However, this form of non-stable interference can lead to data 
that is difficult or impossible to modulate. However, inducible shRNA vectors provide a 
much more convenient method by which to regulate protein expression in stable 
mammalian cell lines (Szulc et al., 2006; Laurenti et al., 2010).  
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Using the same siRNA designs that were previously validated, we designed 
shRNA hairpin constructs, which would be ligated as oligonucleotides into the 
pSUPERIOR.puro vector at the location of a HindIII restriction site (Table 3.4). 
pSUPERIOR.puro allows for the inducible expression of genes using the doses of 
tetracycline, meaning that the activation of the shRNA hairpins could be carefully 
regulated in order to knock down the expression of ZNF286A, ZNF286B, and REST in 
cell lines that have been stably transfected with the vector. 
All eight shRNA were correctly ligated into pSUPERIOR.puro and confirmed by 
sequencing (Table 3.5). One of these vectors, pSUPERIOR.puro_sh-REST-1, was stably 
transfected into the Neuro2A cell line, which develops neuron-like properties when 
differentiated with retinoic acid (Mao et al., 2000). The same vector was also transfected 
successfully into the human U-2 OS (ATCC® HTB-96) osteosarcoma. 
 
Discussion 
 
This analysis of KRAB(+) and KRAB(-) isoforms of human ZNF286A and mouse 
Zfp286 has revealed several important findings. First, while the two isoforms that they 
are similarly expressed in human and mouse whole-tissue RNA, the human isoforms, at 
least are differentially expressed in isolated cell types, including during neuronal 
differentiation in vitro. In contrast, ZNF286B, which is structurally very similar to 
ZNF286A (K-), is closely co-expressed with ZNF286A (K+) and appears to function very 
similarly to, and perhaps cooperatively with, the ancestral full-length protein. While 
understanding the functions of these proteins definitively will require further study, our 
data suggest that the (K+), (K-) and human-specific ZNF286B protein serve distinct 
functional roles.  
The constructs I have generated to tag individual isoforms and to knockdown the 
individual human proteins stably in human and mouse cells provide new tools to address 
these hypotheses definitively. For example, future experiments can utilize the inducible 
shRNA vectors that have been constructed as a part of this project to test the roles of each 
protein at specific steps in neuronal differentiation. Inducible knockdowns of REST can 
now be carried out in a human non-neuronal (U-2 OS) and a mouse neuronal (Neuro2A) 
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cells lines, and these constructs, in addition to the ZNF286/Zfp286 vectors can now be 
introduced into SH-SY5Y or SK-N-SH neuroblasts for temporal control of gene 
knockdown during differentiation. 
Data from Chapter 2 of this thesis suggested that the inclusion or omission of the 
KRAB domains in ZNF286A and ZNF286B proteins does not necessarily determine 
distinct functions. Indeed, ZNF286B appears to function as a repressor, even without the 
KRAB domain, at least in SH-EP cells. This function may indeed be context-dependent, 
as has been demonstrated for REST (Perera et al., 2015; Spencer et al., 2006). How the 
KRAB-less duplicate of the human protein carries out its repressive function is presently 
not understood. It is possible that both ZNF286A and B proteins include repressive 
domains aside from the KRAB, for example, within their shared “tether” regions. In this 
case, one would expect the (K-) versions of ZNF286A to also possess intrinsic repressor 
function. A second possibility is that the additional protein segment co-opted by 
ZNF286B from its FOX03B insertion has conferred a novel repressive role. However, it 
is also possible that the ZNF286B protein (and by analogy, possibly the protein encoded 
by the ZNF286A (K-) isoform) interacts with ZNF286A (K+) protein as a dimer, with the 
repressive function of K- proteins dependent on the KRAB-containing ancestral partner. 
The very similar functions detected after siRNA knockdown of the two human genes is 
consistent with such a cooperative function. 
Whatever the specific mode of interaction, together our data do strongly suggest 
that, in contrast to serving as a “dominant negative” version of the (K+) full-length 
ZNF286A protein with opposite interactions to REST, ZNF286B and the (K-) isoform of 
the ancestral proteins may serve more complex functions than previously imagined. Since 
the isoforms of ZNF286A are not distinguishable on the protein level and cannot be 
targeted specifically, the functions of these individual proteins may be best addressed 
through tagged protein expression constructs, such as the ZNF286A (K-) isoform 
expression construct described in this study. 
Further studies, for example, with tagged constructs, should focus on 
identification of binding partners for the (K+) and (K-) versions of ZNF286A or its 
unique mouse counterpart, to better understand the regulatory functions and possible 
differential interactions with REST during neuron development. The data and tools 
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described here will streamline this analysis permitting a new understanding of ZNF286 
gene function and the novel human functions that arose through creation of ZNF286B. 
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FIGURES 
 
Figure 3.1. Structure of human ZNF286 genes. (A) In mice, Zfp286A codes for a Krüppel-type 
zinc finger transcription factor with a ten-finger long DNA-binding domain tethered to its KRAB 
domain. (B) This structure is conserved in mammals and marsupials, along with a “KRAB-
minus” alternatively-spliced isoform that lacks the KRAB domain. (C) ZNF286A is the human 
paralog of Zfp286, including a KRAB-A and KRAB-B domain. (D) Like the mouse paralog, 
ZNF286A also codes for a KRAB-minus isoform. (E) ZNF286B similarly lacks the KRAB-
coding domain that is present in ZNF286A, incorporating a novel sequence in its place. The 
locations of the 5’ UTR (“5”), pre-KRAB region (“P”), KRAB-A domiain (“A”), the tether 
region (“T”), zinc finger domain (“F”), and 3’ UTR (“3”) regions are represented with letters 
above each exon. In addition, the locations of primers used in this study are outlined in red, with 
an asterisk used to indicate the location of primer sequences that are isoform-specific. 
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Figure 3.2. Relative expression of ZNF286 transcripts in adult and fetal human tissues. The 
expression of both (A) ZNF286A(K+) and (B) ZNF286A (K-) transcripts in various human tissues 
was determined by performing QPCR on each sample using sequence-specific primers for each 
gene. The 2-ΔCt values for each sample were calculated in relation to GAPDH positive controls 
(Livak and Schmittgen, 2001) and then normalized against the highest-expressed tissue for each 
primer set, in order to minimize primer-specific effects when comparing both genes. The pattern 
for both isoforms is mostly comparable across tissues. (C) This is in contrast to the human 
duplicate ZNF286B, which is expressed much higher in fetal tissues than in adult tissues. (D) 
REST expression is higher in non-neuronal tissues. 
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Figure 3.3. Relative expression of ZNF286 and REST transcripts in human cell lines. The 
relative expression of select gene transcripts in various human cell lines, as calculated through 
QPCR and subsequent analysis using GAPDH as a positive control. Relative gene expression was 
calculated for (A) KRAB-plus ZNF286A isoform, (B) KRAB-minus ZNF286A isoform, (C) 
ZNF286B, and (D) REST transcripts. Each data set has been normalized against the cell line with 
the highest-expression in that set. For each gene, expression is highest in either SHEP or JEG-3 
cell lines. 
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Figure 3.4. Relative expression of Zfp286 and Rest transcripts in embryonic mouse tissues. The 
relative expression of (A) Zfp286 (K+), (B) Zfp286 (K-), and (C) Rest was calculated using whole 
tissue RNA collected from whole mouse heads and bodies collected at various stages of 
embryonic development from E13.5 to E18.5. The patterns of expression between each transcript 
very closely coincide. 
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Figure 3.5. Relative expression of ZNF286 transcripts during neural differentiation. (A) SH-
SY5Y neuroblastoma are induced to differentiate after the addition of retinoic acid (RA). Cells 
are considered fully differentiated after treatment for 7-10 days. (B) The relative expression of 
ZNF286A (K+), ZNF286A (K-), ZNF286B, and REST transcripts was calculated in the 
differentiating SH-SY5Y cell line over the course of differentiation using retinoic acid. (C) Semi-
QPCR show the expression of REST and REST4 transcripts in differentiating SH-SY5Y, using 
primers from Palm et al. (1999). As REST expression goes down after differentiation, REST4 
remains. Note that SHEP cells only contain the full-length REST. 
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TABLES 
 
Table 3.1. Primer sequences for human (Hu) and mouse (Ms). 
Gene Target  FWD Primer (5’-to-3’)  RVS Primer (5’-to-3’) 
 
Ms-Gapdh  Qiagen Cat. QT01658692 
Ms-Rest   TGGCCACCCAGGTGATGGGG  TGAGCTGAGGGGCTGCCAGT 
Ms-Zfp286 (K+)  ACGGGTTTGGCCGAAGTGCC  TGGGAAGCCAGAGCGAGACC 
Ms-Zfp286 (K-)  GCAGTGACTCAGCTATTCGTCT  CTGACGCTCTTACTGGATGGT 
 
Hu-GAPDH  Qiagen Cat. QT01192646 
Hu-REST   TGGGGCCTGCTCCCACAGAG  GCAGGCCGTATCTGGGCACC 
Hu-ZNF286A  TGTGAGGCCCGGGATGGGAG  TGCCTCAGTCCTACGGCGCT 
Hu-ZNF286A (K+) GGAAGCTGGATCCTGCACAA  TGTGCTCAACAAAAAGGCAGT 
Hu-ZNF286A (K-) GGAAGCTGGATCCTGCACAA  TGTGCTCAACAAAAAGGCAGT 
Hu-ZNF286B  GCCATTCAGTGCATATTCAACACCAG TACACTCATAGGGTTTCTCTCCAGTGTGA 
 
Hu-REST/REST4  Palm et al. (1999) h-p2-s Palm et al. (1999) h-p8-as 
GTGACCGCTGCGGCTACAATACTAA GGACAAGTAGGATGCTTAGATTTGA 
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Table 3.2. pTTS plasmid outline. 
pTTS-Zfp286(KRAB-); 3897bp 
 
CTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAA
CGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATA
GAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAAC
CGTCAGATCGCCTGGAGAATTCGAGCTCGGTACCCGGGGATCCTCTAGTCAGCTGACGCGTGCTAGCGCGGCCGCATCGAT^ 
 
^AGCTggttgctttattgctgcgATCTCCTAACTCCACAAAGGCATGCTTCCATCTTGATTCATCTTCACCTGTTATAGGACTGTGTTACTGTT
GAGCACAGAAAACAAAGAACATGTGCATTTGCAATGTCTTTTCAGACATGGAAACCAGACCTGAGAGCAAGGAGTCAACTTCAGTGCTAGACTT
TTCCAAAGAAGAGTCAAACAGACTGACAGAAAATACTGCTTCTGACTCCGACATTGAAACTGCTCTTGAATGTGAGCGTTGGCTAGAACATCGT
CAAAGAAATCGGGAGAGGTACCCAAGACAAATGTCTGCTCACAGGAACTCCCTCCCTGCGCAAGAAGATGGTGAACGTGATGTATATTGGAAAA
GCTTCAGTCAGAAACCTCTCCTTACAACTGATGACAGAGACCCCAAAGGATCCTGGGACGTTCACACGCTTGGGAAAAGACTGAAGCAGAAATC
AAAGTTAATGACAAAGCAGAGACCTTATAAAGAGAAAAAACCTCATAAGTGTGATGAGTGTGGCGAACTCTTCACTTACCGTTCGGTACTTATC
CGACACCAGAGAGTTCACACTGGAGAGAAACCTTATACCTGCAGTGAGTGCGGGAAGTCCTTCAGCCACAGAGCCAATCTGACTAAGCACCAGA
GAACCCACACTAGGATTCTCTTCGAGTGTGGCGAGTGCAAGAAAACCTTCATAGAAAGTTCATCCCTTGAGGTACATCAGAGAATCCACATCGG
GGAGAGACCTTACGAATGCGCCGAGTGTGGGAAAGGCTTCAACCGAAGTACACACCTTGCCCAGCATCAGCTGATTCATACTGGGGTGAAGCCT
TATGAATGTAACGAATGTGACAAAGCTTTCATTCACTCATCAGCTCTCATTAAGCATCAAAGAACTCATACTGGAGAGAAGCCCTATAAATGTC
AAGACTGTGGGAAAGCCTTCAGCCACTGCTCATCTCTTACGAAGCACCAGAGGGTTCACACGGGGGAAAGGCCATATGAGTGCAGTGAGTGTGG
GAAGACTTTCAGTCAGAGCACGCACCTTGTTCAGCACCAGAGAATCCACACTGGAGAAAAGCCCTACGAATGTAACGAATGTGGGAAAACATTC
AGCCGGgaggtgcaagtgagtgttGAT^ 
 
^ATCTCTAGATCTAGACCATATGGGTGCATGGAGCCACCCGCAGTTCGAAAAGTGGAGCCACCCGCAGTTCGAAAAGGGTGCATACCCATACGATGTTCCAG
ATTACGCTTACCCATACGATGTTCCAGATTACGCTTACCCATACGATGTTCCAGATTACGCTTAATCTAGA GGTTTTACTTCAGCCATACCACATTTGTAGA
GCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAA
AGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCCTCGAGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCG
GTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGT
AAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTA
TAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGC
GTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGC
TGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTAT
GTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGA
AAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAA
GAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAG
ATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCA
GCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATA
CCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATC
CAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCG
TCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCG
ATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTG
ACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGA
ACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCC
AACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGT
TGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAA
ATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCC
TTTCGTCTTCA 
 
In order from start to end, the following regions are outlined in the above sequence: 
 
TRE   Tet-response Element 
MCS   Multiple Cloning Site with EcoRV (GAT^ATC) site 
XbaI site  T^CTAGA (insert removal marker) 
NdeI site  CA^TATG (cloning selection marker) 
Gly-Ala spacer  GGTGCA 
Strep-tag x2  TGGAGCCACCCGCAGTTCGAAAAG 
Gly-Ala spacer  GGTGCA 
HA-tag x3  TACCCATACGATGTTCCAGATTACGCT 
Stop codon  TAA 
XbaI site  T^CTAGA (insert removal marker) 
 
The indented region represents the MGC Image Clone insert amplified out of mouse cDNA. The following 
“linker” sequences were added to each side of the insert to allow it to ligate to the vector:  
 
IMAGE Clone FWD Linker: 5’-pTTS-  (HindIII)-AGCTTgattgctttattgctgA     -Zfp286-3’ 
3’-pTTS-         ActaacgaaataacgacTCTAG-(BglII)-Zfp286-5’ 
 
IMAGE Clone RVS Linker: 5’-Zfp286-(HpaII)-CGGgaggtgcaagtgagtgttGAT     -pTTS-3’ 
3’-Zfp286-    CctccacgttcactcacaaCTA-(EcoRV)    -pTTS-5’ 
 
In addition, the following primers were used for sequencing and ligation confirmation: 
 
pTTS_seq_FWD  5’-AGGCGTATCACGAGGCCCTTTCGT-3’ 
pTTS_seq_RVS  5’-TCAGCTCACTCAAAGGCGGTAATA-3’ 
pQE-For   5’-CCCGAAAAGTGCCACCTG-3’ (Sequencing Primer) 
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Table 3.3. shRNA oligos for ligation into pSUPERIOR plasmid. 
siRNA oligo name Company, product ID  siRNA sequence (5’-to-3’) 
 
SI-286A-1  Qiagen Cat. SI04135600  CACCTACCATTCAGTGCTTAT 
SI-286A-5  Qiagen Cat. SI03227448  TAGCAGTACGAACATTGTGAA 
SI-286B-1  Qiagen Cat. SI04868115  CAGGCCCTTATAAGGGCACTA 
SI-286B-2  Qiagen Cat. SI05457697  TACCATCAATTAAGTTTCATT 
SI-286B-3  Qiagen Cat. SI05457704  TAACTCTTACCTATTACAGAA 
SI-NRSF-1-1597  Proligo, 1300782-H  GTGCATACAGGAAGCAATTCAGA 
SI-NRSF-2-2612  Proligo, 1300784-H  TAGTGCCTGTTAAAGATAGCTGG 
SI-NRSF-3-2902  Proligo, 1300786-H  CAGACTGACAGTATAGTTTGTGA 
 
SI-Zfp286-1  Not used in this study. AACCATCCAGTAAGAGCGTCAGA 
SI-Zfp286-2  Not used in this study. CTCCTAACTCCACAAAGGCATGC 
SI-Zfp286-3  Not used in this study. TCCACAAAGGCATGCTTCCATCT 
SI-Zfp286-4  Not used in this study. ATCTTCACCTGTTATAGGACTGT 
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Table 3.4. shRNA oligos for ligation into pSUPERIOR plasmid. 
shRNA oligo name 5’- BglII-SenseSequence–Hairpin-AntisenseSequence-HindIII –3’ 
 
sh-ZNF286A-1-S  GATCCCCACCTACCATTCAGTGCTTATTCAAGAGATAAGCACTGAATGGTAGGTTTTTTA 
sh-ZNF286A-1-AS AGCTTAAAAAACCTACCATTCAGTGCTTATCTCTTGAATAAGCACTGAATGGTAGGTGGG 
sh-ZNF286A-5-S  GATCCCCAGCAGTACGAACATTGTGATTCAAGAGATCACAATGTTCGTACTGCTTTTTTA 
sh-ZNF286A-5-AS AGCTTAAAAAAGCAGTACGAACATTGTGATCTCTTGAATCACAATGTTCGTACTGCTGGG 
 
sh-ZNF286B-1-S  GATCCCCAGGCCCTTATAAGGGCACTTTCAAGAGAAGTGCCCTTATAAGGGCCTTTTTTA 
sh-ZNF286B-1-AS AGCTTAAAAAAGGCCCTTATAAGGGCACTTCTCTTGAAAGTGCCCTTATAAGGGCCTGGG 
sh-ZNF286B-2-S  GATCCCCACCATCAATTAAGTTTCATTTCAAGAGAATGAAACTTAATTGATGGTTTTTTA 
sh-ZNF286B-2-AS AGCTTAAAAAACCATCAATTAAGTTTCATTCTCTTGAAATGAAACTTAATTGATGGTGGG 
sh-ZNF286B-3-S  GATCCCCAACTCTTACCTATTACAGATTCAAGAGATCTGTAATAGGTAAGAGTTTTTTTA 
sh-ZNF286B-3-AS AGCTTAAAAAAACTCTTACCTATTACAGATCTCTTGAATCTGTAATAGGTAAGAGTTGGG 
 
sh-NRSF-1-S  GATCCCCGCATACAGGAAGCAATTCATTCAAGAGATGAATTGCTTCCTGTATGCTTTTTA 
sh-NRSF-1-AS  AGCTTAAAAAGCATACAGGAAGCAATTCATCTCTTGAATGAATTGCTTCCTGTATGCGGG 
sh-NRSF-2-S  GATCCCCGTGCCTGTTAAAGATAGCTTTCAAGAGAAGCTATCTTTAACAGGCACTTTTTA 
sh-NRSF-2-AS  AGCTTAAAAAGTGCCTGTTAAAGATAGCTTCTCTTGAAAGCTATCTTTAACAGGCACGGG 
sh-NRSF-3-S  GATCCCCGACTGACAGTATAGTTTGTTTCAAGAGAACAAACTATACTGTCAGTCTTTTTA 
sh-NRSF-3-AS  AGCTTAAAAAGACTGACAGTATAGTTTGTTCTCTTGAAACAAACTATACTGTCAGTCGGG 
 
sh-Zfp286-1-S  GATCCCCCCATCCAGTAAGAGCGTCATTCAAGAGATGACGCTCTTACTGGATGGTTTTTA 
sh-Zfp286-1-AS  AGCTTAAAAACCATCCAGTAAGAGCGTCATCTCTTGAATGACGCTCTTACTGGATGGGGG 
sh-Zfp286-2-S  GATCCCCCCTAACTCCACAAAGGCATTTCAAGAGAATGCCTTTGTGGAGTTAGGTTTTTA 
sh-Zfp286-2-AS  AGCTTAAAAACCTAACTCCACAAAGGCATTCTCTTGAAATGCCTTTGTGGAGTTAGGGGG 
sh-Zfp286-3-S  GATCCCCCACAAAGGCATGCTTCCATTTCAAGAGAATGGAAGCATGCCTTTGTGTTTTTA 
sh-Zfp286-3-AS  AGCTTAAAAACACAAAGGCATGCTTCCATTCTCTTGAAATGGAAGCATGCCTTTGTGGGG 
sh-Zfp286-4-S  GATCCCCCTTCACCTGTTATAGGACTTTCAAGAGAAGTCCTATAACAGGTGAAGTTTTTA 
sh-Zfp286-4-AS  AGCTTAAAAACTTCACCTGTTATAGGACTTCTCTTGAAAGTCCTATAACAGGTGAAGGGG 
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Table 3.5. shRNA construct sequences confirmed by sequencing. 
pSUPERIOR.puro (with no shRNA inserts) 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGAGATCTA^AGCTTATCGATACCGTCGACCTC
GAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGT
GAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTC
ACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAG
AGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTC
ACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC
CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT
ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCC
AAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACA
CGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGC
CTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGA
TCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCA
CCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATC
AGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGG
CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAA
GGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCA
GTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTC
CCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGT
GAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACA
TAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGA
TGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCC
GCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTG
TCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold and highlighted. It is into this restriction 
site that the shRNA constructs are ligated. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-286A-1 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCACCTACCATTCAGTGCTTATTC
AAGAGATAAGCACTGAATGGTAGGTTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-286A-5 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCAGCAGTACGAACATTGTGATTC
AAGAGATCACAATGTTCGTACTGCTTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-286B-1 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCAGGCCCTTATAAGGGCACTTTC
AAGAGAAGTGCCCTTATAAGGGCCTTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-286B-2 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCACCATCAATTAAGTTTCATTTC
AAGAGAATGAAACTTAATTGATGGTTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-286B-3 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCAACTCTTACCTATTACAGATTC
AAGAGATCTGTAATAGGTAAGAGTTTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-REST-1 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCGCATACAGGAAGCAATTCATTC
AAGAGATGAATTGCTTCCTGTATGCTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-REST-2 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCGTGCCTGTTAAAGATAGCTTTC
AAGAGAAGCTATCTTTAACAGGCACTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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Table 3.5. (Continued) 
pSUPERIOR.puro_sh-REST-3 
 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCA
AAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGAC
TCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTG
CCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCG
CTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCATGGGGTC
GTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCG
GGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCAC
CCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGG
CCAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAACTCG
GCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGC
GACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGATCGA
CGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCTGGGGACGTCGTCGCGGGTGGCGAGGCGCACC
GTGGGCTTGTACTCGGTCATGGTAAGCTAGCTTGGGCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGG
ACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGC
TCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGG
GAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAAT
GTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCC
TCCCCTACCCGGTAGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCG
CGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGAAATCA
CCATAAACGTGAAATGTCTTTGGATTTGGGAATCTTATAAGTTCCCTATCAGTGATAGA^GATCCCCGACTGACAGTATAGTTTGTTTC
AAGAGAACAAACTATACTGTCAGTCTTTTTA^AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCTT
TAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACAT
ACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC
AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATA
GGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTT
TTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTC
GTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCG
CGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATC
CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATG
TTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC
ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTA
TGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
The digested HindIII site (A^AGCTT) is shown in bold, with the inserted shRNA construct 
located in between them. The sequence of interest is highlighted in yellow, and was sequenced to 
confirm proper insertion of the shRNA construct. 
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CONCLUSIONS 
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In summary 
 
ZNF286A is a unique member of the mammalian KRAB-ZNF gene family. 
Originally arising in metatherian lineages, it has remained conserved for hundreds of 
millions of years. We demonstrate here that sometime during very recent primate 
evolution, and most probably in the hominid lineage, ZNF286A was involved in a large 
duplication event that led to the creation of ZNF286B. Concomitantly or shortly after, a 
FOXO3B pseudogene inserted into the duplicate in place of a functional KRAB domain, 
creating the human-specific version of this gene with structural elements and regulatory 
sequences that distinguish it clearly from its metatherian ancestor. 
Putative regulatory targets, defined as differentially expressed genes (DEGs) that 
are flanked by or contain ChIP-enriched binding sites, implicate ZNF286A as a regulator 
of cell cycle function and cell proliferation. It is well established that the cell cycle is 
carefully regulated during neurogenesis, and differences in cell cycle regulation can very 
likely explain many aspects of the evolution of the larger primate brain (Calegari et al., 
2005). Although this hypothesis will require additional testing in the future, we speculate 
that ZNF286A and ZNF286B may play important roles in brain development, and that 
the generation of the ZNF286B gene duplicate had an impact on evolution of the human 
brain. 
Explorations of RNA expression in cells and tissues confirm that ZNF286A and 
ZNF286B are highly expressed in the brain and differentiated neural cells, and yet their 
overall patterns of expression are not identical in all issues. This, as well as the structural 
differences between the two paralogs, leads us to believe that their functions are closely 
related, but distinct from one another. It is likely that, given their shared zinc finger 
domains, the two paralogs interact at the same DNA-binding sites. Whether they compete 
or co-operate in binding at those sites remains unanswered, and an important question for 
further study. 
Close analysis of ZNF286 binding regions as discovered through ChIP-seq 
revealed a high degree of overlap with the known recognition motif of REST, as well as a 
secondary G-rich motif to which REST also binds in neuronal cells. All three proteins of 
interest – ZNF286A, ZNF286B, and REST – were shown to bind to these two motifs in 
	 122 
vitro, as evidenced through EMSA. We could not find evidence, however, that the 
ZNF286 paralogs interact directly with REST, and we surmise that it is much more likely 
that they compete for DNA-binding sites, or possibly, prefer different “half-sites” without 
direct protein:protein contact. 
We predict that the ZNF286 proteins inhibit the proliferation and stimulation of 
neuronal differentiation – a function that is opposite to the known functions of REST in 
neuronal cells (Schoenherr & Anderson, 1995). We hypothesize, therefore, that the 
ZNF286 paralogs evolved as competitive modulators of REST activities in the brain, with 
the duplication and divergence of ZNF286B having allowed for separate regulation of this 
deeply conserved activity, that is, adding a novel layer of REST modulation in fetal and 
adult brain, as well as other human tissues. 
To further complicate the interpretation of these functions, ZNF286A additionally 
codes for a KRAB(-) isoform that is conserved across species. We show that the 
expression of both KRAB(+) and KRAB(-) transcripts is mostly comparable across 
tissues, which consist of multiple cell types, but differs in individual cell lines, including 
neuroblastoma cell lines that can be induced towards neuronal differentiation. This 
suggests that, at least under certain conditions, ZNF286A (K+) and (K-) can serve 
different functions. Since we were unable to target the (K-) isoform specifically, our 
current study cannot definitively address this assumption. However, the tagged 
expression constructs that have been generated for the (K-) isoform may help solve this 
puzzle in the future. 
As such, we have identified three distinct proteins that can be predicted to bind to 
the same binding sites as REST. One might expect that ZNF286 (K+), possessing what 
we have shown to be a functional KAP-1 interacting KRAB domain, would act as a 
repressor at these sites (Friedman et al., 1996). Indeed, our data suggest this is most likely 
true, at least for a majority of the “target” genes. However, it is most surprising that, after 
knockdown of ZNF286A by siRNA, we do find genes – including some closely 
neighboring ones – that appear to be up-regulated by the protein. This suggests that 
KRAB may not be a simple transcriptional repressor (Margolin et al., 1994; Friedman et 
al., 1996; Urratia, 2003; Sripathy et al., 2006), but might have more complex functions 
that have not yet been fully described. There are hundreds of KRAB-ZNF proteins, and 
	 123 
yet studies into KRAB domains have predominantly focused on KRAB activity using the 
KOX1 “consensus KRAB” as a model to represent all KRAB domains across the 
proteome (Moosman et al., 1996). Given what we know about ZNF286A and its KRAB 
domain, it is very likely that these other studies into KRAB are lacking in scope. 
From our EMSA competition data, it appears that ZNF286B has a slight 
preference for the “left” REST half-site, and it is possible that ZNF286A and ZNF286B 
could both occupy the REST site. Such “cooperative binding” could elicit a stronger 
regulatory effect, and might explain the very similar results we obtained when we 
knocked down each gene specifically. Furthermore, complete blockage of the RE-1 site 
could more effectively block REST’s ability to bind, and have a stronger effect on 
adjacent genes. Indeed, it is possible the ZNF286 proteins’ regulatory function results 
primarily from the blockage of REST. However, both ZNF286 paralogs have functionally 
identical zinc finger domains, and it is difficult to explain how they might have distinct 
half-site preference. The hypothesis of cooperative binding thus remains to be tested and 
further explored. 
As such, it is likely that the FOXO3B region that has inserted into ZNF286B is 
introducing some additional function into the human-specific transcription factor that 
would affect its binding affinity (either to DNA or to the ZNF286A protein) in some way. 
Fully understanding this would require more research into ZNF286B interactions, for 
example, through co-immunoprecipitation followed by protein mass spectroscopy or 
through other types of co-IP experiments. Co-IP like this would require the use of tagged 
proteins, as the only effective ZNF286A and ZNF286B antibodies that we have found 
were derived in rabbit, and co-IP requires antibodies from two different species. Already, 
the groundwork for tagged ZNF286 construct has been laid out by the work done in this 
thesis, as we now have a pTRE-tight inducible vector with a strep and HA-tags, along 
with a modified multiple cloning site to allow for easy insertion of a gene sequence. 
Further utilizing these vectors in human cell lines would open up a large number of 
possibilities for new experiments into this transcription factor family. Future research 
should provide insight into the full range of cofactors interacting with ZNF286A and B, 
as well as the different contexts in which ZNF286A and B functions; we have examined 
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functions in neuroblastoma, but we do not have a clear picture of whether these results 
can predict functions in different types of cells. 
Additionally, humans possess two versions of ZNF286 as we have seen, but other 
mammals like mice only possess one – Zfp286. By focusing on how ZNF286A and B 
function in human cells, and contrasting that with how Zfp286 functions by itself in mice, 
we should have a much better understanding of these systems than is presently possible. 
The inducible shRNA constructs that have been designed as a part of this thesis will be an 
indispensible tool for this type of study in the future. 
 
Closing remarks 
 
This thesis has attempted to elucidate the functions and regulatory activities of 
both ZNF286A isoforms, ZNF286B, and their potential interplay with REST. ZNF286 
represents an interesting case study into a recent KRAB-ZNF segmental duplication, 
demonstrating how novel functions can arise over an evolutionarily short period of time 
(Lynch & Conery, 2000). There is still much that we do not know about these TFs, and 
future studies may help to expand the scope of our understanding. However, we now 
know that these TFs play a role in neural development. 
Neural development is human development – our species has spent a lot of energy 
over the course of evolution in developing our brains in a manner that is unique to other 
species. The regulation of cell division in neural progenitor cells, like the ones examined 
in this thesis, has played crucial evolutionary roles in affecting brain size (Fish et al., 
2008), with the number and complexity of neural networks being reflected by the 
outgrowth of cortical neurons (Hofman, 2014). Indeed, the mechanisms that govern 
neurite outgrown have been linked to neuronal plasticity, as regulated by REST 
(Lepagnol-Bestel et al., 2006) and possibly further regulated by the ZNF286 proteins. 
This thesis represents a small and focused study into a very specialized set of 
genes, singled out from a genome of thousands. There are countless examples of 
segmental duplications and novel functions that have evolved in countless species. As 
such, it may be tempting to dismiss these genes as insignificant to the greater picture – 
here we have yet another study of miniscule mechanisms, which is certainly of miniscule 
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importance to the field as it is unlikely to cure any diseases or revolutionize the field. 
And yet, each new discovery is revolutionary in its own way. Each new gene that we 
investigate provides us with novel perspectives, and allows us to use the tools we have at 
our disposal to tackle problems in new and creative ways. Each answer that we articulate 
helps us to more coherently respond to questions that have already been answered, and 
more confidently respond to those we will ask in the future. While it is certainly true that 
the mechanisms studied in this work are miniscule, the wealth of understanding we gain 
in their pursuit is anything but. 
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Appendix Figure A.1. Confirming the human specificity of the ZNF286B gene. ZNF286B’s 
role as a human-specific duplicate of ZNF286A was first confirmed using PCR, with the forward 
primer targeting the first finger that distinguishes the two paralogs to amplify the ZNF286B gene 
sequences in genomic DNA from six primates: human (Hu), Chimpanzee (Ch), Bonobo (Bo), 
Gorilla (Go), Orangutan (Or), and Rhesus macaque (Rh). A size standard ladder and no-template 
negative control (NC) are also included. The ZNF286B-specific PCR product was generated only 
in human templates (lower panel). These same DNA preparations were tested with control PCR 
primer sets designed against several other genes, including ZNF286A, which is known to be 
present in all species (upper panel). The production of clear PCR products for this and other 
shared genes confirmed the quality of the non-human primate DNA. ZNF286B panel reproduced 
from Nowick et al.1 
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Divergence in Primate Zinc-Finger Genes: A Rich Resource for Evolution of Gene Regulatory 
Differences between Species. PLOS One 6(6):e21553. 
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Appendix Figure A.2. Full expanse of the ch17 duplicon, including genes. UCSC Genome 
Browser including the full expanse of the ch17 duplicon, in which ZNF286A and a number of 
surrounding genes duplicated. Here, the duplicated region around ZNF286A (top panel) can be 
seen, while the corresponding sequence around ZNF286B (bottom panel) can be seen. 
 
 
 
 
 
